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INTRODUCTION
Heart Failure 1.1 
Heart Failure (HF) is defined as a clinical syndrome with impaired ventricular 
function that results  from any structural or functional cardiac disorder 1. 
The characteristics of ventricular dysfunction divide HF into two broad 
categories. Systolic HF is marked by impaired ventricular ejection 
performance, while abnormal ventricular filling with preserved systolic 
function characterizes diastolic HF. Systolic HF is most often associated 
with a dilated left ventricle, while diastolic HF is usually accompanied by 
left ventricular hypertrophy. These structural abnormalities are generally 
irreversible, which makes HF a chronic condition. HF is also a progressive 
disease, since compensatory mechanisms initiated to correct hemodynamic 
disorders ultimately exert cardiotoxic effects 2. Despite recent therapeutic 
improvements HF is therefore an utmost deadly disorder with a high 
one-year mortality rate 3,4. Although HF can evolve during a variety of 
conditions, main causes are coronary artery disease, hypertension and 
dilated cardiomyopathy 5. HF is the most common medical disorder in 
the Western world today, with a prevalence estimated at 1-2% and an 
incidence approaching 5 per 1000 persons each year 6. Because there is no 
single diagnostic test for HF, its clinical diagnosis is based on historical 
and physical examination. The New York Heart Association (NYHA) 
classification of the severity of HF is commonly used to quantify the degree 
of functional disability in patients with HF (Table 1). Exercise intolerance 
is the most disabling symptom of HF, which results from dyspnea and 
fatigue. Many studies have shown that the origin of dyspnea and fatigue 
cannot directly be ascribed to hemodynamic disturbances. For instance, left 
ventricular performance is poorly related to exercise capacity in CHF 7 and 
acute improvements of hemodynamic function have no immediate impact 
on exercise capacity 8,9. In attempt to identify the causes of dyspnea and 
fatigue many studies in the last decade have focused on the contribution 
of peripheral skeletal muscle dysfunction in HF patients. Impaired 
contractile function of peripheral muscles is characterized by early fatigue 
and reduced maximal strength, originating from different abnormalities 
such as substantial wasting (i.e. cachexia), impaired oxygen delivery and 
metabolic adaptations that promote fatigue (for reviews see 10,11,12). The 
severity of these abnormalities indeed show a better correlation with 
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exercise intolerance than the degree of hemodynamic disturbances. Thus, 
peripheral skeletal muscle remodeling seems to contribute to exercise 
limitations of HF patients.
Table 1  Classification of the severity of heart failure.
HF and respiratory muscle weakness 1.2 in vivo 
In contrast to peripheral skeletal muscles, few investigations have assessed 
respiratory muscle function in HF. The capacity of both inspiratory as 
expiratory muscles to generate maximal mouth pressures are reduced 
by 30-60% in HF patients 13,14. These reductions correlate well with 
the severity of experienced dyspnea 15,16 and exercise intolerance 17,18. 
Interestingly, inspiratory muscle strength seems to be more affected than 
expiratory muscle strength 19,20 and reduced inspiratory muscle strength 
independently predicts mortality 21. These studies indicate that respiratory 
muscle dysfunction and inspiratory muscle weakness in particular, strongly 
contribute to limited daily life activities of HF patients. 
The diaphragm is the main inspiratory muscle, therefore the majority of 
studies investigating inspiratory muscle weakness in HF have focused on 
the diaphragm. Analysis of diaphragm function specifically, by phrenic 
nerve stimulation, showed that trans-diaphragmatic pressure generation is 
significantly reduced in HF patients 19,22. Since nerve stimulation eliminates 
the effect of patients motivation and central drive on muscle force, these 
studies point to intrinsic diaphragm abnormalities. Intuitively it may be 
anticipated that the pathophysiology of inspiratory and peripheral muscle 
weakness follow similar pathways. However, several lines of evidence 
demonstrate a distinct response of inspiratory and peripheral muscles to 
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HF. First, the magnitude and time course of developing impairments is 
different. Reductions of inspiratory muscle strength exceed reductions of 
peripheral muscle strength measured in the same HF patient 14. Moreover, 
some HF patients show inspiratory muscle weakness without reduced 
peripheral muscle strength 18,23. Second, the nature of abnormalities in 
inspiratory muscles is different from the above mentioned abnormalities 
in peripheral muscles of HF patients 24. 
Figure 1. Transverse section of the diaphragm from control and a subject with HF. 
The	arrows	point	to	the	central	cores	in	dark	stained	(type	1)	fibers	in	the	HF	diaphragm.		
Bar	=	100µm.	Printed	from	Lindsay	et	al.	European	Heart	Journal	(1996)	17,	1239-1250
Origin of diaphragm weakness in HF1.3 
1.3.1 Altered diaphragm mechanics
A recent study on diaphragm mechanics in vivo reported that at the beginning 
of inspiration the diaphragm is shorter in HF patients compared to healthy 
controls 25. This diaphragm displacement was proposed to be consequence 
of decreased thoracic volume, probably resulting from increased heart 
size. At shorter length the diaphragm is placed at a sub-optimal position 
on its force-length relationship, which could indeed explain reduced force 
generating capacity of the diaphragm in HF. Nevertheless, studies in animal 
models of HF have shown that reduced force generation of diaphragm occurs 
independently of diaphragm length 26,27,28. In these studies, force generation 
of diaphragm bundles was measured upon electrical stimulation in vitro. 
At optimal length, force generation was reduced in diaphragm bundles 
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from HF animals. Although caution is needed when extrapolating these 
in vitro studies on experimental HF to the clinical setting, this indicates 
that mechanical disadvantages do not provide a conclusive explanation for 
diaphragm dysfunction in HF.
1.3.2 Histological abnormalities
The single study that investigated the histology of diaphragm specimens 
from patients with HF reported histological abnormalities such as, internal 
nuclei, central cores and neonatal myosin 29 (Figure 1). The presence of 
internal nuclei and neonatal myosin are features previously related to 
muscle fiber regeneration and transformation 30,31. These abnormalities 
were more prominent in the diaphragm than in other respiratory and 
limb muscles from the same HF patients. The diameter of cross-sectioned 
diaphragm fibers from HF patients was not significantly different from 
controls, while reduced fiber diameters were reported in other thoracic 
muscles. This indicates that decreased capacity of the diaphragm to 
generate force in HF can probably not be explained by diaphragm fiber 
atrophy. Of note, subdividing the patients according to the origin of heart 
failure indicated that abnormalities were more marked in dilated than 
in ischemic cardiomyopathy. These histological observations in human 
diaphragm are in keeping with studies in different animal models for heart 
failure. For example, in hamsters with dilated cardiomyopathy features 
like internal nuclei, central nuclei and necrosis were also noted 27, while 
these abnormalities were absent in a myocardial infarction model of HF 
32. Thus, the etiology and/or severity of heart failure may influence the 
characteristics of diaphragm injury.
1.3.3	 Fiber	type	shift
The only other study on diaphragm specimens from heart failure patients 
(origin: dilated cardiomyopathy and coronary artery disease) described a 
fiber type shift from fast-glycolitic fibers towards slow oxidative fibers 33. 
Since slow muscle fibers generate less force per cross-sectional area than 
fast muscle fibers 34, a fiber type redistribution in the HF diaphragm could 
contribute to the reduced capacity to generate force. However, given the 
difference of force generation between slow and fast muscle fibers and the 
magnitude of the observed fiber type shift in the diaphragm of HF patients 
35, this shift could maximally account for a 4% reduction of maximal force. In 
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other words, a large part of the 30-60% reduction of inspiratory muscle force 
generating capacity in HF patients remains unexplained. In accordance with 
a fiber type shift towards slow-oxidative fibers, the activities of oxidative 
enzymes, like citrate synthase and beta-hydroxylacylCoA dehydrogenase, 
were increased 33. This adaptation in the HF diaphragm should be in favor 
of diaphragm endurance. However, endurance of the diaphragm in HF 
patients is decreased, i.e. the capacity of the diaphragm to maintain a 
certain force over time is reduced 36. Accordingly, diaphragm dysfunction 
in HF cannot be ascribed to altered fiber type distribution.
1.3.4 Impaired contractility
Altogether, the apparent mild alterations on histological and metabolic level 
do not seem to stroke with diaphragm dysfunction established in vivo. At this 
point it must be emphasized, however, that diaphragm force generation in 
vivo not solely depends on muscle function, but on other parameters, such 
as central drive, phrenic nerve function and neuromuscular transmission. 
Therefore, direct measurements of diaphragm contractile performance 
provide more information on the nature of diaphragm muscle dysfunction 
in HF. No studies on contractile function of diaphragm tissue from HF 
patients have been described today, so here we are completely confined to 
results from animal studies. 
Investigations on the contractility of diaphragm bundles in vitro show that 
isometric force generation is reduced by 30-60% in several animal models 
for HF, such as aortic constriction 26, idiopathic dilated cardiomyopathy 27 
and ventricular pacing 28. Interestingly, it appeared that sub-maximal force 
generation is more reduced than maximal force generation 26,27,28. In addition 
to impaired isometric contractility, diaphragm bundles isolated from 
animals with HF (induced by aortic constriction) display slower maximal 
shortening velocities 26. These studies strongly suggest that impaired muscle 
contractility is involved in HF-induced diaphragm dysfunction in vivo, at 
least in experimental HF. Nevertheless, the exact nature of diaphragm 
dysfunction cannot be elucidated by these studies. As mentioned for the 
human diaphragm, the magnitude of fiber type redistribution towards 
slow fibers fails to explain diaphragm weakness in experimental HF as 
well 37. Moreover, reduced diaphragm force generating capacity has been 
measured in the absence of a fiber type shift 27. Furthermore, it is important 
to note that diaphragm force generation is reduced per cross-sectional area 
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26,27,28, excluding a possible contribution of diaphragm fiber atrophy. These 
findings point to the involvement of impaired muscle quality rather than 
reduced muscle quantity and stress the necessity to study the performance 
of contractile proteins within individual diaphragm muscle fibers, i.e. 
independent of fiber type. The next paragraph will address the most 
important determinants of muscle fiber force generation.  
(Skinned) Muscle fiber physiology1.4 
1.4.1	Organisation	of	the	sacromere
Sarcomeres are the most fundamental contractile units of striated muscle. 
Sarcomeres are composed of highly organized filament systems and can 
be divided in four major regions; Z-disc, I-band, A-band and M-line. Thin 
filaments run from the Z-disc through the I-band into the A-band where 
they overlap with thick filaments. Thin filaments are composed of actin 
monomers, which contain binding sites for myosin. The latter is the major 
component of the thick filament system. The interaction between actin and 
myosin, also referred to as cross-bridges, enables the sarcomere to develop 
force and movement. The formation of these cross-bridges is regulated by 
tropomyosin and troponins, which block or unblock myosin binding sites 
on the thin filament. Myosin and actin account for ~80% of  total protein 
content within a muscle fiber. The third filament system is made up of titin 
molecules. Titin is a giant protein that spans the half-sarcomeric distance 
from Z-line to M-line and contains an elastic segment in the I-band region 
38. The passive elastic properties of titin are essential for optimal force 
generation, as they maintain the thick filaments in a central position within 
the sarcomere, thereby providing structural and mechanical stability 
of the sarcomere 39,40. Another giant protein, nebulin, covers the entire 
length of the thin filament and represents the fourth filament system in 
the sarcomere. Nebulin functions as a ruler for thin filament length 41. A 
simplified model of the sarcomere with its key elements is given in Figure 
2. As Z-discs constitute anchoring sites for thin, titin and nebulin filaments 
of adjacent sarcomeres, they are the primary conduits of force generated by 
contraction. The coordinated transmission of contractile force from Z-discs 
to muscle membrane is provided by linkages known as costameres. The 
dystroglycan complex is among others, one of the costameric structures 
that attaches Z-discs to the muscle membrane. Striated muscle fibers are 
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surrounded by a basement membrane rich in extracellular matrix proteins, 
such as collagen, laminin and fibronectin. Within the basement membrane 
force from individual fibers is laterally transmitted to myotendinous 
junctions, the muscle termini. Besides an important role in transmitting force 
effectively, costameric and basement membrane proteins are necessary to 
maintain the structural integrity of the muscle during force generation.
Figure 2  A simplified  representation of the sarcomere. 
Thick	 (myosin)	 and	 thin	 (actin)	 filaments	 can	 interact	 and	 develop	 force	 and	movement	 during	
activation.	The	tropomyosin	and	troponins	regulate	the	interaction	between	thick	and	thin	filaments.	
Titin	maintains	the	central	position	of	the	thick	filament	during	activation.	Nebulin	is	a	ruler	for	
thin	filament	length.
Determinants	of	active	force	generation1.4.1 
Force generation of striated muscles, like the diaphragm, results from 
the linked action of electrophysiological, biochemical and mechanical 
processes and is called excitation-contraction coupling. Striated 
muscle fibers are innervated by motor neurons through contacts called 
neuromuscular junctions. An activated motor neuron initiates muscle 
excitation by depolarizing the muscle membrane at the neuromuscular 
junction. Depolarization leads to an action potential that propagates along 
the muscle fiber length and passes down T-tubules into the interior of the 
fiber. Depolarization of the T-tubules leads to unblocking of channels in 
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the sarcoplasmic reticulum, which results in a subsequent release of large 
quantities of stored calcium ions (Ca2+) into the cytoplasm. Released Ca2+ 
binds to troponin complexes on actin filaments. This binding changes the 
conformation of troponin into an open state, which pulls tropomyosin 
away from potential myosin binding sites on actin. Exposure of these sites 
allow myosin heads to attach to actin and form cross-bridges between the 
thin and thick filament. The open conformation of troponin can revert to a 
closed state, that blocks myosin binding sites on actin (Figure 3). Therefore, 
the amount of formed cross-bridges depends on the stability of the open 
troponin state. Upon cross-bridge formation, stored energy in the myosin 
head is released and results in a subsequent rotation of the myosin head. 
This rotation is called the power strokes as it 1) generates force by stretching 
the compliant S2 portion of the myosin molecule and 2) induces movement 
by dragging actin and myosin filaments in opposite directions. After the 
power stroke the myosin head detaches from actin, rotates back into its 
original position where is able to attach again. This cyclic interaction 
between myosin and actin is termed the cross-bridge cycle. 
As mentioned above, contractile properties of individual diaphragm fibers 
must be assessed to get more insight into the mechanisms of diaphragm 
dysfunction in HF. Skinned single fibers provide an excellent model for 
studying myofilament function in the HF diaphragm for every fiber type 
separately. In skinned fibers, membranous structures, like the sarcolemma, 
sarcoplasmic reticulum and mitochondria are made highly permeable 
(i.e. skinned), while leaving the myofilaments intact. A skinned fiber can 
thus be regarded as a collection of functional sarcomeres, which ensures a 
specific evaluation of contractile protein function. 
Measuring force generation upon Ca2+ activation in skinned fibers provides 
important information on the functionality of contractile proteins. The 
steady state level of force (F) developed by a skinned muscle fiber is the 
product of the maximum number of cross-bridges that can be formed per 
half sarcomere (n), the fraction that is actually formed (αfs) and the mean 
force generated per cross-bridge (fm):
    F = n × αfs × fm         (1)
The fraction that is actually formed (αfs) reflects the number of exposed 
myosin binding sites on actin. The maximum number of cross-bridges per 
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half sarcomere (n) depends on the amount of overlap between thin and 
thick filaments and the content of myosin per half sarcomere. The nature of 
reduced force generating capacity of the diaphragm muscle in HF patients 
could originate from one or more of these three determinants. Firstly, the 
number of exposed binding sites is regulated by the binding of Ca2+ to 
troponin, as described above. 
Figure 3  Regulation of contraction by the troponin complex.
During relaxation myosin binding sites on actin are covered by tropomyosin. Upon Ca2+ binding the 
troponin	complex	conformation	changes	(close	to	open	state),	which	pulls	tropomyosin	away	from	
myosin binding site and myosin can interact with actin (contraction). The equilibrium between open 
and	closed	troponin	determines	the	probability	of	exposed	myosin	binding	sites	on	actin. 
The relation between Ca2+ concentration ([Ca2+]) and a steady state force 
follows a dose-response curve, described by the Hill equation:
   Fss = Fmax / (1 + 10 n(pCa50-pCa))    (2)
in which Fmax is the maximal force, pCa is -log [Ca2+], pCa50 is the -log 
[Ca2+] at which 50% of Fmax is developed and n is the Hill coefficient, which 
determines the steepness of the linear part of the curve. The pCa50 gives 
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a measure of Ca2+ sensitivity of force generation. Reduced Ca2+ sensitivity 
will, at a sub-maximal [Ca2+] level, result in a lower number of potential 
cross-bridges and thus lower force generation. Secondly, the force-length 
relationship of a muscle fiber results directly from the dependency of 
the maximum number of cross-bridges for myofilament overlap. As 
mentioned above, in HF patients the diaphragm is shortened 25, so reduced 
myofilament overlap could contribute to reduced force generating capacity. 
Finally, myosin content per half sarcomere is another determinant for the 
maximum number of cross-bridges that can be formed. As a consequence, 
the force generating capacity of a muscle fiber depends on myosin content 
42,43. Accordingly, in limb muscles of HF patients reduced myosin content 
strongly relates to decreased muscle strength 44. The content of a protein is 
the net result of its synthesis and degradation. Therefore small disturbances 
in the balance between these two can significantly affect protein content. 
Myosin synthesis was not different from control in limb muscles of HF 
patients 44, suggesting that myosin loss results from increased myosin 
breakdown. 
Contractile protein degradation1.5 
Results from recent studies on muscle wasting in other diseases than 
HF provide strong evidence that the ubiquitin-proteasome pathway is 
responsible for the degradation of contractile proteins such as myosin 
45,46. The ubiquitin-proteasome is the major proteolytic system for non-
lysosomal degradation of cellular proteins in all eukaryotic cells 47. In both 
health and diseased cells, the ubiquitin-proteasome pathway plays a role 
of vital importance, as it tightly regulates numerous cellular processes 
such as protein turnover, quality control of proteins, cell cycle, apoptosis, 
transcription and cell signaling. The pathway comprises concerted actions 
of enzymes that mark proteins to be degraded by tagging them with 
ubiquitin chains (Figure 4). The 26S proteasome, a barrel-shaped complex 
containing various proteases, recognizes this degradation signal and 
cleaves the ubiquitinated proteins to small peptides. A key step in protein 
ubiquitination is the recognition of substrates by a specific subset of E3-
ligases, enabling selective degradation. Since the ubiquitin-proteasome 
pathway is unable to degrade intact actomyosin complexes 48, preceding 
cleavage of these proteins from the sarcomere is necessary for subsequent 
degradation. The exact mechanisms for cleaving contractile proteins from 
the sarcomere are unknown, but the involvement of proteolytic enzymes, 
such as calpains 49,50 and caspase-3 51,52 has been proposed. 
18
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Figure 4  Proposed mechanisms of contractile protein degradation through the ubiquitin-
proteasome pathway.
Proteolytic	 enzymes	 like	 caspase-3	 and	 calpains	 cleave	 contractile	 proteins	 from	 the	 sarcomere.	
Contractile	proteins	are	then	ubiquitinated	by	specific	E3-ligases,	which	marks	them	to	be	destined	
for	the	proteasome.	Finally,	proteolytic	enzymes	within	the	proteasome	cleave	the	contractile	proteins	
to	peptides.	Adapted	from	Jackman,	American	Journal	of	Physiology,	Cell	Physiology	2004.
Pharmacological targets1.6 
As mentioned, reduced force generating capacity of the HF diaphragm can 
originate from several determinants that affect cross-bridge formation (see 
formula	(1)). Accordingly, these determinants offer potential pharmacological 
targets for improving diaphragm force generation in HF. 
1.6.1 Proteasome inhibition 
Firstly, increasing myosin content could improve diaphragm force 
generation. Because myosin appears to be degraded by the ubiquitin-
proteasome pathway, inhibition of proteasome activity seems an appropriate 
therapeutic target for muscle wasting in HF. However, as mentioned, the 
ubiquitin-proteasome pathway serves numerous basic housekeeping cell 
functions 47, therefore the cytotoxic potential of proteasome inhibitors 
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has long hampered their therapeutic applicability. Nevertheless, recent 
advances have lead to the development of bortezomib, the first proteasome 
inhibitor approved for use in human 53. Bortezomib, is a monomeric boronic 
acid that interacts with a threonine residue located on the β-subunit that 
confers chymotryptic-like proteolytic activity of the 26S proteasome 54. 
Peptide boronic acids, such as bortezomib are highly specific and up to 
100-fold more potent than their peptide aldehyde analogs 55. In different 
animal models of muscle wasting bortezomib treatment has been shown 
to prevent loss of muscle mass 56,57,58. However, the effect of proteasome 
inhibition on content of specific contractile proteins and more importantly, 
on muscle function has not yet been investigated. 
1.6.2 Calcium sensitizing
Secondly, increasing the number of exposed myosin binding sites on actin 
would enhance cross-bridge formation and thus force generation. The 
number of exposed myosin binding sites at a sub-maximal [Ca2+] depends 
on the sensitivity of myofilaments for Ca2+. Since during normal breathing 
the diaphragm is sub-maximally loaded, increasing calcium sensitivity 
seems an interesting therapeutic target for improving diaphragm function 
in HF. Furthermore, calcium cycling is one of the most energy consuming 
process during muscle contractions 59, in particular in the diaphragm 
during breathing, where it undergoes repetitive cycles of contraction 
and relaxation. Increased calcium sensitivity implicates that the same 
amount of force can be generated by using less calcium. Consequently, 
an additional advantage of increasing calcium sensitivity is reducing 
energy cost of force generation, i.e improved efficiency. Given the fact 
that the work of breathing is increased threefold in HF patients 16, it seems 
of major clinical relevance to improve diaphragm efficiency. Currently, 
levosimendan is the only calcium sensitizer approved for use in human (~40 
countries worldwide). Levosimendan has been shown to improve cardiac 
contractility in vivo 60 and in vitro 61 by enhancing calcium sensitivity of force 
generation.  Levosimendan improves calcium sensitivity by stabilizing the 
open conformation of troponin C (Figure 5), which leads to an increased 
number of myosin binding sites on actin 62. The effects of levosimendan on 
peripheral- or respiratory skeletal muscle have not been investigated. 
20
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Figure 5  Mechanisms of the calcium sensitizer levosimendan.
Levosimendan binds to the troponin complex and stabilizes its open state. The equilibrium between 
the	open	and	closed	troponin	is	shifted	and	results	in	a	higher	probability	of	exposed	myosin	binding	
sites	on	actin.	Consequently,	levosimendan	facilitates	cross-bridge	formation	at	the	same	amount	of	
Ca2+. 
AIMS AND OUTLINE OF THE THESIS
This thesis focuses on the nature of diaphragm contractile dysfunction in HF. 
Numerous in vivo and in vitro studies have described impaired diaphragm 
contractility in HF patients and in animal models for HF. However, the 
pathophysiological basis from which diaphragm dysfunction arises in 
HF is unclear. Therefore, we investigated if HF affects contractile protein 
function in the diaphragm muscle of HF animals. In addition, we studied 
specific therapeutic targets aiming to improve diaphragm contractility in 
HF.
In chapter 2 we measured isometric and isotonic contractility of diaphragm 
muscle bundles from animals with HF. Since inspiratory loading is known 
to result in diaphragm injury and HF is associated with increased work 
of breathing, we evaluated diaphragm injury at the ultra-structural and 
sarcolemmal level in HF animals.
21
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In chapter 3 contractile protein function was studied in skinned diaphragm 
fibers from HF animals. Maximal force generation, cross-bridge cycling 
kinetics and calcium sensitivity were determined. Since it is well known 
that force generating capacity of skinned fibers strongly depends on 
contractile protein content we established myosin content in the same fibers. 
Furthermore, the proteolytic activities of caspase-3 and the proteasome were 
assessed to ascertain the involvement of increased protein degradation. 
Based on the findings that impaired contractility of HF diaphragm fibers 
was associated with myosin loss and activation of the ubiquitin-proteasome 
pathway we studied the effect of proteasome inhibition on contractile 
function of diaphragm fibers from HF animals in chapter 4. To evaluate the 
mechanisms of contractile protein degradation, we additionally examined 
the effect of proteasome inhibition on essential steps acting upstream of 
the proteasomes, such as ubiquitin-conjugation by specific E3-ligases and 
caspase-3 activation.
For optimal muscle function and sarcomeric stability passive elastic 
structures are indispensible. The study in chapter 5 investigated the 
passive elastic properties of diaphragm fibers from HF animals. Titin has 
been shown to be the most  important passive-elastic structure within 
the sarcomere, therefore we additionally studied titin content and titin’s 
length in HF diaphragm. Finally, as it has been recognized that respiratory 
and peripheral muscles are differently affected by HF we also examined 
passive elastic properties of soleus muscle fibers from HF animals.
Besides HF, other diseases like chronic obstructive pulmonary disease 
(COPD) are known to affect diaphragm function. Previous investigations 
from our lab showed that impaired diaphragm contractility in both HF 
animals as COPD patients was associated with reduced sensitivity of 
contractile proteins for Ca2+. These findings prompted us to study the 
pharmacological modulation of regulatory proteins as an effective strategy 
to improve diaphragm contractility in both diseases. Therefore we examined 
the effect of a calcium sensitizer on contractile function of diaphragm fibers 
from HF animals in chapter 6 and COPD patients in chapter 7.
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ABSTRACT 
Rationale Metabolic alterations and decreased isometric force generation 
have been demonstrated in different animal models for congestive heart 
failure (CHF). However, as few morphological examinations have been 
performed on the CHF diaphragm, it is unknown if structural abnormalities 
comprise a substrate for diaphragm dysfunction in CHF. Therefore, we 
investigated CHF diaphragm isometric and isotonic contractility together 
with the presence of structural abnormalities. 
Methods Isometric twitch (Pt) and maximal (Po) force, shortening velocity 
and power generation were determined in diaphragm bundles from rats 
with CHF, induced by myocardial infarction,  and sham-operated rats. 
Immunofluorescence staining of myosin and sarcolemmal components 
fibronectin, laminin and dystrophin were performed on diaphragm 
cryosections. Electron microscopy was used to study the ultrastructure of 
diaphragm fibres. 
Main Results Pt and Po were respectively ~30% and ~20% lower in CHF 
diaphragm bundles than sham. Maximal shortening velocity was reduced 
by ~20% and maximal power generation by ~35%. Structural abnormalities 
were frequently observed in CHF diaphragm fibres and were mainly 
marked by focal degradation of sarcomeric constituents and expansion 
of intermyofibrillar spaces with swollen and degenerated mitochondria. 
Immunofluorescence microscopy showed reduced staining intensities of 
myosin in CHF diaphragm fibres compared to sham. No differences were 
found regarding the distribution of fibronectin, laminin and dystrophin, 
indicating an intact sarcolemma in both groups.
Conclusion This study demonstrates impaired isometric and isotonic 
contractility together with structural abnormalities in the CHF diaphragm. 
The sarcolemma of CHF diaphragm fibres appeared to be intact, excluding 
a role for sarcolemmal injuries in the development of CHF diaphragm 
dysfunction.
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INTRODUCTION
Inspiratory muscle dysfunction is known to occur in patients with 
congestive heart failure (CHF). Maximal inspiratory pressure is reduced 
in patients with mild to moderate CHF 1 and has been identified as an 
independent predictor of mortality 2. As the diaphragm is the most 
important inspiratory muscle, several studies investigated functional and 
metabolic alterations in the CHF diaphragm. In diaphragm biopsies from 
CHF patients a fibre type redistribution towards slow oxidative fibres was 
observed 3. Studies of different CHF animal models confirmed this fibre 
type shift and described decreased maximal isometric force generation 
of diaphragm bundles in vitro 4,5. In vivo however, the diaphragm does 
not perform maximum isometric contractions, but shortens against a sub-
maximal load. Measuring shortening velocity and power generation of the 
diaphragm is therefore physiologically more relevant. 
CHF is associated with an increased workload on the diaphragm 6, 
probably as a consequence of reduced compliance of the respiratory 
system, increased airflow resistance and decreased diffusing capacity 7. 
Increased workload on a muscle could result in sarcolemmal damage and 
sarcomeric disruptions, as observed in the diaphragm after inspiratory 
loading 8,9. Sarcolemmal damage after increased muscle loading has been 
established by intracellular localization of the extracellular matrix element 
fibronectin 10 and loss of the sarcolemma-associated protein dystrophin 
11. Sarcomeric disruptions, assessed by electron microscopy, are observed 
in the diaphragm of patients with chronic obstructive pulmonary disease 
(COPD) and increase after inspiratory loading 9. In CHF, few histologic 
abnormalities of diaphragm myofibres have been described, these include 
decreased cross-sectional areas, increased amount of necrotic fibres and 
centralisation of nuclei 5,12. However, it is unknown if sarcolemmal damage 
and  sarcomeric disruptions are present in the CHF diaphragm. 
In the present study we investigated the isometric and isotonic contractile 
properties of the diaphragm in CHF. We hypothesized that isometric 
force generation, maximal shortening velocity and power generation are 
decreased in the diaphragm from rats with CHF, induced by myocardial 
infarction. In addition, we hypothesized that structural injuries of the 
sarcolemma and sarcomeres are present in the diaphragm fibres of CHF 
rats. To test the latter hypothesis, we investigated the ultrastructure 
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of CHF and sham diaphragm fibres with electron microscopy and the 
immunofluorescence distribution of the contractile protein myosin and the 
sarcolemmal components fibronectin, dystrophin and laminin. 
MATERIALS & METHODS
Experimental	model
Male outbred Wistar rats (260 to 300 g) were used in this study. Rats were fed 
with rat chow (RMH-B 1010, Hope Farms B.V., Woerden, The Netherlands) 
and water ad libitum. Animals were housed (two per cage) under 12:12 
hour light-dark cycle. All procedures were approved by the Animal 
Ethics Committee, Radboud University Nijmegen, The Netherlands and 
experiments were performed in an ISO 9001 certified animal facility (Central 
Animal Laboratory, Radboud University Nijmegen, The Netherlands).
Rats were anesthetized by inhalation of an isoflurane-oxygen mixture 
(2% to 5% isoflurane), intubated, and mechanically ventilated. A left 
thoracotomy between the fourth and fifth ribs was performed, exposing 
the left ventricular wall. The left coronary artery was ligated at its origin by 
a 5-0 silk suture. Subsequently, the thorax was closed in three layers with 
3-0 vicryl sutures. Sham operations were performed identically, without 
ligating the coronary artery. After the operation and during the following 
two days, buprenorphine (20 µg/kg, subcutaneously) was administered 
daily for postoperative analgesia. Seventy coronary artery ligations and 
sixteen sham operations were performed. Perioperative survival was 
49% in the ligated group and 100% in the sham operated group and 
comparable with previous studies using this model of heart failure 13,14. At 
14 weeks after ligation or sham operation, the rats were anesthetized with 
pentobarbital (70 mg /kg IP) and mechanically ventilated. Aortic pressure 
and left ventricular pressure were measured by a micromanometer-tipped 
catheter (SPC 330, Millar Instruments, Texas, USA) inserted through the 
right carotid artery. At the end of the hemodynamic measurements, a 
combined thoracotomy/laparotomy was performed, and the diaphragm, 
lungs and heart were quickly excised. Heart weight was determined and 
the heart was fixed in 4% formalin solution for >72h. Subsequently, the left 
ventricle of each heart was cut into three transverse sections parallel to the 
atrioventricular groove. These sections were cut and stained with Masson’s 
trichrome. The size of the infarct areas was determined by planimetry, as 
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described previously 15. Only rats with infarcts >35% of the left ventricle 
(n = 17) were included in this study. Lungs were weighed before and after 
desiccation (3 days at  40°C). The diaphragm and adherent lower ribs were 
quickly excised and immediately submersed in cooled oxygenated (95% 
O2-5% CO2) Krebs solution at pH ~7.4. This Krebs solution consisted of 
137 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM KH2PO4, 24 mM 
NaHCO3, 7 mM glucose, and 25 µM D-tubocurarine (Sigma, Bornem, 
Belgium). From the central costal region of the right hemi-diaphragm a 
biopsy was clamped and prefixed in the clamp in 2% glutaraldehyde in 0.1 
M phosphate buffer for electron-microscopy. Subsequently two rectangular 
bundles from the left and right hemi-diaphragm were dissected parallel to 
the long axis of the muscle fibres. One bundle from each hemi-diaphragm 
was quickly frozen in liquid nitrogen cooled isopentane and stored at 
-80˚C for immunofluorescence microscopy, the second bundle from each 
hemidiaphragm was immediately used for diaphragm bundle contractile 
measurements. From 7 CHF and 6 sham rats a part of the right hemi-
diaphragm was cut and weighed before and after desiccation (3 days at 
40°C) to measure water content in the diaphragm muscle. 
Diaphragm bundle contractile measurements
Diaphragm bundle contractile properties were measured as described 
previously 16. Silk sutures were tied firmly to both ends of the diaphragm 
bundle. The bundles were mounted vertically in separate tissue baths 
containing Krebs solution, maintained at 26°C, and perfused with a 95% 
O2-5% CO2 gas mixture. The costal margin of the diaphragm bundle was 
clamped to a micromanipulator for adjustment of length. The central tendon 
of the diaphragm bundle was attached to a force transducer (Cambridge 
Technologies, model 308B; Cambridge, MA). The muscle bundle was 
stimulated directly by using platinum plate electrodes placed in close 
apposition of the bundle. Stimuli were applied with a pulse duration of 
0.2 ms and train duration of 400 ms. Muscle preload force was adjusted 
until optimal fibre length (Lo) for twitch force was achieved. After 10 min. of 
thermoequilibration, isometric measurements were determined: maximal 
(Po) and sub-maximal (Pt) isometric force was measured at 1 Hz and 100 
Hz respectively, at 2-min intervals. Subsequently, the muscle was allowed 
to shorten after stimulation at 100 Hz (330-ms train duration) while force 
(P) was clamped at different levels ranging from 1 to 100% of Po. There 
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was a 2-min interval between each force clamp level. The time window 
for shortening velocity measurements was set to begin 10 ms after the 
first detectable change in length. The muscle shortening velocity at each 
load clamp was expressed as muscle lengths per second (Lo/s). After each 
experiment, muscle bundle length and weight were determined. Cross-
sectional area was calculated by dividing diaphragm strip weight (in g) by 
strip length (in cm) times specific density (1.056). Force (P) was expressed 
as Newton per cross-sectional area (in N/cm2). Force-velocity characteristics 
were plotted and fitted to the Hill equation 17: (P + a) (V + b) = (Po + a) b, 
where Po is maximum isometric force, V is velocity of shortening, and a and 
b are constants with dimension of force and velocity, respectively. When 
force (P) is zero, V is maximal (Vmax) and equal to bP0/a. Power, i.e. force (N/
cm2) × shortening velocity (Lo/s), was calculated for each load clamp release 
and plotted with respect to P/Po. Contractile properties of the right and left 
hemi-diaphragm of each rat were averaged.
Electron	microscopy
After prefixation in 2% glutaraldehyde in 0.1 M phosphate buffer, clamped 
diaphragm biopsies were osmicated for one hour in 1% osmium tetroxide 
in 0.1 M phosphate buffer, rinsed in phosphate buffer, dehydrated 
through graded series of ethanols and embedded in Epon 812. One-micron 
thick sections were collected, toluidine blue-stained and screened light 
microscopically. Examination of these semi-thin sections was carried out 
by two experienced independent observers. Twenty five muscle fibres in 
each section (three sections per animal) were investigated. Subsequently, 
the semi-thin sections were photographed with a Dialux 20Leitz (Digital 
camera Coolpix 990, Nikon).  The observed abnormalities appeared to be 
in concordance for both investigators. Based on the abnormalities found at 
the light microscopic level, ultrathin sections for electron microscopy were 
cut, double contrasted with uranyl-acetate/lead citrate and photographed 
in a transmission electron microscope (JEOL 1010).
Immunofluorescence	microscopy
The monoclonal mouse antibodies against the following proteins were 
purchased from Sigma-Aldrich (St. Louis, Mo., USA); laminin, fibronectin 
(clone FN-15) and dystrophin C-terminus. The antibody clones Brd-5 and 
sc-71, directed against the slow and fast isoform of myosin heavy chain 
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respectively, were kindly provided by the dept. of Cell Biology Radboud 
University Nijmegen Medical Centre, the Netherlands. Cryosections 
(7 µm thick) were rehydrated for 10 minutes in phosphate buffer and 
subsequently blocked with phosphate buffer containing 0.3% (w/v) 
bovine serum albumin. Immunofluorescence labelling was performed by 
incubation with the above-mentioned antibodies, and demonstrated with 
appropriate fluorescent ALEXA-labelled secondary antibodies (Molecular 
Probes, Eugene, Oregon, USA). Following each incubation, cryosections 
were washed three times for 5 minutes with phosphate buffer. Finally, the 
sections were embedded in Mowiol (10% (w/v) in 0.1M Tris-HCl, pH 8.5 / 
25% (v/v) glycerol / 2.5% (w/v) NaN3). As a control, primary antibodies were 
omitted. Consecutive sections were stained and visualized by a fluorescence 
Zeiss Axioscope Nikon digital DXM 1200 (Göttingen, Germany). Digital 
images were collected using a Nikon Act-1 version 2.10 software package. 
Statistical methods
Differences in animal characteristics and contractile properties between 
groups were analyzed with a Student t-test. Parameters requiring repeated 
measures over time (i.e. force-velocity and force-power) were estimated by 
using repeated measurement models and post hoc testing if appropriate. 
Data are expressed as means ± SE. Differences were considered significant 
at p< 0.01.
RESULTS
CHF	indexes
All rats with infarct sizes >35% of the left ventricle (n = 17) showed clinical 
signs of severe heart failure, including ascites, pleural effusion, pulmonary 
congestion and cardiomegaly. The latter two are supported by increased 
wet to dry lung weight ratio and heart weight, respectively (Table 1). 
Cardiac dysfunction was demonstrated by elevated left ventricular end 
diastolic pressure, decreased left ventricular peak systolic pressure and 
decreased aortic pressure (Table 1). Diaphragm weight wet to dry ratio 
was not significantly different between CHF and sham rats (3.6 ± 0.3 vs. 
3.5 ± 0.2).
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Table 1. Animal characteristics
Values	 are	means	 ±	 SE.	 *	 p	 <	 0.01	 different	 from	 sham	 group.	Abbreviations:	 CHF	 =	
congestive	heart	failure,	LV	=	left	ventricle.
Figure 1. (A)	Maximal	isometric	force	generation	
of	 diaphragm	bundles	 from	CHF	and	 sham	 rats.	
(B)	 Sub-maximal	 isometric	 force	 generation	 of	
diaphragm	bundles	from	CHF	and	sham	rats.	(C) 
Ratio	of	sub-maximal	and	maximal	isometric	force	
generation	 of	 diaphragm	bundles	 from	CHF	 and	
sham	rats.	Data	are	presented	as	mean	±	SE.	*	p	<	
0.01	different	from	sham	group.
Diaphragm bundle contractility
Diaphragm bundle contractility from CHF rats was severely impaired
compared to the sham group (Figures 1-3). Both Pt and Po were significantly 
decreased in diaphragm bundles from CHF animals compared to sham 
(Figure 1). Pt was more affected than Po resulting in a significant difference 
in Pt/Po between diaphragm bundles from CHF and sham animals (Figure 
1C). The force-velocity characteristics of the CHF diaphragm bundles were 
significantly impaired compared to sham (Figure 2A). Maximal shortening 
velocity (Vmax ) was significantly slower in CHF diaphragm compared to 
sham  (Figure 2B). The force-power curve of the CHF diaphragm bundles 
was shifted downward compared to sham (Figure 3A). Maximal power 
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output, observed at ~30% Po in both groups, was ~35% lower in CHF 
diaphragm compared to sham (Figure 3B).
Figure 2. (A)	Force	velocity	relation	of	diaphragm	bundles	from	CHF	and	sham	rats.	(B) Maximal 
shortening	velocity	of	diaphragm	bundles	from	CHF	and	sham	rats.	Data	are	presented	as	mean	±	
SE.	*	p	<	0.01	different	from	sham	group.
Figure 3. (A) Force	power	relation	of	diaphragm	bundles	from	CHF	and	sham	rats. (B) Maximal 
power	generation	of	diaphragm	bundles	from	CHF	and	sham	rats.	Data	are	presented	as	mean	±	SE.	
*	p	<	0.01	different	from	sham	group.
Light microscopy
Light microscopic examination of semi-thin sections displayed distinctly 
more abnormal fibres in diaphragm from CHF rats compared to sham. These 
abnormalities were mainly marked by distended myofibrils, sarcomeres 
out of register and focal dissolution of sarcoplasm (Figure 4). 
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Figure 4. (A)	 Representative	 toluidine	 blue	 stained	 diaphragm	 section	 (1µm)	 from	 sham	 rat.	 I:	
type	1	fibre	with	*	light	stained	fat	vacuoles	and	dark	stained	mitochondria,	II:	type	2	fibre	with	a	
generally larger diameter and less organelles. (B) Representative toluidine blue stained diaphragm 
sections	(1µm)	from	CHF	rat.	*	Widening	of	inter	myofibrillar	spaces	and	loss	of	Z-line	appearance.	
Sarcomeres	out	of	register	are	circled.	Bar	=	0.05	mm
Electron	microscopy
Electron microscopy confirmed the light microscopic observations and 
revealed focal expansion of intermyofibrillar spaces, progressing from 
one to numerous sarcomeres (Figure 5). This expansion appeared to be 
partly caused by swelling and dissolution of mitochondria (Figures 5B-
D). Additionally, endosarcomeric aberrations characterized by irregular 
or absent Z-lines as well as focal degradation of sarcomeric constituents 
were frequently observed in diaphragm myofibres from CHF rats but 
not in sham (Figures 5F-G). A semi-quantitative representation of the 
electronmicroscopical observations is shown in Table 2.
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Figure 5. (A) Representative electron microscopy photograph from sham rat. Arrows indicate 
normally shaped and intact mitochondria, bar: 3μm. (B-G) Representative electron microscopy 
photographs	 from	CHF	rats.	 (B-D)	 show	progressive	 expansion	of	 inter	myofibrillar	 spaces	with	
swollen	and	degraded	mitochondria	 in	various	stages,	*	splitted	myofibrils,	bar	2.5µm.	(E) shows 
sarcomeres	out	of	register	bar	2.5	µm	.	(F)	shows	circled	focal	degenerative	lesions,	bar	2.5µm.	(G) 
shows	disruption	of	a	sarcomere	with	loss	of	Z-line,	*	loss	of	myofilaments,	bar	1.0µm.
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Table 2. Semiquantitative representation of the electronmicroscopical observations.
- = not detected, +/- = incidentally, + = several, ++ = numerous
Immunofluorescence	microscopy
Figure 6 shows a set of representative cryosections of the diaphragm from 
CHF and sham-operated rats, stained with antibodies against myosin, 
laminin, fibronectin and dystrophin. Immunofluorescence intensities of the 
myosin slow and fast antibodies were distinctly decreased in diaphragm 
fibres from CHF rats. Reduced intensities were observed throughout the 
whole fibre length on the cryosection. Laminin staining proved to be 
continuously distributed over the basal laminae of the diaphragm fibres 
in both CHF and sham rats. Fibronectin showed similar staining in the 
extracellular matrix of the diaphragm from CHF and sham rats. No 
intracellular presence of this protein appeared in the diaphragm fibres 
of both groups. No differences were also found between CHF and sham 
rats regarding the distribution of the sarcolemma-associated protein 
dystrophin, both groups showed a regular and uninterrupted staining 
along the sarcolemma.
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Figure 6. Representative diaphragm sections from CHF and sham rats stained with 
immunofluorescence antibodies against mentioned proteins.	Distinctly	decreased	staining	of	
slow	and	fast	myosin	heavy	chain	in	the	CHF	diaphragm	compared	to	sham.	No	difference	of	staining	
intensity	and	distribution	of	sarcolemma	associated	proteins	between	CHF	and	sham	group.	Bars	
0.05mm.
DISCUSSION
The main findings of the present study show that 1) isometric force 
generation and shortening velocity of diaphragm bundles from CHF rats 
are decreased, 2) structural abnormalities within the CHF diaphragm fibres 
are indicated by distinctly decreased myosin immunofluorescence staining 
and ultrastructural observations of focal degeneration in various stages, 
and 3) the sarcolemma of these fibres appears not to be injured.
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Contractile	dysfunction	of	the	CHF	diaphragm
The present study demonstrates reduced sub-maximal and maximal 
force generation of diaphragm bundles in a myocardial infarct model 
of CHF (Figure 1). In vivo, the diaphragm does not perform maximum 
isometric contractions, but shortens against a certain load. Measuring 
shortening velocity or power generation of diaphragm bundles is therefore 
physiologically more relevant. Our data demonstrate that diaphragm 
shortening velocity and power generation are reduced in a myocardial 
infarct model of CHF. These data are in line with in vitro diaphragm 
function studies of other animal models for CHF 4,5,18,19.  Decreased force 
generation and slowed shortening velocity in these studies have been 
ascribed to changes of fibre type distribution, as contractile properties differ 
between fibre types 20,21. However, intrinsic alterations of CHF diaphragm 
fibres may also be involved. The decreased myosin immunofluorescence 
staining in CHF diaphragm fibres in this study suggests a loss of myosin 
concentration, which has been shown to cause reduced diaphragm force 
generation in COPD 22 and hypothyroidism 23. Furthermore, the finding 
that sub-maximal force is more affected than maximal force generation 
(Figure 1C) implies that either the release of calcium from the sarcoplasmic 
reticulum is limited or the calcium sensitivity of force generation is 
decreased in CHF diaphragm bundles. Finally, a recent in vitro motility 
study demonstrated decrease sliding velocities of myosin isolated from 
CHF rats, without a fibre type redistribution 24. Although diaphragm single 
fibre studies are needed to provide direct evidence, the present study 
supports the hypothesis that intrinsic contractile alterations contribute to 
CHF-induced diaphragm dysfunction.
Morphological	abnormalities;	a	substrate	for	CHF	diaphragm	dysfunction
Impaired isometric and isotonic contractility were found together with 
morphological abnormalities in the CHF diaphragm. Distinctly decreased 
fluorescence staining of the contractile protein myosin was observed in 
both slow and fast diaphragm fibres from CHF rats. Additionally, loss of 
sarcomeric constituents was indicated by light microscopy and electron 
microscopy, which showed dissolution of sarcoplasm and degenerative 
sarcomeric lesions respectively. Interestingly, the reduced myosin 
fluorescence staining was extended throughout the CHF fibres, while 
the ultrastructural abnormalities were observed focally next to areas that 
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appeared intact. This suggests that myosin loss precedes degeneration 
of sarcomeric integrity and supports the previous stated hypothesis that 
specifically targeting myosin constitutes an initial step during muscle 
wasting 25,26. 
Next to loss of sarcomeric material, progressive expansion of 
intermyofibrillar spaces was found in CHF diaphragm fibres. Unaltered 
dry to wet ratio of CHF diaphragm bundles indicates that the expansion 
of intermyofibrillar spaces is probably not the result of oedema. Yet, the 
expanded intermyofibrillar spaces contained swollen and degenerating 
mitochondria. These observations provide morphologic evidence 
for previously demonstrated impaired mitochondrial function in the 
diaphragm of CHF animals 27. Swollen and damaged mitochondria were 
previously found in fatigued muscle fibres and accompanied reduced force 
generation 28,29. Although the nature of the morphological abnormalities 
remains speculative, this study shows that morphological abnormalities 
coincide with impaired contractility in the CHF diaphragm.
Sarcolemmal	integrity	and	induction	of	degeneration
In contrast to peripheral muscle disuse, the diaphragm is increasingly 
loaded in CHF 6. Increased diaphragm loading is known to induce injuries 
of the muscle cell membrane 8. Damage of the muscle cell membrane could 
result in homeostatic disturbance of the muscle fibre and induce protein 
degradation 30. Intracellular localization of fibronectin, normally present 
in the basal lamina and endomysium, is a sign of lost integrity of the 
muscle cell membrane 10 and has been shown to be a reliable indicator of 
sarcolemmal damage 31. In the diaphragm fibres of both CHF and sham-
operated rats we found no fibres with intracellular staining for fibronectin, 
indicating that there was no sarcolemmal damage. Also, the regular and 
continuously staining of the basal lamina component laminin proved the 
intactness of the sarcolemma. However, it has been demonstrated that 
a single bout of eccentric contraction induces sarcolemmal disruption 
without affecting laminin organization, yet with a highly selective loss 
of the sarcolemma-associated protein dystrophin 11. Dystrophin seems 
to be the most vulnerable link in the transduction of lateral forces in 
skeletal muscles 32. Loss of dystrophin causes loss of the link between 
the cytoskeleton and extracellular matrix, which renders the sarcolemma 
susceptible to contraction-induced injury 33. Nonetheless, in the present 
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study dystrophin stained uninterruptedly along the sarcolemma of 
CHF diaphragm fibres, which provides further indication for preserved 
sarcolemmal integrity. Therefore, these data do not support our second 
hypothesis that the increased workload to which the diaphragm is exposed 
in CHF results in sarcolemmal dammage. Previous studies of diaphragm 
weakness in COPD patients also found loss of myosin 22 and sarcomeric 
disruptions 9, while the sarcolemma of COPD diaphragm fibres appear to 
be intact 34. Therefore, it is more likely that other mechanisms than loss 
of sarcolemmal integrity, e.g. effects of circulatory molecules via receptor-
mediated processes like angiotensin 2 35 and TNF- α 36, are responsible for 
the induction of degeneration in CHF diaphragm fibres. 
CONCLUSION
This study shows that isometric and isotonic contractile properties of 
the diaphragm from CHF rats are impaired. Distinctly reduced myosin 
staining and ultrastructural signs of degeneration in the diaphragm fibres 
could provide a morphological substrate for contractile dysfunction of the 
diaphragm in CHF. Though intracellular areas of degeneration are present, 
the sarcolemma of the diaphragm fibres appeared to be still intact. This 
suggests that sarcolemmal injuries are not involved in the development of 
CHF diaphragm dysfunction.
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ABSTRACT
Rationale Diaphragm weakness commonly occurs in patients with 
congestive heart failure (CHF) and is an independent predictor of 
mortality. However, the pathophysiology of diaphragm weakness is poorly 
understood. We hypothesized that CHF induces diaphragm weakness 
at the single fiber level by decreasing myosin content. In addition, we 
hypothesized that myofibrillar Ca2+ sensitivity is decreased and cross-bridge 
kinetics are slower in CHF diaphragm fibers. Finally, we hypothesized that 
loss of myosin in CHF diaphragm weakness is associated with increased 
proteolytic activities of caspase-3 and the proteasome. 
Methods & Results In skinned diaphragm single fibers of rats with CHF, 
induced by left coronary artery ligation, maximum force generation 
was reduced by ~35% (p<0.01) compared to sham, for slow, 2a and 2x 
fibers. In these CHF diaphragm fibers, myosin heavy chain content per 
half sarcomere was concomitantly decreased (p<0.01). Ca2+ sensitivity of 
force generation and the rate constant of tension redevelopment were 
significantly reduced in CHF diaphragm fibers compared to sham, for all 
fiber types. The cleavage activity of the proteolytic enzyme caspase-3 and 
the proteasome were respectively ~30% (p<0.05) and ~60% (p<0.05) higher 
in diaphragm homogenates from CHF rats than sham. 
Conclusions The present study demonstrates diaphragm weakness at 
the single fiber level in a myocardial infarct model of CHF. The reduced 
maximal force generation can be explained by a loss of myosin content 
in all fiber types and is associated with activation of caspase-3 and the 
proteasome. Furthermore, CHF decreases myofibrillar Ca2+ sensitivity and 
slows cross-bridge cycling kinetics in diaphragm fibers. 
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INTRODUCTION
The most important clinical manifestations of congestive heart failure (CHF) 
include impaired exercise capacity and dyspnea. Yet, the severity of these 
symptoms poorly correlate with measures of left ventricular performance in 
CHF patients 1. Interestingly, the degree of exercise intolerance is significantly 
correlated with peripheral muscle mass and function 2,3,4. Likewise, the 
sensation of dyspnea is closely related to respiratory muscle dysfunction 5. 
Moreover, maximal inspiratory pressure is reduced in patients with mild 
to moderate CHF 6 and has been identified as an independent predictor of 
survival in these patients 7. Although peripheral skeletal muscle alterations 
in CHF have been investigated in detail 2,3,4, relatively little is known about 
the pathophysiology of diaphragm weakness in CHF.
In line with reduced maximal inspiratory pressure in CHF patients, several 
animal studies of CHF described decreased specific force generation of 
diaphragm muscle bundles in vitro 8,9,10. Recently, Coirault et al. 11 found 
reduced in vitro motility of isolated myofilaments from the diaphragm 
of CHF rats, suggesting slower cross-bridge cycling kinetics. In addition 
a rightward shift of the force-frequency relationship of CHF diaphragm 
bundles could involve a decreased Ca2+ sensitivity of force generation 
12. Contractile properties are known to differ among fiber types in the 
diaphragm muscle 13,14,15. As CHF has been shown to induce a fiber type 
shift in the diaphragm 16,17, changes in contractile properties could be 
ascribed to this fiber type shift. However, to improve understanding of 
the pathophysiology of diaphragm weakness in CHF, diaphragm muscle 
function should be evaluated independently of a fiber type shift, which has 
not been done yet. Skinned diaphragm single fibers provide an excellent 
model for studying myofilament function in the CHF diaphragm for every 
fiber type separately. The first hypothesis of the present study is that CHF 
decreases maximum force generation, slows cross-bridge cycling kinetics 
and reduces Ca2+ sensitivity in skinned diaphragm single fibers.
Force generating capacity of skinned muscle fibers depends on contractile 
protein content per half sarcomere of the muscle fiber 18, 13. CHF is associated 
with peripheral skeletal muscle wasting 19 and more particularly, loss of 
myosin is related to decreased leg muscle strength in CHF patients 20. In 
patients with COPD, in experimentally induced hypothyroidism and in 
unilateral denervation decreased force generation of diaphragm fibers was 
explained by reduced myosin content per half sarcomere 21,22,23. Myosin 
50
Diaphragm	single-fiber	weakness	in	heart	failure	rats
content in CHF diaphragm fibers has not been studied. The second 
hypothesis of the present study is that impaired force generation of skinned 
fibers is associated with reduced myosin content per half sarcomere in CHF 
diaphragm fibers.  
Selective degradation of myosin through the ubiquitin-proteasome 
pathway seems to play an important role in the loss of muscle mass in 
various diseases 24,25. Caspase-3 activation has been proposed to be an 
initial step in the cleavage of the myofilaments, yielding fragments that 
are subsequently degraded by the ubiquitin-proteasome pathway 26. 
Our group has recently shown that loss of myosin is a key event in the 
pathophysiology of diaphragm muscle weakness in patients with chronic 
obstructive pulmonary disease (COPD) 21. Loss of myosin is associated 
with activation of the ubiquitin-proteasome pathway and the proteolytic 
enzyme caspase-3 in the diaphragm of these patients 27. It is yet unknown 
if activation of the proteasome and caspase-3 also occur in the CHF 
diaphragm. The third hypothesis of the present study is that CHF enhances 
the proteolytic activity of caspase-3 and the proteasome in the diaphragm. 
MATERIALS & METHODS
Experimental	model
Adult male Wistar rats (260 to 300 g) were anesthetized by inhalation 
of an isoflurane-oxygen mixture (2% to 5% isoflurane), intubated, and 
mechanically ventilated. Ligation of the left coronary artery or sham 
operation were executed as described previously 28. In short, a left 
thoracotomy between the fourth and fifth rib was performed, exposing the 
left ventricular wall. The left coronary artery was ligated at its origin by a 
5-0 silk suture. Subsequently, the thorax was closed in three layers with 
3-0 vicryl sutures. Sham operations were performed identically, without 
ligating the coronary artery. After the operation and during the following 
two days, buprenorphine (20 µg/kg, subcutaneously) was administered 
daily for postoperative analgesia. Fifty coronary artery ligations and ten 
sham operations were performed. Perioperative survival was 42% in the 
ligated group and 100% in the sham operated group and comparable with 
previous studies using this model of heart failure 29,30. At 14 weeks after 
ligation or sham operation, the rats were anesthetized with pentobarbital (70 
mg /kg IP) and mechanically ventilated. Aortic pressure and left ventricular 
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pressures were measured by a micromanometer-tipped catheter (SPC 330, 
Millar Instruments, Texas, USA) inserted through the right carotid artery. 
At the end of the hemodynamic measurements, a combined thoracotomy/
laparotomy was performed, and the diaphragm, lungs and heart were 
quickly excised. Heart weight was determined and the heart was fixated 
in formalin for >72h. Subsequently, the left ventricle of each heart was cut 
into three transverse sections in parallel with the atrioventricular groove. 
Transverse sections (7 µm thick) were cut and stained with Masson’s 
trichrome stain. The size of the infarct areas was determined by planimetry, 
as described previously 28. Only data from rats with infarcts >35% of the left 
ventricle  (n = 14) were  analyzed in this study. Lungs were cleaned of fat 
and weighed before and after desiccation (3 days at 40°C). The diaphragm 
was divided in two parts; the right hemi-diaphragm for determination of 
single fiber contractile properties and the left hemi-diaphragm for caspase-3 
and proteasome analysis. From 7 CHF and 6 sham rats a part of the right 
hemi-diaphragm was cut and weighed before and after desiccation (3 days 
at 40°C) to measure water content in the diaphragm muscle. This study was 
approved by the Animal Ethics Committee, Radboud University Nijmegen, 
The Netherlands.
Diaphragm	muscle	single	fiber	contractile	measurements
Single fiber contractile measurements and experimental protocol were 
performed according to previously described methods 21, with minor 
modifications, as described below.
Composition	of	solutions	for	single	fiber	measurements
Relaxing solution consisted of 1.0 mM MgCl2, 4.0 mM Na2ATP, 5 mM 
EGTA, 10 mM imidazole, 15 mM creatine phosphate and sufficient KCL to 
adjust the total ionic strength to 150 mM at pH 7.0. The negative logarithm 
of the free Ca2+ concentration (pCa) of the relaxing solution was 9.0 while in 
activating solutions the pCa ranged from 7.0 to 4.0 (with maximal activation 
at pCa 4.0). To achieve appropriate pCa in activating solutions, sufficient 
CaCl2 was added to solutions. The composition of the solution for maximal 
rigor activation was the same as that of the pCa 4.0 solution, except that 
Na2ATP was omitted. 
Diaphragm	muscle	single	fiber	preparation	and	experimental	set-up
After excision, the diaphragm and adherent lower ribs were immediately 
submersed in cooled oxygenated (95% O2-5% CO2) Krebs solution at pH 
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~7.4. This Krebs solution consisted of 137 mM NaCl, 4 mM KCl, 2 mM CaCl2, 
1 mM MgCl2, 1 mM KH2PO4, 24 mM NaHCO3, 7 mM glucose, and 25 µM 
D-tubocurarine (Sigma Aldrich, Bornem, Belgium). From the central costal 
region of the right hemi-diaphragm, a rectangular bundle was dissected, 
parallel to the long axis of the muscle fibers, for single fiber contractile 
measurements. The muscle bundle was pinned to cork and stored at 4°C in 
a relaxing solution, containing 50% glycerol (vol/vol). After 24 hours, the 
muscle strip was stored at -20°C for later analysis. 
Approximately one hour prior to determination of single fiber contractile 
properties, the muscle bundle was transferred to  relaxing solution (5°C) 
containing 1% Triton X-100 to permeabilize lipid membranes. From 
the muscle bundle ~2mm segments of single fibers were isolated using 
microforceps. Subsequently, the fiber ends were attached to aluminium 
foil clips, and mounted on the single fiber apparatus. Fibers were mounted 
in a temperature-controlled (20 °C) flow-through acrylic chamber (120-
µl volume), with a glass coverslip bottom, on the stage of an inverted 
microscope (model IX-70; Olympus, Amsterdam, The Netherlands). Two 
stainless steel hooks were used to mount the fiber horizontally in the 
chamber. One end of the fiber was attached to a force transducer (model 
AE-801; SensoNor, Horten, Norway) with a resonance frequency of 10 kHz, 
whereas the other end was attached to a servomotor (model 308B; Aurora 
Scientific, Aurora, ON, Canada) with a step time of 250 µs. In relaxing 
solution, sarcomere length was set at 2.4 µm as the optimal length for force 
generation 31,32 with the use of a calibrated eyepiece micrometer. During 
experiments, sarcomere length was stabilized with the Brenner cycling 
method 33 as modified by Sweeney et al. 34. MIDAC software (Radboud 
University, Nijmegen, The Netherlands) and a data-acquisition board were 
used to record signals. Muscle fiber length ( 1–1.5 mm) was measured using 
a reticule in the microscope eyepiece [×10 Olympus Plan 10, 0.30 numerical 
aperture (NA)]. The XY fiber diameter (width) was measured with a ×40 
objective [×40 Olympus Plan 40, 0.60 NA]. The ×40 objective also was used 
to measure the XZ fiber diameter (depth) by noting the displacement of the 
microscope’s objective while focusing on the top and bottom surfaces of the 
fiber. Three width and depth measurements were made along the length of 
the fiber, the average values were used to calculate the fiber cross-sectional 
area, assuming that the fiber was ellipsoid in shape. Similar incidences 
of fibers that appeared injured (i.e., sarcolemmal damage, loss of cross-
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striation or other irregularities) during microscopic examination were 
found in both groups and those fibers were excluded from the study. 
Diaphragm	muscle	single	fiber	contractile	determinations
Maximum specific force was determined by dividing the isometric force 
generated at pCa 4.0  by CSA. Maximum force at pCa 4.0 was also divided 
by the estimated value of myosin heavy chain content per half sarcomere 
(see Myosin	 heavy	 chain	 isoform	 composition	 and	 content	 per	 half	 sarcomere	
determination) to determine the force per half sarcomere myosin heavy 
chain content.
The rate constant for tension redevelopment (ktr) was measured as described 
by Brenner and Eisenberg 35 during activation at pCa 4.0. In short, fibers 
were rapidly released by 15% and then 50 ms later, restretched to their 
original length. During the rapid release and restretch, cross-bridges 
detach and force drops to zero. The cross-bridges then reattach, and force 
redevelops. The ktr value was determined using a computer algorithm for 
least-squares fit of a first-order exponential. 
Fiber stiffness was determined during sinusoidal length oscillations of 
0.4% at 1 kHz.  Stiffness provides an estimation of the number of strongly 
attached cross bridges 36. Stiffness was measured during Ca2+ activation at 
pCa 4.0 in the presence and absence (rigor solution) of ATP. Assuming that, 
during rigor activation, all cross-bridges are in the strongly attached state, 
the ratio of stiffness during Ca2+ activation to that during rigor activation 
(αfs) provides an estimate of the fraction of cross-bridges in the strongly 
attached state. 
To determine force-pCa relationship, the isometric force generated in 
response to incubation with incremental [Ca2+] (pCa 9.0, 7.0, 6.3, 6.0, 5.8, 
5.5, 5.2, 5.0, 4.7, 4.5 and 4.0) was recorded. Graphpad software (Graphpad 
Software Inc., San Diego, CA) was used to calculate the [Ca2+] required 
for half-maximum activation (pCa50), as an index of Ca2+ sensitivity of 
force generation and the Hill coefficient, as a measure of myofilament 
cooperativity. 
Diaphragm	muscle	single	fiber	experimental	protocol 
Maximal specific force was determined by perfusing the experimental 
chamber at, successively, pCa 9 and 4.0. During the plateau phase of 
maximal activation at pCa 4.0, ktr was determined. Then pCa 9.0 solution 
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was perfused through the chamber to relax the fiber. 
Subsequently, fibers were perfused with solutions containing incremental 
[Ca2+]. Each time a plateau was reached, the next pCa solution was perfused 
through the experimental chamber. When maximum force was reached at 
pCa 4.0, ktr was determined followed by a determination of fiber stiffness. 
Subsequently, the fiber was perfused with rigor solution of pCa 4.0 to 
determine stiffness during rigor activation. Finally, the fiber was perfused 
at pCa 9 to verify baseline force. 
Structural and functional instability of skinned single muscle fibers, reflected 
by an increased heterogeneity of sarcomere spacing during activation and 
reduced force generation over time, is a well-recognized problem 37. To 
improve functional stability of muscle fibers, we applied Brenner cycling 
33 throughout the experimental protocol, except during determination of 
ktr, stiffness and rigor. Accordingly, no functional decline in maximal force 
generation and ktr over time was observed. 
Myosin	 heavy	 chain	 isoform	 composition	 and	 content	 per	 half	 sarcomere	
determination
Determination of myosin heavy chain isoform composition and content by 
SDS-PAGE was adapted from Geiger et al. 13. Single fibers were detached 
from the force transducer and servo-motor and placed in 25 µl of SDS 
sample buffer containing 62.5 mM Tris⋅HCL, 2% (wt/vol) SDS, 10% (vol/
vol) glycerol, and 0.001% (wt/vol) bromophenol blue at a pH of 6.8. The 
samples were stored at -20˚C until assayed. The samples were denaturated 
by boiling for 2 min. The stacking gel contained a 4% acrylamide 
concentration (pH 6.8), and the separating gel contained 7% acrylamide 
(pH 8.8) with 30% glycerol (v/v). Control samples of rat diaphragm bundles 
were run on the gels for comparison of migration patterns of the myosin 
heavy chain isoforms. Sample volumes of 8 µl were loaded per lane. The 
gels were silver stained according to the procedure described by Oakley et 
al. 38. A standard curve of known contents of purified rabbit myosin heavy 
chain (M-3889, Sigma, Zwijndrecht, The Netherlands) was run on every gel 
to determine myosin heavy chain content in rat diaphragm muscle fibers. 
After silver staining, the gels were scanned with an imaging densitometer 
and optical densities of the electrophoretic bands were quantified with 
GeneTools software (Syngene, Cambridge, UK). Background staining was 
subtracted from the density of the electrophoretic bands to determine the 
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brightness-area product for each diaphragm muscle fiber. The relationship 
between the brightness area product and myosin heavy chain content 
was linear across a range from 0.01 to 0.25 µg. The myosin heavy chain 
content in the loaded 8 µl SDS buffer was determined from the standard 
curve. Subsequently, the total myosin heavy chain content of the fiber (in 
25 µl SDS buffer) was determined. Myosin heavy chain concentration was 
determined by dividing total myosin heavy chain content by fiber volume. 
Myosin heavy chain content per half sarcomere, at sarcomere length of 2.4 
µm, was calculated through dividing fiber myosin heavy chain content by 
the amount of half-sarcomeres (2 × length of fiber (µm)/2.4 (µm)).
Measurement	of	caspase-3	activity
Caspase-3 activity was determined as described previously 27. Frozen 
diaphragm samples were pulverized and homogenized on ice in a buffer 
containing 100 mM HEPES (pH 7.5), 10% sucrose, 0.1% Nonidet P-40, 10 mM 
dithiothreitol, and protease inhibitor cocktail (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). Homogenates were subjected to three cycles of freeze-
thaw before centrifugation at 18,000 g for 30 min. The supernatant (92,5 
μg protein) was added to reaction buffer consisting of 100 mM HEPES 
(pH 7.5), 10% sucrose, and 10 mM dithiothreitol. The fluorogenic substrate 
N-acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
was then added and the reaction was performed at 30°C for 60 min. The 
caspase-3 activity was determined by measuring the generation of the 
fluorogenic cleavage product (methylcoumarylamide) at 360 nM excitation 
wavelength and 460 nM emission wavelength with a spectrophotometer. 
Amido-4-methylcoumarin standards were used to quantify activity levels. 
Results were expressed as picomoles per minute per mg protein. Addition 
of N-Acetyl-Asp-Glu-Val-Asp-CHO (a caspase-3 inhibitor) to the reaction 
resulted in inhibition of methylcoumarylamide production, indicating the 
specificity of the assay for measuring caspase-3 activity.
Isolation	of	20S	proteasomes	and	measurement	of	proteasome	activity
The 20S proteasome isolation and proteolytic activities were determined 
as described previously 27. To isolate 20S proteasomes, in liquid nitrogen 
frozen diaphragm samples were homogenized in ice-cold buffer (pH 
7.5) containing 50 mM Tris-HCl, 5 mM MgCl2, 250 mM sucrose, 1 mM 
1.4-dithiothreitol, 0.2 mM phenylmethylsulphonylfluoride, and protease 
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inhibitor cocktail (Sigma-Aldrich, Zwijndrecht, The Netherlands) by means 
of a Dounce homogenizer. Subsequently, the proteasomes were isolated 
from the homogenates by three sequential centrifugation steps; the first 
centrifugation was at 10,000 g for 20 min. The supernatant was centrifuged at 
100,000 g for 1h. The obtained supernatant was then centrifuged at 100,000 g 
for 5h. The final pellet, containing the 20S proteasomes was resuspended in 
buffer (pH 7.5) containing 50 mM Tris-HCl, 5 mM MgCl2, and 20% glycerol. 
The protein content of the proteasome preparation was determined based 
on Bio-Rad Protein Assay (Bio-Rad, Veenendaal, The Netherlands). The 
proteolytic activity of the 20S proteasomes was determined by measuring 
the activity against the fluorogenic substrates succinyl-leu-leu-val-tyr-7-
amido-4-methylcoumarin (LLVY) and N-carbenzoxy-leu-leu-glu-7-amido-
4-methylcoumarin (LLE) (Sigma-Aldrich, Zwijndrecht, The Netherlands). 
These substrates are preferentially hydrolyzed by the chymotrypsin-
like and peptidylglutamyl peptidase activities of the 20S proteasome, 
respectively 39. To measure proteolytic activity, 15 µg proteasome extract 
was added to 60 µL of medium containing 62.5 mM tris-HCl, 12.5 mM 
MgCl2, 1.25 mM 1.4-dithiothreitol, 0.01 U apyrase, and 100 µM of LLVY or 
375 µM of LLE. The reaction took place at 37°C for 45 min. The peptidase 
activity was determined by measuring the generation of the fluorogenic 
cleavage product (amido-4-methylcoumarylamide) at 380 nM excitation 
wavelength and 440 nM emission wavelength with a spectrophotometer. 
Standard curves were established for the fluorogenic product, and 
peptidase activity was expressed as picomoles per microgram protein 
per minute. Addition of MG132 (a specific proteasome inhibitor) to the 
reaction resulted in complete inhibition of amido-4-methylcoumarylamide 
production, indicating successful isolation of proteasomes without the 
presence of significant amounts of other proteases.
Proteasome content analysis
For determining the proteasome content in the diaphragm muscle a 
western blot was performed using an antibody against the 20S proteasome 
subunit C8 (MCP72; mouse monoclonal; 1:10,000; Affiniti, Gorinchem, The 
Netherlands). In short, frozen diaphragm samples were homogenized in 
~200 μl ice-cold buffer (pH 7.5), containing 50 mM Tris, 1 mM EDTA, 1 
mM dithiothreitol, 1 mM phenylmethylsulphonylfluoride (PMSF), and 
protease inhibitor cocktail (Sigma-Aldrich, Zwijndrecht, The Netherlands), 
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by means of a Dounce homogenizer. Homogenates were centrifuged at 
10,000 x g, 4 °C for 10 min and the protein concentration of the resulting 
supernatants was determined using the Bio-Rad protein assay (Bio-Rad, 
Veenendaal, The Netherlands). Soluble proteins (10 µg) were subjected 
to routine Western blotting using 10% polyacrylamide sodium dodecyl 
sulfate (SDS)-gels and the antibody against the 20S proteasome subunit 
C8 (MCP72; mouse monoclonal; 1:10,000; Affiniti, Gorinchem, the 
Netherlands). After washing, the blot was incubated with a horseradish 
peroxidase conjugated goat anti-mouse Ig (1:10,000, Pierce, Etten-Leur, 
The Netherlands). Chemiluminiscence was performed using an ECLTM 
Western blotting analysis system (Amersham Biosciences, Roosendaal, The 
Netherlands). Protein bands were quantified using optical densitometry 
software (GeneTools, Syngene, Cambridge, UK). An isolated proteasome 
fraction (see above) from a sham rat was used as a positive control and 
for the negative control a homogenate of a sham rat was stained without 
addition of the primary (anti-C8) antibody. Equally loading was controlled 
by Coomassie Blue staining.
Data treatment & statistical methods
Contractile properties of 82 diaphragm muscle single fibers from 14 CHF 
rats and 70 single fibers from 6 sham operated rats were measured. These 
fibers expressed a single myosin heavy chain isoform and contractile 
data were grouped per fiber types slow, 2a and 2x. Every rat was equally 
represented in the fiber type groups. None of the fibers solely expressed 
myosin heavy chain 2b isoform. Fibers that coexpressed myosin heavy 
chain isoforms (n=3 in CHF fibers and n=4 in sham fibers) were excluded 
from further analysis. Due to technical circumstances, in some fibers not all 
contractile parameters could be measured. Therefore, the number of single 
fibers analyzed differs per parameter.
Differences in animal characteristics, caspase-3 and proteasome activity 
between groups were analyzed with a Student t-test. Differences 
in parameters describing single fiber characteristics and contractile 
properties between groups were tested with one-way ANOVA, followed 
by the Student-Newman-Keuls post hoc test. Because of a limited amount 
of diaphragm tissue per rat, proteasome activity, caspase-3 activity and 
Western blotting studies are not based on the same rats, although there is 
extensive overlap. A probability level of p<0.05 was considered significant 
unless otherwise indicated. Mean ± SE values are presented in text, tables 
and figures. 
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RESULTS
CHF	indexes
All rats with infarct sizes >35% of the left ventricle (n = 14) showed 
clinical signs of severe heart failure, including pulmonary congestion and 
cardiomegaly as supported by increased wet to dry lung weight ratio and 
heart weight, respectively (Table 1). Elevated left ventricular end diastolic 
pressure, decreased left ventricular peak systolic pressure and decreased 
aortic pressures indicate impaired left ventricular function (Table 1). 
Maximum	force	per	cross	sectional	area
Single fiber CSA did not differ significantly between CHF and sham fibers 
(1.0 ± 0.1 × 10-3 vs.  1.1 ± 0.1 × 10-3 mm2 for type slow; 2.5 ± 0.5 × 10-3 vs.  2.4 
± 0.5 × 10-3 mm2 for type 2a and 3.3 ± 0.3 × 10-3 vs.  3.5 ± 0.4 × 10-3 mm2 for 
type 2x, CHF and sham fibers respectively).  CSA’s of type slow fibers were 
significantly smaller compared to 2a and 2x fibers for both groups (p<0.05). 
Maximum force per CSA of single fibers from the diaphragm of CHF rats 
was significantly reduced compared to fibers from sham rats for all fiber 
types (p<0.01, Figure 1). Maximum force per CSA did not significantly 
differ between fiber types within groups (Figure 1).   
Table 1 Animal characteristics.
Values	 are	means	 ±	 SE.	 *	 p	 <	 0.05	 different	 from	 sham	 group.	Abbreviations:	 CHF	 =	
congestive	heart	failure,	LV	=	left	ventricle.
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3Figure 1. Maximum force per CSA in type slow, 2a and 2x diaphragm muscle single fibers. Maximum	force	per	CSA	of	single	fibers	from	the	diaphragm	of	CHF	rats	was	significantly	reduced	
compared	to	sham	for	all	fiber	types.	The	numbers	above	bars	represent	the	number	of	single	fibers	
analyzed.	Data	are	presented	as	mean	±	SE.	*	p	<	0.01	different	from	sham	group.	Abbreviations:	
Fmax=	Maximum	force,	CHF	=	congestive	heart	failure,	CSA	=	cross	sectional	area
Diaphragm	muscle	fiber	myosin	heavy	chain	concentration
Myosin heavy chain concentration in single fibers from CHF rats was 
significantly lower than in sham, for all fiber types (p<0.05, Figure 2A). 
Diaphragm	muscle	fiber	myosin	heavy	chain	content	per	half	sarcomere	
Myosin heavy chain content per half sarcomere reflects the number of 
cross-bridges in parallel and was determined from myosin heavy chain 
concentration and half sarcomere volume. Myosin heavy chain content 
per half sarcomere is reduced in single fibers from CHF rats compared to 
sham rats for all fiber types (p<0.01, Figure 2B). Type 2x fibers contain more 
myosin heavy chain per half sarcomere than slow fibers (p<0.001 for both 
CHF and sham, Figure 2). Figure 2B shows a representative silver stained 
gel.
Maximum	force	per	half	sarcomere	myosin	heavy	chain	content
To evaluate the effect of the number of cross-bridges in parallel on the 
maximum force per CSA, maximal force generated by single fibers was 
normalized to myosin heavy chain content per half sarcomere volume. 
Maximum force per myosin heavy chain content per half sarcomere was 
not significantly different between CHF and sham diaphragm for all fiber 
types (Figure 3). Maximum force per myosin heavy chain content per half 
sarcomere was lower in slow fibers than in 2a and 2x fibers for both groups, 
but this difference did not reach significance (Figure 3).
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Figure 2A:	Myosin	heavy	chain	concentration	in	type	slow,	2a	and	2x	fibers	from	the	diaphragm	of	
CHF	rats	are	decreased	compared	to	sham,	for	all	fiber	types.	2B: Myosin heavy chain content per 
half	sarcomere	in	type	slow,	2a	and	2x	fibers	from	the	diaphragm	of	CHF	are	reduced	compared	to	
sham	for	all	fiber	types.	Type	2x	fibers	contained	more	myosin	heavy	chain	per	half	sarcomere	than	
slow	fibers,	 for	both	 the	CHF	and	sham	group.	The	numbers	above	bars	 represent	 the	number	of	
single	fibers	analyzed.	2C: Representative silver stained gel loaded with; rat diaphragm homogenate, 
single	fibers	from	the	diaphragm	of	CHF	and	sham	rats,	and	myosin	standards.	Data	are	presented	
as	mean	±	SE.	*	p	<	0.05	different	from	sham	group.	†	p	<	0.001	compared	to	type	slow	within	group.	
Abbreviations:	CHF	=	congestive	heart	failure,	MHC	=	myosin	heavy	chain
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3Figure 3. Single fiber maximum force per half sarcomere myosin heavy chain content in 
type slow, 2a and 2x from the diaphragm of CHF and sham-operated rats.	Maximum	force	
normalized	for	half	sarcomere	myosin	heavy	chain	content	provides	an	estimation	for	the	average	
force	generated	per	 cross-bridge.	Maximum	force	per	half	 sarcomere	myosin	heavy	chain	content	
was	not	significantly	different	between	CHF	and	sham	diaphragm	for	all	fiber	types.	The	numbers	
above	bars	represent	the	total	number	of	single	fibers	analyzed.	Data	are	presented	as	mean	±	SE.	
Abbreviations:	CHF	=	congestive	heart	failure,	MHC	=	myosin	heavy	chain
Fraction	of	cross-bridges	in	strongly	attached	state	during	maximal	activation
Maximum force also depends on the fraction of all available cross-bridges 
that are in the strongly attached state during maximal activation. The 
fraction of cross-bridges in the strongly attached state during maximal 
activation was not significantly different between diaphragm muscle single 
fibers from CHF and sham rats (Figure 4).
Figure 4. Fraction of strongly attached cross-bridges (αfs) at maximal activation. 
Fraction	of	strongly	attached	cross-bridges	at	maximal	activation	was	not	significantly	different	
between	type	slow,	2a	and	2x	fibers	from	the	diaphragm	of	CHF	and	sham-operated	rats.	The	
numbers	above	bars	represent	the	total	number	of	single	fibers	analyzed.	Data	are	presented	as	
mean	±	SE.	Abbreviations:	CHF	=	congestive	heart	failure
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Cross-bridge cycling kinetics
The rate constant of force redevelopment (ktr) was slower in diaphragm 
muscle fibers from CHF rats than sham fibers  (p<0.05, Figure 5). As 
expected, ktr of type 2a and 2x fibers was significantly faster than in slow 
fibers in both groups (p<0.01, Figure 5). Figure 5B shows representative 
force redevelopment signals for the different fiber types.
Figure 5. The rate constant of force 
redevelopment (ktr) was used as a 
measure for cross-bridge cycling 
kinetics. 5A: ktr in type slow, 2a 
and	 2x	 fibers	 from	 the	 diaphragm	 of	
CHF	 was	 slower	 than	 in	 diaphragm	
fibers	 from	sham-operated	rats.	ktr	at	
maximal	 activation	 was	 significantly	
faster	 in	 type	 2a	 and	 2x	 fibers	 than	
in	 slow	 fibers,	 for	 both	 groups.	 	 The	
numbers above bars represent the total 
number	of	single	fibers	analyzed.	5B: 
Representative	 plots	 of	 force	 versus	
time	during	 the	 ktr	 protocol	 for	 slow	
fibers	(panel	B1),	2a	fibers	(panel	B2)	
and	 2x	 fibers	 (panel	 B3).	After	 rapid	
detachment	 of	 all	 cross	 bridges	 force	
redevelops	 from	 zero	 according	 to	 a	
first-order	 exponential	 curve.	The	 ktr	
value	 represents	 the	 time	 constant	 of	
this curve. Data are presented as mean 
±	SE.	 *	p	<	0.05	different	 from	sham	
group.	 †	 p	 <	 0.01	 compared	 to	 type	
slow within group. Abbreviations: 
CHF	=	congestive	heart	failure
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Ca2+	sensitivity	of	force	generation
The force-pCa curves for slow and 2x fibers of CHF rats are shifted 
rightwards compared to sham (Figure 6). Consequently, the negative 
logarithm of the Ca2+ concentration required for half-maximal activation 
(pCa50) is significantly reduced for type slow and 2x diaphragm fibers 
from CHF rats compared to sham (5.36±0.05 vs. 5.73±0.02, p<0.01 for type 
slow and 4.91±0.06 vs. 5.16±0.04, p<0.05 for type 2x, CHF and sham fibers 
respectively). The pCa50 of type 2x fibers was significantly lower compared to 
slow fibers in both groups (p<0.001). Hill coefficients were not significantly 
different between CHF and sham fibers (1.9±0.2 vs. 1.8±0.2, for type slow 
and 2.3±0.2 vs. 2.6±0.3 for type 2x, CHF and sham fibers respectively). The 
Hill coefficients for type 2x fibers were significantly higher than for slow 
fibers, in the sham group (p<0.01). Due to a limited presence of 2a fibers in 
the rat diaphragm we were unable to measure the force-pCa relation of a 
sufficient amount of 2a fibers in both CHF and sham group. 
Figure 6.  Force-pCa relation of single fibers from the diaphragm of CHF and sham-operated 
rats.	 Isometric	 force	generated	 in	 response	 to	 incubation	of	 single	fibers	with	 incremental	 [Ca2+] 
was	determined.	Force-pCa	relations	of	CHF	diaphragm	slow	and	2x	fibers	are	shifted	to	the	right	
compared	to	sham.	Data	are	presented	as	mean	±	SE.	Abbreviations:	CHF	=	congestive	heart	failure,	
pCa	=	-log[Ca2+]
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Caspase-3 activity
Caspase-3 activity of diaphragm homogenates was ~1.3-fold higher for 
CHF compared to sham  rats (p < 0.05, Figure 7).
Proteasome activity and content
The proteasome activity against both the substrate LLVY and LLE were 
~1.6-fold higher in diaphragm from CHF rats compared to sham rats 
(p<0.05, Figure 8A). To investigate if changes in proteasome activity are the 
result of changes in the number of proteasomes, we determined the protein 
level of the C8 subunit of the 20S proteasome. Figure 8B demonstrates that 
the protein levels of the 20S proteasome C8 subunit were not significantly 
different between the diaphragm from CHF  and sham  rats. 
Figure 7. Caspase-3 activity in the diaphragm of CHF (n=10) and sham-operated (n=10) 
rats.	 Caspase-3	 activity	 against	 the	 fluorogenic	 substrate	N-acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin	(Ac-DEVD-AMC)	was	higher	in	the	diaphragm	homogenates	from	CHF	than	in	
sham-operated	rats.	Data	are	presented	as	mean	±	SE.	*:	p	<	0.05	difference	from	sham.	Abbreviations:	
CHF	=	congestive	heart	failure,	AMC	=	amido-4-methylcoumarin
DISCUSSION
The present study is the first to investigate the effects of CHF on diaphragm 
skinned single fiber function. The data from our study show that single 
fibers from the diaphragm of CHF rats generate less force per cross sectional 
area, for every fiber type. In these fibers, myosin heavy chain content per 
half sarcomere was concomitantly reduced. Therefore, when normalized 
for myosin content per half sarcomere, maximum force of diaphragm fibers 
was not different between CHF and sham operated rats, for every fiber 
type. In addition to reduced maximal force generation, CHF decreased Ca2+ 
sensitivity of force generation and slowed cross-bridge cycling kinetics in 
every fiber type. Finally, CHF enhanced caspase-3 and proteasome activity 
in the diaphragm. 
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Figure 8   Proteasome activity and content in the diaphragm of CHF (n=6) and sham-operated 
(n=6) rats.	 8A:	 Proteasome	 activity	 against	 fluorogenic	 substrates	 succinyl-leu-leu-val-tyr-7-
amido-4-methylcoumarin	(LLVY)	and	N-carbenzoxy-leu-leu-glu-7-amido-4-methylcoumarin	(LLE)	
was	higher	in	CHF	than	in	sham-operated	rats.	8B:	Subunit	C8	protein	content	was	determined	in	
diaphragm	homogenates	by	Western	blotting	and	subsequent	densitometric	quantification	of	protein	
bands.	Upper	panel:	our	analyses	revealed	no	significantly	different	contents	of	subunit	C8	in	the	
diaphragm	of	CHF	and	 sham-operated	 rats.	Lower	panel:	 representative	C8	 subunit	 immunoblot	
from	diaphragm	homogenates	from	CHF	and	sham-operated	rats.	Data	are	presented	as	mean	±	SE.	
*:	p	<	0.05	difference	from	sham.	Abbreviations:	CHF	=	congestive	heart	failure,	AMC	=	amido-4-
methylcoumarin.
Comparisons	of	control	data	with	
other studies
Single fiber specific force in 
sham rats was not different 
between fiber types, which 
is in line with previous 
publications from other groups 
40,41, although some controversy 
exists 13,42. In agreement with 
the first report on diaphragm 
fiber type differences in cross-
bridge cycling kinetics 14, the 
present study shows that ktr of slow fibers is lower than for fast (2x and 
2a) fibers. Differences in myosin heavy chain content per half sarcomere, 
calcium sensitivity and Hill coefficients between fiber types are also in 
accordance with previous studies on rat diaphragm fibers 15,23,43. However, 
absolute values of myosin content per half sarcomere and pCa50 in sham 
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diaphragm single fibers were slightly different from reports by other 
groups 15,40 23.  These differences could possibly have arisen from the use 
of dissimilar compositions of activating solutions, animal race and age. 
Nevertheless, it is unlikely that the discrepancies can explain the significant 
differences between sham and CHF diaphragm fiber contractile properties 
presented in this study. Values of CSA and αfs of sham diaphragm fibers 
were comparable with results of previous studies on rat diaphragm fibers 
22,23.
Causes	of	impaired	diaphragm	muscle	single	fiber	contractility	in	CHF
Diaphragm muscle bundle isometric contractility has been evaluated in 
several animal models for CHF 8,9,10. However, no previous studies have 
investigated the contractile performance of diaphragm muscle single fibers 
in CHF. This study shows that maximal force generating capacity of skinned 
single fibers from the diaphragm of CHF rats is reduced in all fiber types. 
This suggests that the reduced maximal force generation of the diaphragm 
in CHF patients 6 and animal models 8,9,10 is not merely attributable to a 
fiber type shift, but rather to a decrease of maximal force generation of 
individual fibers. 
Maximal force generation of skinned muscle fibers is determined by the 
sum of forces generated by individual cross-bridges 18, 13. 
Therefore:
Fmax = n ×	fm ×	αfs
where	n	is	the	number	of	available	cross-bridges	in	parallel	per	half	sarcomere,	fm is 
the	mean	force	per	attached	cross-bridge	in	the	force	generating	state,	and	αfs	is the 
fraction	of	all	available	cross-bridges	that	are	in	the	strongly	attached	state.
The reduced maximal force generation of the diaphragm muscle fibers 
from CHF rats should be reflected by a reduction in one or more of these 
determinants. Indeed, we showed that myosin heavy chain concentration 
was decreased in all fiber types in the diaphragm from CHF rats (Figure 
2A). As fiber CSA’s were not different between groups this indicates that 
myosin heavy chain content per half sarcomere was significantly reduced 
in CHF fibers compared to sham (Figure 2B). This reduction causes a 
proportional decrease in the number of available cross-bridges in parallel 
per half sarcomere (n). The fraction of cross-bridges in the force generating 
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state during maximal activation (αfs, figure 4) was not different between 
diaphragm fibers from CHF and sham-operated rats. Also, the mean force 
per attached cross-bridge (fm), which can be derived from the maximum 
force per half sarcomere myosin heavy chain content (figure 3) and αfs (see 
formula), did not differ between both groups. Therefore the reduction 
in maximal force generation of diaphragm fibers from CHF rats can be 
mainly explained by the loss of myosin heavy chain content (n) in these 
fibers, although the involvement of other processes cannot be excluded. A 
recent study showed no differences of myosin heavy chain content between 
diaphragm homogenates of Dahl salt-sensitive rats with heart failure and 
without heart failure 44. Next to a different animal model of heart failure 
that was used in that study, another reason for dissimilar results lies in the 
difference in reliability of the methods that were used to measure myosin 
heavy chain content. Measuring myosin content in diaphragm homogenates 
is sensitive for differences in the amount of connective tissue and fiber 
type distribution, whereas this variance is omitted in myosin content 
determinations on single fibers, as was done in the present study. Moreover, 
correcting myosin content for the total amount of protein in diaphragm 
homogenates underestimates a loss of myosin, as myosin constitutes a 
significant fraction of the total protein amount. Correcting myosin content 
for fiber volume in single fibers is therefore more accurate.
The most important findings of this study include decreased maximal 
force generation together with a loss of myosin in CHF diaphragm fibers. 
However, in vivo the diaphragm does not perform maximal isometric 
contractions during normal breathing, but shortens against a certain load. 
Therefore, sub-maximal and kinetic parameters of single fiber measurements 
provide more relevant physiological information. The rightward shift of 
the pCa-force curve displays that at a certain Ca2+ concentration, a smaller 
percentage of maximal force is generated in diaphragm fibers from CHF 
rats compared to sham. In other words, Ca2+ sensitivity of force generation 
is reduced. This implies that force generation in the CHF diaphragm is 
even more affected at sub-maximal than at maximal activation, which is 
in line with a previously observed rightward shift of the force-frequency 
relation in CHF diaphragm bundles 12. The decreased rate constant of force 
redevelopment shows that cross-bridge cycling kinetics are slower in CHF 
diaphragm fibers compared to sham. This observation is in accordance 
with the decreased in vitro sliding velocities of myosin, isolated from the 
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diaphragm of CHF rats, recently described by Coirault et al. 11. However, by 
using an in vitro motility assay Coirault et al. could not exclude a possible 
effect of fiber type shift on the decreased sliding velocities of myosin. Our 
single fiber data unambiguously show that slower cross-bridge kinetics is 
an intrinsic phenomenon of all fiber types in the CHF diaphragm. 
The causes of slower cross-bridge cycling kinetics and decreased Ca2+ 
sensitivity in the CHF diaphragm remain speculative. Previous studies 
showed that increased filament lattice spacing result in slower rates of 
tension redevelopment 45 and decreased Ca2+ sensitivity 46. Indeed in our 
study, myosin content per half sarcomere is reduced in the CHF diaphragm 
(Figure 2) without alterations of CSA, indicating increased filament lattice 
spacing. Thus, myosin loss in CHF diaphragm fibers could not only result 
in decreased maximal force generation, but may as well affect sub-maximal 
and kinetic parameters of diaphragm contractility. Besides, modification of 
the myosin head or the Ca2+ binding protein complex troponin could also 
account for slower cross-bridge kinetics and reduced Ca2+ sensitivity 47,48,49. 
For example, in their in vitro motility study, Coirault et al. showed that the 
decreased sliding velocities of myosin are associated with increased levels 
of myosin oxidation in the diaphragm of CHF rats 11. However, further 
studies on filament lattice spacing and post-translational modifications 
of contractile proteins are needed to establish the precise origin of slower 
cross-bridge kinetics and decreased Ca2+ sensitivity in CHF diaphragm 
fibers.
Pathways	towards	a	loss	of	myosin	heavy	chain	content	in	CHF	
The loss of myosin heavy chain in the CHF diaphragm suggests an 
imbalance between the synthesis and degradation of this contractile 
protein. In peripheral skeletal muscles of CHF patients, rates of myosin 
heavy chain synthesis were not different from control patients, whereas 
the decrease in muscle strength was closely related to the loss of myosin 20. 
This suggests that enhanced degradation of myosin needs to be involved. 
Indeed, recent studies have indicated that the degradation of myosin plays 
an important role in diseases associated with diaphragm 27 and peripheral 
muscle wasting 25,50, including CHF 51. It is well recognized that myofibrillar 
proteins such as myosin are degraded by the ubiquitin-proteasome 
pathway 52,53,54. The present study shows that the activity of the ubiquitin-
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proteasome pathway is increased in the CHF diaphragm. More specifically, 
these data indicate that the proteolytic activity per proteasome is increased 
rather then the number of proteasomes. Thus in the CHF diaphragm, the 
loss of myosin heavy chain is associated with an increased activity of the 
ubiquitin-proteasome pathway. 
Since the ubiquitin-proteasome pathway is unable to degrade intact 
actomyosin complexes 55,  preceding cleavage of these proteins from the 
sarcomere is necessary for subsequent degradation. The exact mechanisms 
for cleaving contractile proteins from the sarcomere are unknown, but 
an important role is ascribed to proteolytic enzymes, such as calpains 56,57 
and caspase-3 26,58.  Previously, a twofold increase of calpain activity in the 
diaphragm of CHF rats has been reported 59. This study demonstrates that 
caspase-3 activity is enhanced in the CHF diaphragm and is associated 
with loss of myosin and activated proteasomes. However, further studies 
are needed to elucidate the exact role for caspase-3 activation in CHF 
diaphragm weakness.
CONCLUSION
This study shows diaphragm weakness at the single fiber level in a 
myocardial infarction model of CHF. Maximal force generation of
diaphragm muscle single fibers from CHF rats is reduced and can be 
explained by a decreased myosin heavy chain content in all fiber types. 
Additionally, cross-bridge kinetics are slower and Ca2+ sensitivity is 
decreased in the diaphragm fibers of CHF rats. Finally, CHF diaphragm 
weakness and the loss of myosin heavy chain are associated with an 
increased activation of the ubiquitin proteasome pathway and its upstream 
proteolytic enzyme caspase-3.
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Chapter 4
Proteasome inhibition improves diaphragm 
function in congestive heart failure rats
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ABSTRACT
Rationale In congestive heart failure (CHF) diaphragm weakness is known 
to occur and is associated with myosin loss and activation of the ubiquitin-
proteasome pathway. The effect of modulating proteasome activity on 
myosin loss and diaphragm function is unknown. The present study 
investigated the effect of in vivo proteasome inhibition on myosin loss and 
diaphragm function in CHF rats. 
Methods Coronary artery ligation was used as animal model for CHF. 
Sham-operated rats served as controls. Animals were treated with the 
proteasome inhibitor bortezomib (iv) or received saline (0.9%) injections. 
Force generating capacity, cross-bridge cycling kinetics and myosin 
content were measured in diaphragm single fibers. Proteasome activity, 
caspase-3 activity and MuRF-1 and MAFbx mRNA levels were determined 
in diaphragm homogenates. 
Main Results Proteasome activities in the diaphragm were significantly 
reduced by bortezomib. Bortezomib treatment significantly improved 
diaphragm single fiber force generating capacity (~30-40%) and cross-
bridge cycling kinetics (~20%) in CHF. Myosin content was ~30% higher in 
diaphragm fibers from bortezomib treated CHF rats than  saline. Caspase-3 
activity was decreased in diaphragm homogenates from bortezomib 
treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the 
diaphragm and bortezomib treatment diminished this rise. 
Conclusion The present study demonstrates that treatment with a clinically 
used proteasome inhibitor improves diaphragm function by restoring 
myosin content in CHF.  
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INTRODUCTION
The diaphragm is the main inspiratory muscle. Weakness of the diaphragm 
is associated with dyspnea and increased morbidity and mortality in 
patients with congestive heart failure (CHF) 1,2,3. Although mechanisms 
of impaired respiratory muscle function are incompletely understood, 
recent work from our group  point towards a prominent role for enhanced 
myosin degradation through the ubiquitin-proteasome pathway 4,5,6. This 
is of interest as muscle strength strongly depends on myosin content 7,8. In 
CHF rats, single fibers dissected from the diaphragm generate less force 
compared to diaphragm fibers of sham-operated rats 6. Reduction in force 
generating capacity was proportional to the reduction in myosin content 
in these fibers. Furthermore, diaphragm weakness in CHF was associated 
with increased activity of the proteasome. Although these data indirectly 
suggest  that activation of the ubiquitin-proteasome pathway plays a key 
role in respiratory muscle dysfunction, this was not specifically investigated 
in previous studies.
Bortezomib is the first proteasome inhibitor that has been approved for 
use in humans, to treat patients with multiple myeloma 9, and its use in 
other malignancies is under investigation. Bortezomib is one of the most 
specific and potent proteasome inhibitors currently available 10,11 and 
exhibits relatively mild toxicity 9. Treatment with bortezomib has been 
shown to prevent muscle mass loss in several experimental conditions 
12,13,14. However, these studies did not investigate the effect of proteasome 
inhibition on content of specific contractile proteins and more importantly, 
on muscle function.
The aim of the present study was to investigate the effects of proteasome 
inhibition on diaphragm function and myosin content in CHF rats. We 
hypothesized that proteasome inhibition improves diaphragm function by 
restoring sarcomeric myosin content. 
Essential steps in muscle protein degradation act upstream of the proteasome 
and include ubiquitin-conjugation by specific E3-ligases 15,16 and caspase-3 
activation 17. To further evaluate the mechanisms of contractile protein 
degradation, we examined the effect of bortezomib on these steps. 
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MATERIALS & METHODS
CHF	animal	model
Myocardial infarction was induced by ligation of the left coronary artery, 
as described previously 6,18,19. Briefly, adult male Wistar rats (250 to 300 
g) were anesthetized by inhalation of an isoflurane-oxygen mixture (2-
5% isoflurane), intubated, and mechanically ventilated. After a left lateral 
thoracotomy between the fourth and fifth rib, the left coronary artery was 
ligated at its origin by a 5-0 silk suture. Sham-operated rats underwent 
a similar procedure without the actual ligation. After the operation and 
during the following two days, buprenorphine (20 µg/kg, subcutaneously) 
was administered daily for postoperative analgesia. 
At the end of the experiment rats were anesthetized with pentobarbital (70 
mg /kg IP) and mechanically ventilated. Aortic pressure and left ventricular 
pressures were measured by a micromanometer-tipped catheter (SPC 330, 
Millar Instruments, Texas, USA) inserted through the right carotid artery. 
After a combined thoractomy/laparotomy, the diaphragm muscle and 
adherent ribs were quickly excised and divided in parts. One part was 
snap-frozen in liquid nitrogen and stored at – 80 ºC for later biochemical 
analyses and the other parts were prepared for contractile measurements. 
As described previously, heart weight and infarct size were determined 
and lung wet to dry ratio was assessed 6. Only data from rats with infarcts 
>35% of the left ventricle (n = 25) were analyzed. This study was approved 
by the Animal Ethics Committee, Radboud University Nijmegen, The 
Netherlands. During the experiments animals were fed ad libitum.
Treatment with proteasome inhibitor
Thirteen weeks after coronary artery ligation (n = 25) or sham-operation (n 
= 17), animals were randomly assigned to bortezomib treatment or control 
group. Bortezomib (Velcade®, Millennium Pharmaceuticals, Cambridge, 
MA) was injected intravenously (1.3 mg/m2 body surface area) on days 1, 4, 
8 and 11. Similar dose and scheme were previously used in a phase 2 study 
of bortezomib for the treatment of multiple myeloma 9. Control animals 
were injected on the same days with an equal volume (0.6 ml) of the vehicle 
saline (0.9%). One hour after the last injection animals were sacrificed as 
described above. 
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Measurement	of	proteasome	activity
Proteasome activity was determined as described previously 5,6. 20S 
proteasomes were isolated from solubilized diaphragm samples in ice-cold 
buffer (pH 7.5) containing 50 mM Tris-HCl, 5 mM MgCl2, 250 mM sucrose, 
1 mM 1.4-dithiothreitol, 0.2 mM phenylmethylsulphonylfluoride, and 
protease inhibitor cocktail (Sigma Aldrich, Zwijndrecht, the Netherlands). 
After three sequential centrifugation steps of the supernatants; 10,000 g (20 
min.), 100,000 g (1h.) and 100,000 g (5h.), the final pellet was resuspended in 
buffer (pH 7.5) containing 50 mM Tris-HCl, 5 mM MgCl2, and 20% glycerol. 
The protein content of the proteasome preparation was determined based 
on Bio-Rad Protein Assay (Bio-Rad, Veenendaal, the Netherlands). The 
proteolytic activity of the 20S proteasome extracts (15 µg) was determined 
by measuring the activity against the fluorogenic substrates succinyl-
leu-leu-val-tyr-7-AMC (LLVY-AMC) (Sigma-Aldrich, Zwijndrecht, The 
Netherlands). The peptidase activity was determined by measuring the 
generation of the fluorogenic cleavage product (AMC) at 355 nM excitation 
wavelength and 460 nM emission wavelength. AMC standards were used 
to quantify activity levels. Addition of a specific proteasome inhibitor (MG-
132) confirmed specificity of the assay.
Diaphragm	muscle	single	fiber	contractile	measurements
Single fiber contractile measurements and experimental protocol were 
performed according to previously described methods 6. In short, a 
rectangular bundle from the central costal region of the right hemi-
diaphragm was dissected, parallel to the long axis of the muscle fibers. The 
muscle bundle was transferred to relaxing solution (5°C) containing 1% 
Triton X-100 to permeabilize lipid membranes. Subsequently, single fibers 
were isolated from the muscle bundle, attached to aluminum foil clips 
and mounted in a temperature-controlled (20 °C) flow-through acrylic 
chamber (120-µl volume) on two hooks connected to a force transducer 
(model AE-801; SensoNor, Horten, Norway) and a servomotor (model 
308B; Aurora Scientific, ON, Canada). Sarcomere length was set at 2.4 µm 
as the optimal length for force generation. Muscle fiber cross-sectional 
area was deduced from fiber width and depth measurements using a 
reticule in the microscope eyepiece. MIDAC software (Radboud University 
Nijmegen, the Netherlands) and a data-acquisition board were used to 
record signals. Maximum isometric force was determined by measuring 
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force after perfusing the experimental chamber with, successively, pCa 9.0 
and pCa 4.0 solutions. Maximum specific force was derived from dividing 
maximum isometric force by fiber cross-sectional area. The rate constant 
for tension redevelopment (ktr) was measured as described by Brenner 
and Eisenberg 20 during activation at pCa 4.0. In short, fibers were rapidly 
released by 15% and then 50 ms later, restretched to their original length. 
During the rapid release and restretch, cross-bridges detach and force 
drops to zero. The cross-bridges then reattach, and force redevelops. As 
published previously 21, the ktr value was determined using a computer 
algorithm for least-squares fit of a first-order exponential.
Myosin	 heavy	 chain	 isoform	 composition	 and	 content	 per	 half	 sarcomere	
determination
Determination of myosin heavy chain isoform composition and content 
by SDS-PAGE was described previously 6 and adapted from Geiger et al. 8. 
In short, single fibers were detached from the force transducer and servo-
motor and solubilized in 25 µl SDS sample buffer. Sample volumes of 8 
µl were loaded on 7% SDS-polyacrylamide gels to separate proteins. Gels 
were silver stained according to the procedure described by Oakley et al. 
22. Myosin heavy chain isoforms were identified by comparing migration 
patterns with those of control rat diaphragm bundle samples run on 
the same gels. After densitometer imaging (Syngene, Cambridge, UK) 
myosin heavy chain content in the muscle fibers was deduced from the 
optical densities of known contents of purified rabbit myosin heavy chain 
(Sigma Aldrich, Zwijndrecht, the Netherlands) run on every gel. Myosin 
heavy chain content per half sarcomere, at sarcomere length of 2.4 µm, 
was calculated through dividing fiber myosin heavy chain content by the 
number of half-sarcomeres (2 × length of fiber(µm)/2.4(µm)).
Western	blots
For determining the proteasome content diaphragm samples were 
homogenized in ~200 μl ice-cold buffer (pH 7.5), containing 50 mM Tris, 
1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulphonylfluoride 
(PMSF), and protease inhibitor cocktail (Sigma Aldrich, Zwijndrecht, the 
Netherlands). Homogenates were centrifuged at 10,000 g, 4 °C for 10 min. 
For determining the amount of ubiquitinated myosin and total myosin, 
diaphragm samples were homogenized in 100 volumes ice-cold buffer pH 
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7.4 (20mM Tris, 20 mM EGTA, 1mM DTT, protease inhibitor cocktail, 0,5% 
SDS), boiled for 1 min. and centrifuged at 13,000 x g, 20 °C for 5 min. After 
protein concentration determination of the resulting supernatants soluble 
proteins were subjected to routine Western blotting using polyacrylamide 
SDS-gels and specific antibodies (anti-20S proteasome subunit C8, Affiniti, 
Gorinchem, the Netherlands; anti-poly-ubiquitin, Biomol, Exeter, UK; anti-
myosin heavy chain; Upstate Millipore, Amsterdam, the Netherlands). 
After washing, blots were incubated with a horseradish peroxidase 
conjugated goat anti-mouse antibody (Pierce, Ettenleur, the Netherlands) 
for subsequent chemiluminiscent detection. Protein bands were quantified 
using optical densitometry software (GeneTools, Syngene, UK).
MuRF-1	and	MAFbx	mRNA	determination	with	real-time	quantitative	PCR
MuRF-1 and atrogin/MAFbx mRNA were determined as described 
previously 5,23. Total RNA was extracted from diaphragm samples using 
Trizol Reagent (Invitrogen, Carslbad, CA) and dissolved in diethylpyro-
carbonate (DEPC)-treated water. Total RNA was reverse transcribed 
into cDNA using 50 ng of total RNA in a 20µl reaction volume by using 
SuperScriptTM Reverse Transcriptase (Invitrogen, Carlsbad, CA). 
Quantitative PCR was performed in a total reaction volume of 25 µl per 
reaction, containing 12.5 µl of a SYBR green mix (Bio-Rad), 10 pmol of each 
forward and reverse primer, 1μl cDNA and nuclease free water. Specific 
primer sets for rat MAFbx, MuRF-1 and Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were purchased from SuperArray (Frederick, 
MD). PCR runs were performed in triplicate using MyiQ real time PCR 
detection system (Bio-Rad, Salt Lake City, UT). Levels of MAFbx and 
MuRF-1 mRNA were normalized to that of GAPDH in arbitrary units.
Measurement	of	caspase-3	activity
Caspase-3 activity was determined as described previously 5,6. Frozen 
diaphragm samples were homogenized in a buffer containing 100 mM 
HEPES (pH 7.5), 10% sucrose, 0.1% Nonidet P-40, 10 mM dithiothreitol, and 
protease inhibitor cocktail (Sigma Aldrich). Homogenates were subjected to 
three cycles of freeze-thaw before centrifugation at 18,000 g for 30 min. and 
the supernatant (92,5 μg) was added to reaction buffer consisting of 100 mM 
HEPES (pH 7.5), 10% sucrose, and 10 mM dithiothreitol. The fluorogenic 
substrate N-acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-
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DEVD-AMC) was then added and the reaction was performed at 30°C for 
60 min. The caspase-3 activity was determined by measuring the generation 
of the fluorogenic cleavage product methylcoumarylamide (AMC) from 
the fluorogenic substrate Ac-DEVD-AMC at 360 nM excitation wavelength 
and 460 nM emission wavelength. AMC standards were used to quantify 
activity levels. Specificity of the assay was confirmed by addition of the 
specific caspase-3 inhibitor Ac-DEVD-CHO the reaction mixture.
Data treatment & statistical methods
All data represent the mean ± SE of at least 6 animals in each group. Single 
fiber data were grouped per fiber types slow and 2x and averaged per 
rat, with 2-4 fibers measured per rat. Differences between groups were 
analysed with a one-way ANOVA. Student-Newman-Keuls post hoc testing 
was performed on data from CHF saline vs. CHF bortezomib groups and 
sham saline vs. sham bortezomib groups. Because of a limited amount of 
diaphragm tissue per rat, proteasome activity, caspase-3 activity, MuRF-1 
and MAFbx mRNA levels and Western blotting studies are not based on 
the same animals, although there is extensive overlap. A probability level 
of p < 0.05 was considered significant unless otherwise indicated.
Table 1 Animal characteristics
Data are presented as mean ± SE * p < 0.05 vs. Sham-Saline
Abbreviations: BW = body weight, SP = systolic pressure, DP = diastolic pressure, 
LV =  Left ventricle, LW = lung weight
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RESULTS
CHF	indexes
As previously reported 6, CHF was characterized by reduced systolic and 
elevated diastolic left ventricular pressures, pulmonary congestion and 
cardiomegaly (Table 1). Bortezomib treatment did not significantly affect 
bodyweight and the severity of heart failure, as indicated by similar blood 
pressures, heart weights, infarct sizes and lung weight wet to dry ratios in 
CHF rats treated with bortezomib and saline. 
Proteasome activity
20S proteasome activity was higher in the diaphragm from CHF-saline rats 
than sham-saline (p < 0.05) and bortezomib treatment significantly inhibited 
proteasome activity in both CHF and sham rats (Figure 1A). To investigate 
if changes in proteasome activity are the result of changes in the number of 
proteasomes, we determined the protein level of the C8 subunit of the 20S 
proteasome. Figure 1B demonstrates that CHF and bortezomib treatment 
did not significantly affect proteasome content in the diaphragm. 
Diaphragm	muscle	single	fiber	contractility	
In line with our previous findings 6, CHF decreased maximal force generation 
in rat diaphragm single fibers (p < 0.01, Figure 2A). Bortezomib treatment 
increased maximal force generation in diaphragm fibers from CHF rats 
(p < 0.05). The rate constant of force redevelopment (ktr) was used as a 
measure for cross-bridge cycling kinetics. ktr was lower in diaphragm fibers 
from CHF saline rats than sham (p < 0.01, Figure 2B). Bortezomib treatment 
improved ktr in CHF diaphragm fibers (p < 0.01). In sham, however, no 
effect of bortezomib treatment on maximal force generation and ktr was 
observed. These findings were observed in two most predominant rat 
diaphragm fiber types; slow and 2x. 
Diaphragm	single	fiber	myosin	content
Myosin content per half sarcomere was reduced in diaphragm fibers from 
CHF-saline rats compared to sham-saline (p < 0.05, Figure 3A). Bortezomib 
treatment increased myosin content per half sarcomere in CHF diaphragm 
fibers of both type slow and 2x (p < 0.05). In sham, bortezomib did not alter 
myosin content per half sarcomere. Cross-sectional area of diaphragm fibers 
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were not significantly affected by CHF or bortezomib treatment (Figure 
3B). Alterations in maximal force generating capacity were proportional to 
changes in myosin content per half sarcomere (Figure 3C).
Figure 1A:	 Proteasome	 activity	 in	 diaphragm	 of	 CHF	 and	 sham-operated	 rats	 treated	 with	
proteasome	inhibitor	bortezomib	or	saline	(n	=	6-7	per	group).	Proteasome	activity	was	significantly	
higher	in	CHF	saline	diaphragm	than	in	sham	saline	and	bortezomib	treatment	significantly	reduced	
proteasome activity in the rat diaphragm. AMC = amido-4-methylcoumarin. Data are presented as 
mean	±	SE.	*	p	<	0.05	vs.	Sham	saline,†	p<	0.01	vs.	CHF	saline.	
1B:	Proteasome	subunit	C8	content	as	determined	by	Western	blotting.	Left:	Signals	on	blots	were	
quantified	with	densitometry	software.	Bortezomib	did	not	affect	the	amount	of	proteasomes	in	rat	
diaphragm.	Data	 are	 presented	 as	mean	±	SE.	Right:	Representative	 immunoblots	 of	 proteasome	
subunit C8.
Figure 2. Diaphragm contractility in chemically skinned single fibers from CHF and sham-
operated rats treated with proteasome inhibitor bortezomib or saline (n = 6-8 per group). 
Fibers	are	grouped	per	myosin	heavy	chain	isoform	slow	and	2x.	
2A:	Maximal	force	generation	in	diaphragm	fibers	from	CHF	saline	rats	was	decreased	compared	to	
sham.	Bortezomib	treatment	improved	force	generating	capacity	in	CHF	diaphragm	fibers,	but	not	
in	sham.	CSA	=	cross	sectional	area,	Fmax	=	Maximal	force	at	pCa	4.0.	Data	are	presented	as	mean	
±	SE.	*	p	<	0.01	vs.	Sham	saline,†	p	<	0.05	vs.	CHF	saline.
2B:	The	rate	constant	of	force	redevelopment	(ktr)	was	lower	in	diaphragm	fibers	from	CHF	saline	
rats	compared	to	sham.	Bortezomib	 treatment	 increased	ktr	 in	CHF	diaphragm	fibers,	but	not	 in	
sham.	Data	are	presented	as	mean	±	SE.	*	p	<	0.01	vs.	Sham	saline,†	p	<	0.01	vs.	CHF	saline.
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Figure 3A:	Myosin	heavy	chain	content	per	half	sarcomere	in	diaphragm	fibers	from	CHF	and	sham-
operated	rats	treated	with	bortezomib	or	saline	(n	=	6-7	per	group).	Fibers	are	grouped	per	myosin	
heavy	chain	isoform	slow	and	2x.	Myosin	heavy	chain	content	was	lower	in	CHF	saline	diaphragm	
fibers	than	in	sham.	Bortezomib	increased	myosin	heavy	chain	content	in	CHF	diaphragm	fibers,	but	
not	in	sham.	Fmax=	Maximal	force	at	pCa	4.0.	Data	are	presented	as	mean	±	SE.	*	p	<	0.05	vs.	Sham	
saline,†	p	<	0.05	vs.	CHF	saline.	
3B:	 Cross	 sectional	 areas	 of	 diaphragm	 fibers	 from	 CHF	 and	 sham-operated	 rats	 treated	 with	
bortezomib	or	saline	(n	=	6-7	per	group).	Fibers	are	grouped	per	myosin	heavy	chain	isoform	slow	
and	2x.	CHF	and	bortezomib	did	not	significantly	affect	cross	sectional	fiber	areas.	Data	are	presented	
as	mean	±	SE.
3C:	Maximal	 force	 (Fmax)	 per	 half	 sarcomere	 myosin	 heavy	 chain	 content	 in	 diaphragm	 fibers	
from	CHF	and	sham-operated	rats	treated	with	bortezomib	or	saline	(n	=	6-7	per	group).	Fibers	are	
grouped	per	myosin	heavy	chain	isoform	slow	and	2x.	Neither	CHF	nor	treatment	with	bortezomib	
did	 significantly	 change	maximal	 force	per	half	 sarcomere	myosin	heavy	chain	content.	Data	are	
presented	as	mean	±	SE.
Ubiquitinated myosin levels
Ubiquitinated myosin heavy chain levels were determined by Western 
blotting. Because total myosin content of the diaphragm is affected by both 
CHF and proteasome inhibition (Figure 3), the amount of ubiquitinated 
myosin was normalized for total myosin content. Myosin ubiquitination 
was higher in diaphragm homogenates from CHF rats compared to sham 
(p < 0.05, Figure 4). Bortezomib treatment increased levels of ubiquitinated 
myosin in sham (p < 0.05), but not significantly (p = 0.17) in CHF.
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. 
Figure 4. Ubiquitinated myosin levels in diaphragm from CHF and sham-operated rats 
treated with bortezomib or saline (n = 6-7 per group). Left:	Signals	on	blots	were	quantified	with	
densitometry	software.	The	amount	of	ubiquitinated	myosin	per	total	myosin	in	CHF	diaphragm	is	
higher	than	in	sham.	Ubiquitinated	myosin	levels	increased	in	the	diaphragm	of	bortezomib	treated	
rats	 compared	 to	 saline.	 Right:	 Representative	 immunoblots	 of	 total	 myosin	 and	 ubiquitinated	
myosin.	MHC	=	myosin	heavy	chain.	Data	are	presented	as	mean	±	SE.	*	p	<	0.05	vs.	Sham	saline
MuRF-1	and	MAFbx	mRNA
Compared to sham-saline, mRNA levels of MuRF-1 and MAFbx were 
higher in the diaphragm muscle of CHF-saline rats (p < 0.01, figure 5). 
Bortezomib treatment resulted in a downregulation of MuRF1 and MAFbx 
mRNA expression in CHF (respectively, p < 0.05 and p =0.06), but not in 
sham
Figure 5: E3-ligase mRNA expression in diaphragm of CHF and sham-operated rats treated 
with bortezomib or saline (n = 7 per group).	 MuRF-1	 and	MAFbx	 mRNA	 expression	 are	
higher	in	CHF	saline	diaphragm	than	in	sham	saline.	Bortezomib	treatment	results	in	a	significant	
downregulation	of	MuRF-1	mRNA	in	CHF	diaphragm.	Data	are	presented	as	mean	±	SE.	*	p	<	0.01	
vs.	Sham	saline,†	p	<	0.05	vs.	CHF	saline.
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Caspase-3 activity 
Caspase-3 activity was higher in diaphragm homogenates from CHF-
saline rats than sham-saline (p < 0.05; Figure 6A). Bortezomib treatment 
significantly decreased caspase-3 activity in the diaphragm of CHF and 
sham rats. Inhibition of caspase-3 by bortezomib was an unexpected 
finding. To examine if bortezomib directly inhibits caspase-3, we measured 
cleaving activity of recombinant caspase-3 in the presence and absence of 
25 nM bortezomib in vitro. Bortezomib did not affect recombinant caspase-3 
activity (Figure 6B). However, addition of bortezomib to diaphragm 
homogenates of untreated CHF and sham rats decreased caspase-3 activity. 
This indicates that bortezomib inhibited caspase-3 in an indirect fashion.
Figure 6A. Caspase-3 activity in diaphragm homogenates from CHF and sham-operated rats 
treated with bortezomib or saline (n = 6 per group). Caspase-3 activity was significantly higher 
in CHF saline diaphragm than in sham saline and bortezomib treatment significantly reduced cas-
pase-3 activity in the rat diaphragm. AMC = amido-4-methylcoumarin. Data are presented as mean 
± SE. * p < 0.05 vs. Sham saline,† p < 0.01 vs. CHF saline. 
Figure 6B. The effect of bortezomib in vitro on caspase-3 activity. Diaphragm homogenates and 
recombinant caspase-3 (10 units) were subjected to caspase-3 activity assay in the presence and 
absence of (25nM) bortezomib. Bortezomib in vitro did not affect recombinant caspase-3 cleaving 
rate (circles), while bortezomib distinctly reduced caspase-3 cleaving rate of diaphragm homoge-
nates from saline treated sham rats (triangles) and CHF rats (squares). AMC = amido-4-methyl-
coumarin.
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DISCUSSION
This study is the first to show that modulation of proteasome activity 
improves diaphragm contractility in an animal model associated with 
muscle wasting. Treatment with the proteasome inhibitor bortezomib 
increased diaphragm contractility in CHF rats by restoring myosin 
content. In addition, our data show that proteasome inhibition affects 
mediators upstream of the proteasome, like MuRF-1 and caspase-3. These 
findings improve the understanding of respiratory muscle wasting in CHF 
and provide a rationale for investigating the therapeutic applicability 
of modulating ubiquitin-proteasome activation in muscle wasting 
conditions.
 
Myosin	degradation	by	the	proteasome	in	CHF	diaphragm	
Recently, treatment with bortezomib has been shown to prevent muscle 
weight loss in experimental muscle wasting 12,13,14. In the present study we 
used a clinical dosage of bortezomib to investigate the effect of proteasome 
inhibition on recovery of specific contractile protein loss and muscle 
dysfunction. The contractile protein myosin seems to be selectively targeted 
by the ubiquitin-proteasome pathway during peripheral muscle wasting in 
cancer cachexia 24. In accordance with those observations, our data provide 
additional evidence for proteasome dependent myosin degradation, as in 
vivo proteasome inhibition increased myosin content in the CHF diaphragm 
muscle. 
Of special interest is our finding that restoring myosin content by 
proteasome inhibition partially reverses diaphragm muscle weakness 
in CHF animals. This implicates that diaphragm weakness results from 
increased myosin degradation by the proteasome. Furthermore, the rise in 
maximal force generation is proportional to the rise in myosin content in 
CHF diaphragm fibers (Figure 3C). Thus maximal force per myosin content 
was not affected by bortezomib treatment in CHF. When one presumes 
that bortezomib does not affect the trigger for respiratory muscle wasting, 
at least bortezomib did not change the severity of CHF (Table 1), then these 
data indicate that the proteasome degrades myosin that is not functionally 
compromised. Indeed, the ubiquitin-proteasome pathway plays a key role 
in recognition and subsequent degradation of dysfunctional proteins, but 
is involved in the turnover of functional proteins as well 25,26. Therefore, it 
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seems that diaphragm dysfunction in CHF results from a general imbalance 
between protein degradation and synthesis, rather than from an increased 
degradation of dysfunctional proteins. The effects of proteasome inhibition 
on protein synthesis have not been studied yet. 
Interestingly, bortezomib treatment not only improved maximal force 
generation of CHF diaphragm fibers, but increased the rate constant of 
tension redevelopment as well. The rate constant of tension redevelopment 
is an estimate for cross-bridge cycling kinetics 27 , which are slowed in 
CHF diaphragm 6,28. Impaired cross-bridge cycling kinetics may arise 
from increased oxidation of contractile proteins 21,29,30,31, but could also be 
a result of increased myofilament lattice spacing 32,33. Although we cannot 
exclude that proteasome inhibition affects contractile protein oxidation, 
our data support the involvement of increased myofilament lattice spacing 
in CHF diaphragm dysfunction, as proteasome inhibition restored myosin 
concentration and improved the rate constant of tension redevelopment. 
In the present study, proteasome inhibition in CHF was effective, but did 
not completely restore diaphragm function. Bortezomib incompletely 
inhibited proteasome activities (Figure 1), but it is unlikely that a complete 
proteasome inhibition would fully restore diaphragm function. On the 
contrary, given the fact that the ubiquitin-proteasome pathway serves 
basic housekeeping cell functions, the incomplete inhibition may suggest 
a therapeutic window between beneficial and toxic effects. A more likely 
explanation for incomplete recovery of diaphragm function is the relative 
short duration of treatment with respect to the chronic stage of disease. In 
addition, although the present study demonstrates major accountability for 
the ubiquitin-proteasome pathway in effectuating diaphragm dysfunction, 
we cannot exclude the possible involvement of proteasome independent 
pathways. For example, increased lysosomal degradation and calpain 
activities have also been associated with diaphragm wasting 34. In contrast 
to other proteasome inhibitors, like MG-132 and lactacystin, bortezomib 
is highly specific for the proteasome and does not target these proteolytic 
systems 11.  Thus, the recovery of diaphragm function in the present study 
is most likely to be the result of proteasome inhibition.
Proteasome inhibition in healthy diaphragm
The present study clearly shows that treatment with a highly specific 
proteasome inhibitor improves diaphragm function by restoring myosin 
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content in CHF. Although not the main focus of this study, we also 
determined the effect of bortezomib on diaphragm function in healthy 
animals. Interestingly, proteasome inhibition did not affect diaphragm 
function and myosin content in healthy animals. As myosin is the most 
predominant muscle protein, this observation is in line with previously 
reported unaltered muscle weight of healthy animals treated with bortezomib 
12,13. Thus, treatment with a highly specific proteasome inhibitor restores 
myosin content in pathologic conditions, but proteasome inhibition seems 
not to be sufficient to induce muscle growth, i.e. hypertrophy. Unaltered 
cross-sectional areas of fibers from bortezomib treated rats, both CHF and 
healthy, confirm the absence of fiber hypertrophy (Figure 3B). Therefore, 
our results strongly suggest that recovery of myosin loss and hypertrophy 
follow different mechanisms.
Proteasome inhibition and upstream signaling pathways
Most proteins to be degraded by the proteasome are in advance marked 
for degradation by covalent linkage to a chain of ubiquitin 15,35. Proteasome 
inhibition has previously been demonstrated to result in accumulation 
of ubiquitinated proteins 36. Indeed, in the present study, bortezomib 
treatment increased the levels of ubiquitinated myosin in sham-operated 
rats. Unexpectedly, proteasome inhibition by bortezomib did not 
significantly increase ubiquitinated myosin levels in CHF rats (Figure 4), 
indicating reduced myosin ubiquitination. MuRF-1 plays a prominent role 
in ubiquitination of myosin 37,38. In line with these observations, in our 
study, bortezomib reduced MuRF-1 expression in CHF diaphragm, but 
not in sham (Figure 5), providing an explanation for the absence of raised 
ubiquitinated myosin levels after bortezomib treatment in CHF (Figure 
4). Indeed, reduced expression of E3-ligases after bortezomib treatment 
has been reported previously in burn-induced muscle atrophy 14. The 
mechanism of bortezomib-induced reduction in MuRF-1 expression has 
not been studied.
Regulation	of	caspase-3	by	bortezomib
For improved muscle function myosin should not only be intact and 
functional, but as well have retained its position in the sarcomere. Caspase-3 
is one of the proteolytic enzymes that is thought to cleave myofilaments 
from the sarcomere preceding degradation by the proteasome 17. Previous 
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studies demonstrated that caspase-3 is activated during muscle wasting 
5,6,39,40. The present study shows that bortezomib treatment decreased 
caspase-3 activity in the diaphragm muscle of CHF rats. This could be a 
critical step in prevention of CHF induced atrophy. Furthermore, caspase-3 
inhibition could play a role in diminishing MuRF-1 and MAFbx levels, as 
administration of a caspase-3 inhibitor in muscle-wasted mice decreased 
mRNA expression of these E3-ligases 39. Thus, the effects of bortezomib on 
myosin content and diaphragm function might be mediated by reducing 
caspase-3 activity. 
Our finding that bortezomib treatment decreases caspase-3 activity 
in the diaphragm muscle is surprising, as several studies have shown 
that bortezomib induces apoptosis by activating caspase-3 in cancer 
cell lines 41,42,43,44. Previously, it has been postulated that the effect of 
proteasome inhibition on caspase-3 depends on cell cycle status 45, as 
proteasome inhibition induces apoptosis in proliferating cells, while it 
protects terminally differentiated cells from apoptosis. The muscle fiber is 
terminally differentiated, thus our findings are consistent with the cell cycle 
dependency of proteasome inhibition on caspase-3 activity. Importantly, 
bortezomib in vitro does not affect recombinant caspase-3 (Figure 6B), 
providing evidence for indirect inhibition of caspase-3 by bortezomib. 
For example, decreased proteasomal degradation of caspase-3 inhibitor 
XIAP may play a role 46. Furthermore, a recent study demonstrated that 
bortezomib increased levels of caspase-8 inhibitor c-FLIP 47 and caspase-8 
has been shown to be responsible for caspase-3 activation in an inflammation 
model for diaphragm weakness 48. Thus, it seems that subsequent effects of 
proteasome inhibition, i.e. caspase-3 inhibition, are involved in effectuating 
the recovery of diaphragm function in CHF rats. However, future studies 
with specific caspase-3 inhibitors are needed to establish the exact role of 
caspase-3 activation in CHF diaphragm dysfunction.
 
Bortezomib
Bortezomib is the first proteasome inhibitor approved for use in humans 
and used for treatment of multiple myeloma 9. Bortezomib, is a monomeric 
boronic acid that interacts with a threonine residue located on the β-subunit 
that confers chymotryptic-like proteolytic activity of the 26S proteasome 
49. Peptide boronic acids, such as bortezomib are highly specific and up 
to 100-fold more potent than their peptide aldehyde analogs 10. Together 
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with its relatively mild toxicity 9, this makes bortezomib the best drug 
candidate to study the proteasome dependency of muscle weakness in 
vivo. The present data show that bortezomib treatment (iv) in CHF rats 
reduces proteasome activity in the diaphragm muscle. Although a tendency 
towards decreased proteasome content in bortezomib treated animals was 
observed, differences between groups did not reach statistical significance 
(Figure 1B). This indicates that bortezomib primarily inhibits proteolytic 
activity per proteasome.
In conclusion, the present study demonstrates that in vivo treatment with 
a proteasome inhibitor improves diaphragm contractility by restoring 
myosin content in CHF. Proteasome inhibition may exert these positive 
effects by subsequently affecting caspase-3 and muscle specific E3-ligases. 
Despite its availability for human use, the application of bortezomib in 
CHF is at this moment strictly experimental. Investigating the effectiveness 
of bortezomib in other models for muscle wasting, such as COPD 5, 
mechanical ventilation 50, sepsis 51 and cancer 52 is needed to further 
explore the therapeutic applicability of modulating ubiquitin-proteasome 
activation to recover contractile function in muscle weakness.
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generation of rat diaphragm fibers 
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ABSTRACT
Rationale Diaphragm dysfunction is well-known to limit quality of life 
and prognosis of patients with heart failure (HF), but its underlying 
mechanisms are not well understood. In an animal model for HF we 
recently showed that impaired diaphragm contractility arises at the single 
fiber level and is associated with sarcomeric injuries. For optimal muscle 
function and sarcomeric stability passive elastic structures, like titin, are 
indispensable. The current study aimed to investigate if impaired passive 
elasticity contributes to diaphragm dysfunction in rats with heart failure. 
Methods Skinned muscle fibers were isolated from the diaphragm and 
soleus of rats with chronic HF, induced by left coronary artery ligation 
and of sham-operated rats. Passive tension–length relationships were 
determined by applying segmental extension tests. Immunofluorescence 
was performed on muscle cryosections  using antibodies (T12) against a 
titin epitope near the Z-line. Titin content was determined by SDS-agarose-
gel electrophoresis. Titin’s mobility on gel was studied to detect changes 
in titin size. 
Main Results Passive tension generation upon stretch was significantly 
reduced (>35%) in HF diaphragm fibers compared to sham. Immunostaining 
intensities against titin were reduced in diaphragm cryosections of HF 
rats compared to sham. Soleus fibers from HF and sham rats did not 
display differences, neither in passive tension nor in immunostaining. No 
differences in titin’s size were detected in HF and sham diaphragm. Titin 
content, however, was significantly reduced (~25%) in HF diaphragm. 
Conclusion We conclude that in the diaphragm of HF rats, passive elasticity 
is impaired, mainly resulting from titin loss.
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INTRODUCTION
Heart failure (HF) is a complex clinical syndrome that can result from any 
structural or functional cardiac disorder that impairs the ability of the 
ventricle to fill or eject blood 1.  It is well recognized that in addition to the heart 
HF affects multiple organ systems. Dyspnea is one of the most important 
clinical manifestations of HF and greatly limits daily-life activities of these 
patients. The sensation of dyspnea is closely related to respiratory muscle 
dysfunction 2,3. Moreover, the capacity to generate maximal inspiratory 
pressure is reduced in patients with mild to moderate chronic HF 4 and has 
been identified as an independent predictor of mortality 5. Most studies 
of respiratory muscle dysfunction have focused on the diaphragm, as it is 
the most important inspiratory muscle. Results showed that in diaphragm 
of chronic HF patients a fibre type redistribution towards slow-oxidative 
fatigue-resistant fibers occurs 6. However, this adaptation appears to be 
insufficient to prevent respiratory muscle fatigue in  chronic HF patients 7. 
In an animal model of chronic HF we recently demonstrated that diaphragm 
fibers display reduced force generating capacity independent of fiber type 
8, which implies intrinsic fiber abnormalities. Indeed, electron microscopic 
investigations on the ultra-structure of HF diaphragm fibers revealed 
sarcomeric disruptions 9. For structural stability and optimal active force 
generation, passive-elastic structures are indispensable 10. The giant protein 
titin is the most important passive-elastic structure within the sarcomere 11. 
Titin spans the half-sarcomeric distance from Z-line to M-line and contains 
an elastic segment in the I-band region that develops passive tension upon 
stretch 12. During calcium activation titin maintains the thick filaments 
in a central position within the sarcomere, thereby providing structural 
and mechanical stability of the sarcomere 10,13. As a consequence, impaired 
titin function results in reduced force generating capacity and a loss of 
sarcomeric integrity 10. This led us to hypothesize that titin impairments 
are involved in HF diaphragm dysfunction. To test this hypothesis we 
measured passive tension generation in diaphragm fibers from HF animals 
and studied expression of titin and other sarcomeric proteins. As it has 
been recognized that respiratory and peripheral muscles are differently 
affected by HF 14, we also examined the soleus muscle. 
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MATERIALS & METHODS
HF	animal	model	and	muscle	tissue	collection
Adult male Wistar rats (~290 g) were anesthetized by inhalation of 
an isoflurane-oxygen mixture (2% to 5% isoflurane), intubated, and 
mechanically ventilated. Ligation of the left coronary artery and sham 
operations were performed as described previously 8. At 15 weeks after 
ligation or sham operation, the rats were anesthetized with pentobarbital (70 
mg /kg IP) and mechanically ventilated. Aortic pressure and left ventricular 
pressures were measured by a micromanometer-tipped catheter (SPC 330, 
Millar Instruments, Texas, USA) inserted through the right carotid artery. 
After completing hemodynamic measurements, a combined thoracotomy/
laparotomy was performed, and the diaphragm, lungs, heart and right 
soleus muscle were quickly excised. Heart weight was determined and the 
heart was fixed in formalin for >72h. Subsequently, the size of the infarct 
areas was determined by planimetry, as described previously 15. Only data 
from rats with infarcts >35% of the left ventricle were analyzed. Lungs were 
cleaned of fat and weighed before and after desiccation (3 days at 40°C). 
The right hemi-diaphragm and soleus were divided in two parts. From 
one part a muscle bundle was dissected parallel to the longitudinal axis of 
the muscle fibers, pinned to cork and stored at 4°C in a relaxing solution, 
containing 50% glycerol (vol/vol). After 24 hours the muscle strip was stored 
at -20°C for later analysis of single fiber contractile properties. The other 
part of the right hemi-diaphragm and soleus were snap-frozen in liquid 
nitrogen cooled isopentane and stored at –80 °C for immunofluorescence 
microscopy. The left hemi-diaphragm was quickly frozen in liquid nitrogen 
and stored at –80°C for SDS-agarose gels. This study was approved by the 
local Animal Ethics Committee (Radboud University Nijmegen). 
Single	fiber	passive	tension	determinations
Composition of activating and relaxing solutions was as reported previously 
8. Briefly, relaxing solution consisted of 1.0 mM MgCl2, 4.0 mM Na2ATP, 5 
mM EGTA, 10 mM imidazole, 15 mM creatine phosphate and sufficient 
KCL to adjust the total ionic strength to 150 mM at pH 7.0. The negative 
logarithm of the free Ca2+ concentration (pCa) of the relaxing solution was 
~9.0 while in activating solutions the pCa was 4.0. 
Approximately one hour prior to determination of single fiber contractile 
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properties, the muscle bundle was transferred to relaxing solution (5°C) 
containing 1% Triton X-100 to permeabilize lipid membranes. From 
the muscle bundle ~2mm segments of single fibers were isolated using 
microforceps. Subsequently, the fiber ends were attached to aluminium 
foil clips, and mounted on the single fiber apparatus. Fibers were mounted 
in a temperature-controlled (20 °C) flow-through acrylic chamber (120-μl 
volume), with a glass coverslip bottom, on the stage of an inverted microscope 
(model IX-70; Olympus, Amsterdam, The Netherlands). Two stainless steel 
hooks were used to mount the fiber horizontally in the chamber. One end 
of the fiber was attached to a force transducer (model AE-801; SensoNor, 
Horten, Norway) with a resonance frequency of 10 kHz, whereas the other 
end was attached to a servomotor (model 308B; Aurora Scientific, Aurora, 
ON, Canada) with a step time of 250 µs. In relaxing solution, sarcomere 
length was set at 2.4 μm as the optimal fiber length for force generation 
16,17 with the use of a calibrated eyepiece micrometer. MIDAC software 
(Radboud University, Nijmegen, The Netherlands) and a data-acquisition 
board were used to record signals. Muscle fiber length (~1.0–1.5 mm) was 
measured using a reticule in the microscope eyepiece [×10 Olympus Plan 
10, 0.30 numerical aperture (NA)]. The fiber width was measured with a ×40 
objective [×40 Olympus Plan 40, 0.60 NA]. The ×40 objective also was used 
to measure the fiber depth by noting the displacement of the microscope’s 
objective while focusing on the top and bottom surfaces of the fiber. Three 
width and depth measurements were made along the length of the fiber, 
the average values were used to calculate the fiber cross-sectional area, 
assuming that the fiber was ellipsoid in shape. To ensure stable attachments 
throughout the mechanical protocol, the fiber and clip-hook attachments 
were first exposed to high forces generated in maximal activating solution 
(pCa 4.0). Then the fiber was kept in relaxing solution (pCa 9.0) and passive 
tension–length relationships were determined by applying a repeated 
stretch-hold protocol, as described previously 18 and adapted from Wang 
et al. 19. In short, the stretch protocol was composed of a stretch of 10% of 
optimal length and 60 s hold to allow for stress relaxation. At the end of 
the 60 s hold, passive tension was recorded and normalized to fiber cross 
sectional area. Fibers were stretched 7 times to a final length of 170% of 
optimal fiber length. Sarcomere lengths were obtained by multiplying 2.4 
μm by percentage of optimal fiber length. Passive tensions were plotted 
against sarcomere lengths. Passive tension at each sarcomere length was 
102
Heart	failure	decreases	passive	tension	generation	of	rat	diaphragm	fibers 
expressed as the difference between recorded passive tension and initial 
passive tension (at 2.4 µm).
Single	fiber	myosin	heavy	chain	isoform	determinations
As contractile properties of muscle fibers may depend on fiber type, 
diaphragm fibers were classified as slow or fast according to their myosin 
heavy chain isoform. Determination of myosin heavy chain isoform 
composition by SDS-PAGE was adapted from Geiger et al. 20 and described 
previously 8. Briefly, single fibers were detached from the force transducer 
and servomotor and were placed in 25 μl of SDS sample buffer containing 
62.5 mM Tris-HCl, 2% (wt/vol) SDS, 10% (vol/vol) glycerol, and 0.001% 
(wt/vol) bromophenol blue at a pH of 6.8. The fibers were stored at -20°C 
until they were assayed. The fibers were denaturated by boiling for 2 min. 
The stacking gel contained a 4% acrylamide concentration (pH 6.8), and 
the separating gel contained 7% acrylamide (pH 8.8) with 30% glycerol 
(vol/vol). As a reference, samples of healthy rat diaphragm bundles were 
run on the gels for comparison of migration patterns of the myosin heavy 
chain isoforms. Sample volumes of 8 µl were loaded per lane. The gels were 
silver stained according to the procedure described by Oakley et al. 21.
SDS-agarose gel electrophoresis
Content of the major sarcomeric proteins titin, myosin heavy chain 
and nebulin were identified as described previously 18. In short, frozen 
diaphragm samples were first weighed and then pulverized to a fine 
powder and solubilized at 60°C in sample buffer (1 mg of tissue per 80 
µl) containing 8M Urea, 2M Thiourea, 3% SDS, 75mM DTT, 0.05M Tris-
HCl, 0.03% bromophenol blue, 25% glycerol and 10 µM leupeptin, 10 µM 
E64 and 0.5 mM phenylmethylsulfonylfluoride (PMSF), pH adjusted to 
6.8. Samples were loaded on SDS-agarose (1%) gels and electrophoresed. 
Gels were stained with Coomassie brilliant blue and scanned. A range 
of volumes (at least three) of each sample was electrophoresed on the 
same gel. Wet gels were scanned and analyzed with one-D scan software 
(Scanalytics Inc, Fairfax, VA). The integrated optical density (OD) of titin, 
nebulin, and myosin heavy chain was determined at each loading. Using 
regression analysis, the slope of the linear range of the relation between 
integrated OD and loading for each protein was calculated.
Titin mobility on SDS-agarose gels was studied to detect changes in titin 
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size. Mobility of titin from equally loaded HF and sham diaphragm samples 
were compared to mobility of intact titin (~3500 kDa) and truncated titin 
(~3300 kDa) from extensor digitorum longus (EDL) muscle of conditional 
titin kinase knock-out mice22. On the same gels, titin band widths of lanes 
loaded with either HF or sham diaphragm samples were compared to titin 
band widths from lanes loaded with a 1:1 mix of HF and sham diaphragm 
samples. Titin band widths were analyzed with one-D scan software 
(Scanalytics Inc, Fairfax, VA).
Immuno-fluorescence	microscopy
Cryosections (7µm thick) from frozen diaphragm and soleus specimens 
were rehydrated for 10 minutes in PBS and blocked with PBS containing 1% 
(w/v) BSA. Cryosections were incubated with antibodies against an epitope 
of titin near the Z-line (T12) and the appropriate fluorescent secondary 
antibodies. As a control, primary antibodies were omitted. Cryosections 
were visualized by a fluorescence Zeiss Axioscope Nikon digital DXM 1200. 
Digital images were collected using a Nikon Act-1 Version 2.10 software 
package. Digital images were processed using Confocal Assistant 4.02 and 
Adobe Photoshop 7.0 software.
Data treatment & Statistical methods
Sample size of approximately 20 fibers per group, calculated a priori, was 
based upon the assumption to detect a reduction of passive force of at least 
40%, with a standard deviation of 50% 18, 80% probability and an alpha 
level of 0.05. 
Repeated-measures analysis was performed with post hoc Student’s 
t-testing at each fiber length to evaluate the statistical significance of 
differences in single fiber passive-tension data between HF and sham-
operated rats. Differences between the HF and sham groups regarding 
titin, myosin heavy chain and nebulin content derived from SDS-agarose 
gels were analyzed with Student’s-t tests. Because of limited diaphragm 
tissue available per rat, data from single fiber contractility, SDS–agarose gel 
and immunofluorescence studies are not based on the same rats, although 
there is extensive overlap. A probability level of p<0.05 was considered 
significant. Mean ± SE values are presented in text, tables and figures.
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RESULTS
Animal characteristics
Marked cardiac dysfunction was present after 15 weeks of coronary 
artery ligation (Table 1). Aortic and left ventricular systolic pressures 
were significantly lower in HF rats than in sham-operated rats. Left 
ventricular diastolic pressure was significantly elevated in HF compared 
to sham. Increased wet to dry lung weight ratios of HF rats indicate the 
presence of pulmonary congestion. Cardiomegaly in HF rats was observed 
macroscopically and is supported by significantly increased heart weights 
(Table 1). 
Table 1 Animal characteristics. 
Values	are	means	±	SE.	*	p	<	0.05	different	from	sham	group.	Abbreviations:	HF	=	heart	
failure,	LV	=	left	ventricle.
Passive	tension-length	relation	of	diaphragm	muscle	fibers.
Single fibers (n=24) from 6 HF rats and single fibers (n=26) from 6 sham-
operated rats were used to study passive tension - length relations. The 
results were grouped according to their myosin heavy chain isoform 
expression. Figures 1A and 1B show results for slow and fast fibers, 
respectively. In both fiber types passive tension generation upon stretch 
was significantly reduced in HF diaphragm fibers compared to sham. 
Results did not differ between slow and fast fibers, in both HF and sham 
groups. 
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Figure 1  Passive tension – sarcomere length relationship of diaphragm fibers from HF and 
sham rats, grouped per A: type slow and B: type fast fibers. Passive tension upon stretch is 
significantly	lower	in	HF	than	sham	fibers,	for	both	slow	and	fast	type	fibers.	Data	are	presented	as	
mean	±	SE.	*	:	p	<	0.05	compared	to	sham.
Passive	tension-length	relations	of	soleus	fibers
To determine if HF reduced passive tension in peripheral muscles as well, 
we studied fibers isolated from the soleus muscle of HF and sham rats. 
All studied fibers in both groups were typed as slow. Figure 2 shows 
that passive tension generated upon stretch was not different between 
soleus fibers from HF and sham rats  (n=23 fibers from 5 animals in both 
groups). 
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Figure 2 Passive tension – sarcomere length relationship of soleus fibers from HF and sham 
rats.	Passive	tension	upon	stretch	did	not	differ	between	soleus	fibers	from	HF	and	sham	rats.
Figure 3 Representative muscle cryosections immunostained against titin epitope T12 
near the sarcomeric Z-line. Staining	intensity	was	decreased	in	diaphragm	samples	from	HF	rats	
compared	to	sham,	whereas	staining	intensity	was	comparable	in	soleus	samples	from	HF	and	sham	
rats.
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Immunofluorescence
Diaphragm and soleus cryosections from HF and sham rats (n=6 in both 
groups) were incubated with T12 antibodies (an antibody raised against 
a titin epitope near the Z-line 23). Immunofluorescence analysis showed 
reduced staining intensities in diaphragm fibers of HF rats compared to 
sham (Figure 3). In soleus fibers there was no obvious difference in staining 
intensity of T12 between HF and sham rats (Figure 3).
SDS agarose gel electrophoresis
Titin expression at protein level was analyzed in diaphragm samples from 
HF rats and sham-operated rats (n = 9 in both groups). Figure 4A shows 
a representative SDS-agarose gel loaded with diaphragm samples from a 
sham and HF rat. Titin content was significantly reduced in HF diaphragm 
samples compared to sham (Figure 4B). The content of titin’s degradation 
product T2 did not significantly differ between HF and sham diaphragm 
samples (Figure 4C). Myosin heavy chain content was significantly 
decreased in diaphragm from HF rats (Figure 4D), confirming previous 
findings from our lab 8. The content of nebulin which also appears on these 
SDS-agarose gels was significantly reduced in HF diaphragm samples 
compared to sham (Figure 4E). The ratios of titin over myosin heavy chain 
content and nebulin over myosin heavy chain content were not different 
between HF and sham diaphragm (Figure 4F and G, respectively). Thus, 
titin and nebulin content were reduced in a similar magnitude as myosin 
heavy chain.  
To gain insights into the size of titin in HF and sham diaphragm muscle 
we studied titin’s mobility on gel. A representative gel (Figure 5) shows 
that titin’s mobility was not different between diaphragm samples from 
HF and sham rats. To explore for the possibility of small differences in 
mobility that are hard to discern when samples are run side by side we 
decided to mix samples, rationalizing that if small size differences were to 
exist we might see a doublet or a broadened singlet band. We found that 
mixing samples of HF and sham diaphragm did not result in a doublet or 
broadened titin band (Figure 5), providing further evidence that there are 
no detectable size differences in titin. 
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Figure 4A:	Representative	SDS-agarose	gels	of	diaphragm	homogenates	 from	HF	and	sham	rats.	
Samples	were	 loaded	at	three	different	volumes.	 	Graphs	show	the	optical	density	at	each	loading	
plotted	 against	 loading	 volume.	 Relative	 protein	 content	 was	 derived	 from	 the	 slopes	 of	 these	
relationships	for	different	diaphragm	samples,	averaged	per	group	for	B: titin, C: titin’s degradation 
product T2,  D: myosin heavy chain (MyHC), E: nebulin. Titin, nebulin and myosin heavy chain 
content	were	significantly	decreased	in	diaphragm	samples	from	HF	rats	compared	to	sham.	F: Ratio 
of	 titin	 over	myosin	heavy	 chain	 content.	G:	Ratio	 of	nebulin	 over	myosin	heavy	 chain	 content.	
Titin and nebulin were reduced in similar magnitudes compared to myosin heavy chain. Data are 
presented	as	mean	±	SE.	*	:	p	<	0.05	compared	to	sham.
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Figure 5: Representative gels loaded with equal amounts of titin protein from HF and sham 
diaphragm samples, and a 1:1 mix of HF and sham diaphragm samples. (To have molecular 
weight	markers,	we	included	EDL	homogenates	from	titin	kinase	knock-out	mice	(titin	~3300	and	
~3500	kDa.))	Titin’s	mobility	is	not	discernable	different	between	HF	and	sham	diaphragm	samples.	
Titin	band	widths	of	either	HF	or	sham	diaphragm	samples	are	not	different	from	mixed	samples.	
DISCUSSION
The present study demonstrates that HF decreases passive tension 
generating capacity of diaphragm fibers. This impairment can be explained 
by reduced content of the elastic protein titin. Conversely, fiber stiffness and 
titin immunostaining are not reduced in soleus muscle of HF rats. Titin loss 
and decreased stiffness are likely to contribute to diaphragm contractile 
dysfunction in HF. 
The current results are in line with a previous study that reported 
decreased stiffness of diaphragm bundles from cardiomyopathic hamsters 
24. However, that study was unable to indicate a specific cause for 
reduced stiffness, because passive tension development of muscle bundles 
depends on elasticity of both intracellular and extracellular components, 
e.g. collagen. In the present study we investigated chemically skinned 
fibers, in which the contribution of extracellular components to muscle 
stiffness has been largely abolished. Indeed, it has been shown that passive 
tension generation of skinned muscle cells largely depend on the elastic 
properties of titin 25. Thus our results on passive tension development 
of skinned diaphragm fibers point to dysfunctional titin or titin loss in 
HF diaphragm. Immunofluoresence staining against a titin epitope near 
the Z-line showed reduced intensity in diaphragm fibers from HF rats. 
Reduced immunostaining could be a consequence of specific epitope 
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modulation and/or lower abundance of titin molecules. An established 
method to investigate titin content is SDS-gel electrophoresis 26. The present 
electrophoresis results show that titin content is reduced in HF diaphragm 
by ~25% (Figure 4B). As titin is a major determinant of fiber elasticity 11, 
this magnitude of titin loss offers an explanation for reduced diaphragm 
fiber stiffness in HF rats. However, diaphragm stiffness is reduced by 
more than 35% at each sarcomere length (Figure 1), thus exceeding the 
loss of titin by ~10%. This suggests that abnormalities of remaining titin 
molecules contribute to decreased diaphragm fiber stiffness. Indeed, in 
other experimental models and diseases associated with muscle weakness 
reduced fiber stiffness was accompanied by titin abnormalities. For 
example, our group and others demonstrated that diaphragm fibers from 
patients with chronic obstructive pulmonary disease (COPD) develop less 
passive tension upon stretch due to expression of additional exons located 
in the extensible spring region of titin 18,27. In the current study we did 
not observe differences in the mobility of titin during gel-electrophoresis 
(Figure 5), suggesting that major alterations of titin’s size are not involved 
in HF diaphragm. However, the resolution of our gel system for titin-sized 
proteins is at best ~ 50 kDa 28. Thus our work does not exclude the presence 
of additional exons in HF diaphragm that render titin more compliant, a 
possibility that warrants future follow-up work. Moore et al. suggested 
that a fiber type shift towards slow oxidative fibers could explain reduced 
fiber stiffness 27. However, we consider this explanation unlikely because 
both in their data as in our previous 18 and current data (Figure 1) passive 
fiber stiffness is not different between slow and fast fibers. In addition, an 
extensive study of titin’s isoform diversity in various muscles demonstrated 
that titin’s isoform can differ between muscles, but within muscles 
(including the diaphragm) a single titin isoform is expressed 29. Therefore, 
it seems unlikely that reduced passive stiffness of diaphragm fibers both 
in HF and COPD results from a fiber type redistribution. In summary, 
our finding that HF reduces diaphragm fiber passive tension upon stretch 
can largely be explained by a loss of titin, although involvement of minor 
additional titin abnormalities cannot be excluded. 
Causes	of	protein	loss	in	HF
In addition to a loss of titin, this study also showed that myosin heavy chain 
and nebulin content are decreased in HF diaphragm. These data indicate 
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a catabolic state of the diaphragm in HF. Reduced myosin content in the 
current study confirms previous data on myosin loss in diaphragm fibers 
from HF rats 8,30. Recently, we showed that myosin in HF rat diaphragm is 
degraded via activation of the ubiquitin-proteasome pathway 30. Whether 
titin and nebulin loss in HF diaphragm are also a consequence of increased 
activity of this pathway is currently unknown. In favor of this explanation, 
the E-3ligase MuRF1, which is known to ubiquitinate titin and nebulin 31, 
is upregulated in the diaphragm of HF rats 30. However, the proteasome 
is limited in the admittance of large proteins 32 and interactions between 
myofilament proteins protect proteins from degradation 33. Thus, for 
proteasomal degradation of such large proteins as titin (~3500 kDa) and 
nebulin (~700 kDa), prior cleavage into smaller fragments is needed. Results 
from previous studies indicate that calpains are able to cleave both titin 
and nebulin 34,35. Indeed, increased calpain activities have been reported in 
diaphragm of HF rats 36. Titin proteolysis by calpains leaves the cleavage 
product T2 35. Instead of an increased T2 level, we observed less T2 (not 
significantly) in our HF diaphragm samples, which is not supportive of 
the concept that titin degradation is increased in HF diaphragm. However, 
it is possible that these cleavage products are eliminated by proteasomes, 
which are known to be activated in HF diaphragm 8. Finally, because 
protein content is the net result of its synthesis and degradation, reduced 
titin synthesis cannot be excluded as an explanation for the low titin content 
in HF samples .
Implications	of	reduced	titin	content
Reduced stiffness and loss of titin, as observed in the present study, may 
contribute to sarcomeric instability in HF diaphragm fibers. Indeed, 
we previously reported ultra-structural abnormalities in sacomeres of 
diaphragm fibers from HF animals 9. Furthermore, titin is recognized to play 
an important role in the formation of thick filaments 37. Likewise, nebulin 
has been demonstrated to be a ruler for the thin filament 38. Considering the 
crucial role of these proteins in sarcomere assembly, loss of both proteins 
in HF diaphragm implicates impaired regenerative capacity.  In addition, it 
is recognized that titin is indispensable for optimal active force generation 
of muscle fibers. Titin deletion from the sarcomere significantly diminishes 
the capacity to generate maximal force 10. Furthermore, titin loss is 
accompanied by reduced calcium sensitivity presumably as a consequence 
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of increased myofilament lattice spacing 39,40. Interestingly, we recently 
observed reduced maximal active force generation and decreased calcium 
sensitivity of HF diaphragm fibers 8. Although caution is needed in relating 
these findings specifically to titin loss (because Figure 4F and G show 
that other sarcomeric proteins are proportionally lost in HF diaphragm), 
we consider it likely that the disappearance of titin negatively impacts 
diaphragm contractility in HF. 
Respiratory versus peripheral muscles
It is known that respiratory and peripheral muscles can be differentially 
affected by HF 14,41. Therefore we additionally investigated passive elastic 
properties of soleus muscle fibers. The results show that, in contrast to the 
diaphragm, passive tension generating capacity is not reduced in soleus 
fibers from HF animals. Accordingly, immunostaining of titin was abnormal 
in HF diaphragm fibers, but preserved in soleus. These data are in line with 
observations in HF patients. For example, active force generation is more 
reduced in respiratory muscles than in peripheral muscles of HF patients 
42. Furthermore, ultra-structural abnormalities are frequently observed 
in the diaphragm, but far less in the quadriceps muscle of HF patients 43. 
These differences have been ascribed to distinct changes in activity level. 
Increased work of breathing in HF imposes a higher load on respiratory 
muscles 2,3, whereas reduced physical activity of HF patients indicates 
that peripheral muscle load is not increased 44. Although we did not asses 
muscle activity levels, our data support the concept that mechanisms in HF 
leading to diaphragm dysfunction differ from those that elicit changes in 
peripheral muscles.
In conclusion, results from this study show that HF decreases passive 
tension generation of diaphragm fibers, which can be explained by reduced 
titin content. Titin loss and decreased stiffness are likely to be functionally 
detrimental, and are part of the mechanisms that underlie diaphragm 
dysfunction in HF.
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Chapter 6
Levosimendan improves calcium sensitivity 
of diaphragm fibers from heart failure rats
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ABSTRACT
Rationale Diaphragm weakness commonly occurs in patients with heart 
failure (HF) and is associated with exercise intolerance and increased 
mortality. Reduced sensitivity of diaphragm fibers for calcium contributes 
to diaphragm weakness in HF. Therefore, this study investigates the effect 
of calcium sensitizer levosimendan on contractility of HF diaphragm fibers. 
We hypothesize that levosimendan restores reduced calcium sensitivity of 
diaphragm fibers in HF.
Methods Coronary artery ligation was used as an animal model for HF in 
rats. Fifteen weeks after induction of HF animals were sacrificed and muscle 
fibers were isolated from the diaphragm. Diaphragm fibers were skinned 
and activated with solutions containing incremental calcium concentrations 
and 10 μM levosimendan or vehicle (0.02% DMSO). Diaphragm fibers 
from sham-operated rats were exposed to vehicle as control. Developed 
force was measured at each step and force vs. calcium concentration 
relationships were derived. Results were grouped per myosin heavy chain 
isoform, which was determined by SDS-PAGE. 
Main Results Calcium sensitivity of force generation was reduced in 
diaphragm fibers from HF rats compared to sham (p<0.01). Maximal 
force generation was ~25% lower in HF diaphragm fibers than in sham 
(p<0.05). Levosimendan significantly increased calcium sensitivity of force 
generation from HF rats, without affecting maximal force generation. 
Conclusion Levosimendan enhances force generating capacity of 
diaphragm fibers from HF rats by increasing calcium sensitivity of force 
generation. These results provide a strong rationale for testing the effect of 
calcium sensitizers on diaphragm weakness in patients with HF.
119
6
INTRODUCTION
Patients with heart failure (HF) commonly suffer from dyspnea, which 
significantly limits their daily life activities. The origin of dyspnea in HF 
patients has been related to the presence of inspiratory muscle dysfunction 
1. Several clinical studies have demonstrated reduced inspiratory muscle 
strength in patients with HF 2,3 and the reduction strongly correlates with 
the severity of dyspnea 4,5. In addition, inspiratory muscle weakness in HF 
is associated with high mortality risks 6. Despite the clinical relevance of 
inspiratory muscle dysfunction no effective treatment aiming at improving 
contractility of the inspiratory muscles is available. The diaphragm is the 
most important inspiratory muscle. Recent work from our lab demonstrated 
that diaphragm contractility is impaired at the muscle fiber level in HF rats 
7. Among other factors, the sensitivity of contractile proteins to calcium 
is reduced. As a result, force generation is reduced at a sub-maximal 
calcium level in HF diaphragm fibers. Because the diaphragm is sub-
maximally loaded during normal breathing, reduced calcium sensitivity 
could contribute to impaired force generation of the diaphragm in vivo. 
Accordingly, improving calcium sensitivity of diaphragm muscle fibers is 
an attractive mechanism to enhance force generation of the diaphragm in 
HF. 
Currently, levosimendan is the only calcium sensitizer approved for use 
in human (~40 countries worldwide). Levosimendan has been shown 
to improve cardiac contractility in vivo 8 and in vitro 9, by enhancing 
calcium sensitivity of force generation through binding with cardiac/slow 
troponin C 10. Very recently, we demonstrated that levosimendan is able to 
improve contractility of human diaphragm muscle as well 11, suggesting that 
levosimendan could be effective to treat diaphragm dysfunction in HF. The 
current study aims to investigate the effect of levosimendan on HF-induced 
reduction of calcium sensitivity in diaphragm fibers. We hypothesize that 
levosimendan improves calcium sensitivity of diaphragm fibers from rats 
with HF. 
Levosimendan has been shown to increase calcium sensitivity by interacting 
with the troponin complex 10. A recent study shows that changes in specific 
parts of the cardiac troponin complex affect the affinity for levosimendan 
12. In skeletal muscle, such as the diaphragm, troponins are expressed in 
different isoforms 13. It is however uncertain if the effect size of levosimendan 
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depends on the troponin isoform expression. Therefore, we additionally 
investigated the effect of levosimendan on calcium sensitivity of skeletal 
muscle fibers that predominantly express either slow or fast troponins.
MATERIALS & METHODS
HF	animal	model
All experiments in this study were approved by the local Animal Ethics 
Committee, Radboud University, Nijmegen. Adult male Wistar rats (~300 
g) were anesthetized by inhalation of an isoflurane-oxygen mixture (2% to 
5% isoflurane), orally intubated, and mechanically ventilated. Ligation of 
the left coronary artery and sham operations were performed as described 
previously 7. 
Fifteen weeks after coronary ligation or sham operation, the rats were 
anesthetized with pentobarbital (70 mg /kg IP), tracheally intubated and 
mechanically ventilated. Aortic pressure and left ventricular pressures 
were measured by a micromanometer-tipped catheter (SPC 330, Millar 
Instruments, Texas, USA) inserted through the right carotid artery. After 
completion of the hemodynamic measurements, a combined thoracotomy/
laparotomy was performed, and the diaphragm, lungs and heart were 
quickly excised. A muscle bundle was cut from the right hemi-diaphragm 
for determination of single fiber contractile properties. Heart weight was 
determined and the heart was fixated in formalin for >72h. Subsequently, 
the size of the infarct areas was determined by planimetry, as described 
previously 14. Only data from rats with infarcts >35% of the left ventricle 
were analyzed in this study. Lungs were cleaned of fat and weighed before 
and after desiccation (3 days at 40°C) to quantify lung congestion. 
Single	fiber	contractile	measurements
Single fiber contractile measurements and experimental protocol were 
performed according to previously described methods 7,11, with minor 
modifications, as described below.
Single	fiber	preparation
The muscle bundles were excised quickly and immediately submersed 
in cooled, oxygenated Krebs solution at pH 7.40. The Krebs solution 
consisted of 137 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM KH2PO4, 24 
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mM NaHCO3, 7 mM glucose, and 25 µM d-tubocurarine (Sigma, Bornem, 
Belgium). A bundle was dissected from the central part of the muscle. 
The muscle bundle was pinned to cork and stored at 4°C in a relaxing 
solution, containing 50% glycerol (vol/vol). After 24 hours, the muscle 
strip was stored at -20°C for later analysis. Approximately one hour prior 
to determination of single fiber contractile properties, the muscle bundle 
was transferred to relaxing solution (5°C) containing 1% Triton X-100 to 
permeabilize lipid membranes. From the muscle bundle ~2mm segments 
of single fibers were isolated using microforceps. Subsequently, the fiber 
ends were attached to aluminium foil clips, and mounted on the single fiber 
apparatus. Fibers were mounted in a temperature-controlled (20 °C) flow-
through acrylic chamber (120-µl volume), with a glass coverslip bottom, on 
the stage of an inverted microscope (model IX-70; Olympus, Amsterdam, 
The Netherlands). Two stainless steel hooks were used to mount the fiber 
horizontally in the chamber. One end of the fiber was attached to a force 
transducer (model AE-801; SensoNor, Horten, Norway) with a resonance 
frequency of 10 kHz, whereas the other end was attached to a servomotor 
(model 308B; Aurora Scientific, Aurora, ON, Canada) with a step time of 
250 µs. In relaxing solution, sarcomere length was set at 2.4 µm as the 
optimal length for force generation 15,16 with the use of a calibrated eyepiece 
micrometer. During experiments, sarcomere length was stabilized with the 
Brenner cycling method 17 as modified by Sweeney et al. 18. MIDAC software 
(Radboud University, Nijmegen, The Netherlands) and a data-acquisition 
board were used to record signals. Muscle fiber length (~1–1.5 mm) was 
measured using a reticule in the microscope eyepiece [×10 Olympus Plan 
10, 0.30 numerical aperture (NA)]. The XY fiber diameter (width) was 
measured with a ×40 objective [×40 Olympus Plan 40, 0.60 NA]. The ×40 
objective also was used to measure the XZ fiber diameter (depth) by noting 
the displacement of the microscope’s objective while focusing on the top 
and bottom surfaces of the fiber. Three width and depth measurements 
were made along the length of the fiber, the average values were used to 
calculate the fiber cross-sectional area, assuming that the fiber was ellipsoid 
in shape. 
Composition	of	solutions	for	single	fiber	measurements
Concentrated stock solutions of levosimendan (kind gift from Orion 
Pharma, Espoo, Finland) were prepared in DMSO and stored at –20 °C. 
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Before use, levosimendan stock solutions were diluted with experimental 
solutions. The response of 10 soleus fibers from a normal rat to different 
doses of levosimendan  was determined during sub-maximal activation (at 
pCa 6.5). Figure 1 shows that levosimendan enhanced sub-maximal force 
generation with a maximal effect at 10 μM, which is similar to previously 
reported dose-response curves for human diaphragm fibers 11 and cardiac 
fibers 9. Accordingly, further experiments were conducted with either 10 
µM levosimendan or vehicle (0.02% DMSO). Relaxing solution consisted 
of 1.0 mM MgCl2, 4.0 mM Na2ATP, 5 mM EGTA, 10 mM imidazole, 15 mM 
creatine phosphate and sufficient KCL to adjust the total ionic strength to 
150 mM at pH 7.0. The negative logarithm of the free Ca2+ concentration 
(pCa) of the relaxing solution was 9.0 while in activating solutions the pCa 
ranged from 7.0 to 4.5 (with maximal activation at pCa 4.5). To achieve 
appropriate pCa in activating solutions, sufficient CaCl2 was added to 
solutions. 
Figure 1 Dose-response effects of levosimendan on sub-maximal force generating capacity 
of rat soleus fibers.	Incremental	levosimendan	concentrations	were	added	to	rat	soleus	fibers	(n=10)	
during	 sub-maximal	 activation	 at	 pCa	 6.5.	 Force	 generation	 increases	with	 rising	 levosimendan	
concentration,	with	a	significant	effect	at	10µM.
Diaphragm	muscle	single	fiber	experimental	protocol 
Maximal force was determined by perfusing the experimental chamber at, 
successively, pCa 9 and 4.5. Then pCa 9.0 solution was perfused through 
the chamber to relax the fiber. Subsequently, fibers were perfused with 
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solutions containing incremental Ca2+ concentrations. Each time a plateau 
was reached, the next pCa solution was perfused through the experimental 
chamber. Structural and functional instability of skinned single muscle 
fibers, reflected by an increased heterogeneity of sarcomere spacing during 
activation and reduced force generation over time, is a well-recognized 
problem 19. To improve functional stability of muscle fibers, we applied 
Brenner cycling 17 throughout the experimental protocol. Accordingly, no 
functional decline in maximal force generation over time was observed. 
Diaphragm	muscle	single	fiber	contractile	determinations
Maximum specific force was determined by dividing the isometric force 
generated at pCa 4.5  by CSA. The force-pCa relationship was derived 
by plotting recorded force against pCa of the corresponding activating 
solution. Graphpad software (Graphpad Software Inc., San Diego, CA) 
was used to calculate the Ca2+ concentration required for half-maximum 
activation (pCa50), as an index of Ca2+ sensitivity of force generation and the 
Hill coefficient, as a measure of myofilament cooperativity. 
Myosin	heavy	chain	isoform	composition	determination
Because pCa50 is significantly different between slow and fast diaphragm 
fibers 20, diaphragm fibers were designated as slow or fast on the basis 
of myosin heavy chain isoform determination. Determination of myosin 
heavy chain isoform composition and content by SDS-PAGE was adapted 
from Geiger et al. 21 and described previously 7. From 19 sham diaphragm 
fibers that were used in this study, 12 were designated as slow and 7 as 
fast. From 26 HF diaphragm fibers that were exposed to levosimendan, 20 
were designated as slow and 6 as fast. From 25 HF diaphragm fibers that 
were exposed to vehicle 17 were designated as slow and 8 as fast.
Troponin	isoform	dependency	of	levosimendan’s	effect
To investigate if the effect of levosimendan depends on the expression of 
troponin isoforms we wanted to use muscle fibers that express either slow 
or fast troponins. In contrast to the rat diaphragm 20, rat soleus and extensor 
digitorum longus (EDL) muscle predominantly express either slow or fast 
contractile proteins respectively 22. Soleus and EDL muscle bundles were 
excised from a normal adult male Wistar rat (300 g) under anesthesia of 
pentobarbital (70 mg/kg IP). Single muscle fibers (n=24 per muscle type) 
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were isolated as described in “Single	fiber	preparation”. Force-pCa relations 
of these fibers were determined in the presence of 10 μM levosimendan 
or vehicle (both n = 12). The expression of either slow or fast contractile 
proteins in soleus and EDL fibers was confirmed by myosin heavy chain 
isoform determination.
Data treatment & statistical methods
Differences regarding force-pCa relations between groups were statistically 
analysed with a two-way repeated measures ANOVA test with pCa as the 
repeated measures factor and the presence of levosimendan as the second 
factor. One-way ANOVA with post-hoc Student-Newman-Keuls testing 
was performed to evaluate the statistical significance of differences between 
groups of other contractile characteristics. A probability level of p<0.05 was 
considered significant. Mean ± SEM values are presented in text, tables and 
figures.
Table 1 Animal characteristics.
LV	=		Left	ventricle
*	p	<	0.05	different	from	sham	group.	
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RESULTS
Animal characteristics
Animal characteristics are shown in Table 1. HF was characterized by 
pulmonary congestion, increased heart weight, elevated left ventricular 
end diastolic pressure, decreased left ventricular peak systolic pressure 
and decreased aortic pressures.
Figure 2 The effect of levosimendan on force-calcium characteristics of HF diaphragm 
fibers.	Diaphragm	fibers	from	HF	rats	were	exposed	to	10	µM	levosimendan	or	vehicle	activating	
solutions.	Diaphragm	fibers	from	sham	operated	rats	were	exposed	to	vehicle	as	a	control.	Isometric	
force	generation	in	response	to	solutions	with	incremental	calcium	concentrations	was	determined.	
Sub-maximal	force	generation	is	higher	in	HF	diaphragm	fibers	treated	with	levosimendan	compared	
to vehicle. 
*:	 two-way	 repeated	measures	 analysis	 showed	 that	 force-pCa	 relations	 of	HF	fibers	 treated	with	
levosimendan	were	significantly	different	from	force-pCa	relations	of	HF	fibers	treated	with	vehicle,	
for	both	slow	and	fast	fibers	(Figures	2A	en	2B	respectively).
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Figure 3 Values of pCa50, an index for calcium sensitivity of force generation, from sham 
diaphragm fibers exposed to vehicle and HF diaphragm fibers exposed to either 10 µM 
levosimendan or vehicle solution.	Calcium	sensitivity	is	lower	in	HF	fibers	than	in	sham	fibers.	
HF	fibers	treated	with	levosimendan	display	higher	calcium	sensitivity	than	HF	fibers	treated	with	
vehicle,	 for	 both	 slow	and	 fast	fibers	 (Figures	3A	 en	3B	 respectively).	 *:	 p<0.05	 compared	 to	HF	
vehicle-treated	fibers;	#:	p	<	0.01	compared	to	vehicle	 treated	sham	fibers.	Abbreviations:	pCa50 = 
-10log[Ca2+]	at	which	50%	of	maximal	force	is	generated.
Calcium	sensitization	in	HF	diaphragm
HF reduced calcium sensitivity of force generation in the diaphragm 
as indicated by a rightward shift of the force-pCa relation (Figure 2). 
Accordingly, the pCa50, which represents the amount of calcium needed 
for 50% of maximal force, is reduced in diaphragm fibers of HF rats (Figure 
3A and 3B). 
Levosimendan improved calcium sensitivity of diaphragm fibers from 
HF rats in both slow and fast typed fibers (Figure 2A and 2B). During 
127
6
sub-maximal activation, for instance at pCa 6.0, levosimendan increased 
diaphragm fiber force by 15-20% compared to vehicle exposed fibers. 
Levosimendan exposure significantly increased pCa50 of both slow and 
fast-typed HF diaphragm fibers, indicating that less calcium is needed to 
generate 50% of maximal force in HF diaphragm fibers. 
Myofilament cooperativity, expressed by the Hill coefficient, was not 
significantly different between sham diaphragm, HF diaphragm and HF 
diaphragm with levosimendan (1.89±0.12 vs. 1.77±0.18 vs. 1.54±0.11 for 
slow diaphragm fibers respectively and 2.30±0.21 vs. 2.45±0.17 vs. 2.19±0.27 
for fast diaphragm fibers respectively). 
Maximal force generation was significantly lower in diaphragm fibers 
from HF rats compared to sham, both in slow and fast diaphragm fibers 
(Figure 4A and 4B). As expected, levosimendan did not affect diaphragm 
fiber maximal force generation.
Figure 4 Maximal force generation of sham diaphragm fibers and HF diaphragm fibers 
exposed to 10 µM levosimendan or vehicle solution.	HF	diaphragm	fibers	generated	significantly	
lower	maximal	forces	than	sham	fibers,	in	both	slow	and	fast	fibers	(Figures	4A	en	4B	respectively).	
Maximal	force	generation	is	not	significantly	different	between	levosimendan	and	vehicle	treated	HF	
fibers.	*:	p<0.05	compared	to	HF	fibers	vehicle	treated.
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Effect	of	troponin	isoform	on	calcium	sensitization
Force-pCa	in	slow	soleus	fibers
Levosimendan increased calcium sensitivity of force generation of rat soleus 
fibers (Figure 5). In accordance, levosimendan significantly increased the 
pCa50 of these fibers (6.32 ± 0.03 vs. 6.16 ± 0.02). 
The Hill coefficient was significantly decreased by levosimendan exposure 
(1.3 ± 0.1 vs. 1.8 ± 0.1). 
Levosimendan did not enhance maximal force generation of soleus fibers 
at pCa 4.5 compared to control (142 ± 8 mN/cm2 vs. 141 ± 9 mN/cm2). 
Force-pCa	in	fast	EDL	fibers
In EDL fibers levosimendan induced a leftward shift of the force-pCa curve 
(Figure 6). The pCa50 was significantly higher in EDL fibers treated with 
levosimendan than control (5.86 ± 0.02 vs. 5.74 ± 0.01). 
The Hill coefficient was not significantly different between EDL fibers 
treated with levosimendan and control (2.6 ± 0.3  vs. 2.9 ± 0.3). Maximal 
force generation of EDL fibers at pCa 4.5 was not affected by levosimendan 
compared to control (149 ± 18 mN/cm2 vs. 143 ± 11 mN/cm2). 
Figure 5 The effect of levosimendan on force-pCa relation of rat soleus fibers. *:	Two-way	
repeated	measures	analysis	showed	that	force-pCa	relations	of	soleus	fibers	treated	with	levosimendan	
were	significantly	different	from	force-pCa	relations	of	soleus	fibers	treated	with	vehicle. 
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Figure 6 The effect of levosimendan on force-pCa relation of rat EDL fibers. *:	 Two-way	
repeated	measures	analysis	showed	that	force-pCa	relations	of	EDL	fibers	treated	with	levosimendan	
were	significantly	different	from	force-pCa	relations	of	EDL	fibers	treated	with	vehicle.
DISCUSSION
This study is the first to show that the calcium sensitizer levosimendan 
improves calcium sensitivity of force generation in the diaphragm of HF 
rats. In addition, the present results indicate that the effect of levosimendan 
depends on skeletal muscle type. Many studies have shown that 
levosimendan improves cardiac contractility, but very few studies have 
evaluated the effect of levosimendan on non-cardiac muscle. The data of 
the present study provide a strong rationale to test the effects of calcium 
sensitizing on diaphragm muscle function in congestive heart failure 
patients. 
For adequate alveolar ventilation, the workload on inspiratory muscles 
in HF patients is increased threefold compared to healthy subjects 5. An 
increased workload demands higher oxygen consumption by inspiratory 
muscles 23, which in turn will reduce energy efficiency of ventilation. Indeed, 
energy efficiency of ventilation is significantly reduced in most patients 
with HF and is closely related to exercise limitation and mortality 24,25,26,27,28. 
Therefore, it is clinically relevant to seek for therapies that aim to improve 
efficiency of inspiratory muscle force generation. In vivo, the diaphragm 
muscle undergoes repetitive cycles of contraction and relaxation, which 
requires continuous sequestration of calcium at the muscle fiber level. 
Calcium cycling is an utmost energy consuming process, in fact comprising 
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30-40% of energy cost during muscle contraction 29. When calcium 
sensitivity is reduced, like in HF diaphragm fibers 7, more calcium is 
required to generate force, which evidently reduces mechanical efficiency 
of contraction. Conversely, by increasing the sensitivity of myofilaments 
for calcium the same amount of force can be generated with less calcium, 
thereby improving the efficiency of muscle contraction. The present study 
demonstrates that levosimendan indeed increases the calcium sensitivity 
of diaphragm fibers in HF. Whether this increases efficiency of respiratory 
muscle work in heart failure patients remains to be investigated. It is 
promising that in cardiac muscle levosimendan increases cardiac output 
without increasing energy demand 30. 
Mechanisms	of	action
Levosimendan increases calcium sensitivity by interaction with the 
troponin complex, which regulates muscle contraction. The binding of 
levosimendan to troponin stabilizes the conformation of troponin during 
cross-bridge formation 31. In the present study levosimendan differently 
affected calcium sensitivity in fibers from slow and fast skeletal muscle. In 
soleus fibers (slow type muscle) the effect of levosimendan seems calcium 
dependent, as indicated by strong effect of levosimendan at low calcium 
concentration, but absence of effect at high calcium concentration (Figure 
5). Alternatively,  in EDL fibers (fast type muscle) levosimendan provoked 
a complete leftward shift of the force-pCa curve (Figure 6). The EDL muscle 
predominantly expresses fast skeletal troponin C, whereas soleus muscle 
expresses the cardiac isoform of troponin, which differ in structure for ~30%. 
32.The fact that the effect of calcium sensitizers depend on troponin isoform 
has been shown previously for bepridil 33,34. This phenomenon has not been 
reported earlier for levosimendan. Diaphragm fibers that are typed slow 
on the basis of myosin heavy chain isoform may express both isoforms of 
troponin C 20, providing an explanation for the less pronounced difference 
of levosimendan effect between fast and slow diaphragm fibers. 
Levosimendan does not affect maximal force generation, indicating that 
the maximal number of attached cross-bridges, and force per cross-bridge 
remain unaltered with levosimendan exposure. Accordingly, levosimendan 
improves sub-maximal force generating capacity of skeletal muscle and 
HF diaphragm fibers by increasing calcium sensitivity.
In addition to calcium sensitization, levosimendan opens ATP-sensitive 
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potassium channels 35, which explains its vasodilatory actions in vivo 36. 
However, in our experimental set-up muscle fibers were chemically skinned 
in order to specifically study effects on the contractile proteins. 
Clinical applicability
The results from this study provide a rationale to further explore the 
feasibility of levosimendan treatment in patients with inspiratory muscle 
dysfunction. Recently, we showed that levosimendan is able to improve 
calcium sensitivity of human diaphragm fibers 11. Levosimendan is 
generally well tolerated, although hypotension is a frequently reported 
side effect, especially at higher doses 37,38. 
Dose response relations in human diaphragm fibers indicate that 
levosimendan improves force generation at concentrations from 0.1µM 
11. Similar values of levosimendan (up to 0.4 µM) in plasma have been 
reported after administration of clinically used dosages (24h infusion with 
0.1 – 0.4 μg/kg/min) 39. However, local levosimendan concentrations seem 
to be more relevant than blood values. These are difficult to determine 
because in vivo levosimendan is quickly metabolized to OR-1896 and OR-
1855 40. OR-1896 is known to have similar effects on calcium sensitization 
in cardiac muscle as levosimendan 41, if OR-1896 also improves calcium 
sensitivity in skeletal muscle is yet unknown. 
In addition to a role in treating inspiratory muscle dysfunction, our data 
on soleus and EDL muscle fibers suggest that levosimendan might also 
improve peripheral muscle function. In fact, calcium desentitization of 
peripheral muscles has been described in fatigued mice with HF 42. These 
data further underline the rationale of testing the effect of levosimendan in 
other diseases associated with skeletal muscle dysfunction. Another group 
of patients that could benefit from the positive effects of levosimendan 
on diaphragm contractility are patients difficult to wean from mechanical 
ventilation. Difficult weaning has been associated with impaired 
diaphragm contractility 43,44. Interestingly, a recent study demonstrated 
that levosimendan facilitates weaning from mechanical ventilation in 
heart failure patients 45. Although the effects of levosimendan on heart and 
diaphragm muscle cannot be considered separately in that study, results 
from the present study at least support a role for improved diaphragm 
contractility.
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In conclusion, the present study clearly demonstrates that levosimendan 
improves calcium sensitivity in diaphragm fibers of an animal model for 
human heart failure. These results suggest that levosimendan increases 
the energy efficiency of diaphragm force generation in vivo. Further 
investigations are needed to establish the applicability of levosimendan as 
a therapeutic for diseases associated with inspiratory muscle failure. 
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Chapter 7
Levosimendan enhances force generation of
 diaphragm muscle from patients with COPD 
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ABSTRACT
Rationale Levosimendan is clinically used to improve myocardial con-
tractility by enhancing calcium sensitivity of force generation. The effects 
of levosimendan on skeletal muscle contractility are unknown. Patients 
with COPD suffer from diaphragm weakness, which is associated with 
decreased calcium sensitivity.  The oblective of this study was to investi-
gate the effects of levosimendan on contractility of diaphragm fibers from 
COPD patients.
Methods Muscle fibers were isolated from diaphragm biopsies obtained 
from thoracotomized COPD and non-COPD patients (both groups n=5, 
10 fibers per patient). Diaphragm fibers were skinned and activated with 
solutions containing incremental calcium concentrations and 10 µM lev-
osimendan or vehicle (0.02% DMSO). Developed force was measured at 
each step and force vs. calcium concentration relationships were derived. 
Results were grouped per myosin heavy chain isoform, which was deter-
mined by SDS-PAGE. 
Main Results At sub-maximal activation levosimendan improved force 
generation of COPD and non-COPD diaphragm fibers by ~25 %, both in 
slow and fast fibers. Levosimendan increased calcium sensitivity of force 
generation (p<0.01) in both slow and fast diaphragm fibers from COPD 
and non-COPD patients, without affecting maximal force generation. 
Conclusion Levosimendan enhances force generating capacity of dia-
phragm fibers from COPD and non-COPD patients by increasing calcium 
sensitivity of force generation. These results provide a strong rationale for 
testing the effect of calcium sensitizers on respiratory muscle dysfunction 
in patients with COPD.
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INTRODUCTION
Weakness of the diaphragm frequently occurs in patients with chronic ob-
structive pulmonary disease (COPD) 1,2. Inspiratory muscle weakness in 
these patients is associated with prolonged mechanical ventilation and in-
creased mortality 3,4. The pathophysiology of inspiratory muscle dysfunc-
tion in COPD is complex 1. Recent studies have shown that in patients with 
COPD impaired contractility of muscle fibers from the diaphragm, the 
most prominent inspiratory muscle, results from loss of contractile protein 
and impaired function of remaining contractile proteins 5,6,7. Diaphragm 
muscle fibers from these patients exhibit reduced ability to respond to cal-
cium, indicating reduced calcium sensitivity of force generation. Based on 
these findings, we proposed that pharmacological modulation of the regu-
latory proteins is an effective strategy to improve diaphragm contractility 
in patients with COPD. 
Calcium sensitizers enhance binding of calcium to the regulatory proteins 
of the contractile apparatus. This improves the responsiveness of myo-
filaments to calcium, resulting in a greater amount of force for the same 
amount of cytosolic calcium. An advantage of this mechanism of action is 
that force generation is improved without increased ATP consumption 8. 
Currently, levosimendan is the only calcium sensitizer approved for use 
in human (~40 countries worldwide). Levosimendan has been shown to 
improve cardiac contractility in vivo 9 and in vitro 10, by enhancing calcium 
sensitivity of force generation through binding with cardiac troponin C 
11. The effects of calcium sensitizers on human peripheral- or respiratory 
skeletal muscle have not been investigated. Nevertheless, cardiac troponin 
C isoform is expressed in human diaphragm muscle. Moreover, Levine et 
al. have shown increased expression of this isoform in the diaphragm of 
patients with COPD 12. Therefore, we hypothesize that levosimendan im-
proves calcium sensitivity of muscle fibers isolated from the diaphragm of 
patients with COPD.  
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MATERIALS & METHODS
Subjects
Diaphragm muscle biopsies (~100 mg) were obtained from 5 COPD pa-
tients (4 males) and 5 non-COPD subjects (2 males). Biopsies from the right 
anterior costal diaphragm were obtained during thoracotomy for lung can-
cer (stage T1-3N0-1Mx). Stages of lung cancer did not significantly differ be-
tween COPD and non-COPD patients. Patients with chronic corticosteroid 
use, primary myopathies, endocrine diseases and more than 10% weight 
loss in the last 6 months prior to surgery were excluded from the study. 
General characteristics and pulmonary function data are shown in table 
1. Informed consent was obtained from each subject. The study was ap-
proved by the local ethical committee.
Table 1 Patient characteristics.
Definition	of	abbreviations:	m	=	male,	f	=	female,	BMI	=	body	mass	index;	FEV1	=	forced	
expiratory	volume	in	first	s;	VC	=	vital	capacity;	TLC	=	total	lung	capacity;	DLco/VA	=	
carbon	monoxide	transfer	coefficient	per	alveolar	volume.
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Single	fiber	contractile	measurements
According to previously described methods 5,13, single fiber contractile 
measurements and experimental protocol were performed as follows.
Single	fiber	preparation
A bundle was dissected from the central part of the fresh muscle biopsy. 
The muscle bundle was pinned to cork and stored at 4°C in a relaxing so-
lution, containing 50% glycerol (vol/vol). After 24 hours, the muscle strip 
was stored at -20°C for later analysis. Approximately one hour prior to 
determination of single fiber contractile properties, the muscle bundle 
was transferred to relaxing solution (5°C) containing 1% Triton X-100 to 
permeabilize lipid membranes. From the muscle bundle ~2mm segments 
of single fibers were isolated using micro-forceps. Subsequently, the fiber 
ends were attached to aluminium foil clips, and mounted on the single 
fiber apparatus. Fibers were mounted in a temperature-controlled (20 °C) 
flow-through acrylic chamber (120-μl volume), with a glass coverslip bot-
tom, on the stage of an inverted microscope (model IX-70; Olympus, Am-
sterdam, The Netherlands).Two stainless steel hooks were used to mount 
the fiber horizontally in the chamber. One end of the fiber was attached to 
a force transducer (model AE-801; SensoNor, Horten, Norway) with a reso-
nance frequency of 10 kHz, whereas the other end was attached to a ser-
vomotor (model 308B; Aurora Scientific, Aurora, ON, Canada)with a step 
time of 250 µs. In relaxing solution, sarcomere length was set at2.4 µm as 
the optimal length for force generation 14,15 with the use of a calibrated eye-
piece micrometer. Muscle fiber length (~1–1.5 mm) was measured using a 
reticule in the microscope eyepiece [×10 Olympus Plan 10,0.30 numerical 
aperture (NA)]. The XY fiber diameter (width)was measured with a ×40 
objective [×40 Olympus Plan 40, 0.60NA]. The ×40 objective also was used 
to measure the XZ fiber diameter (depth) by noting the displacement of 
the microscope’s objective while focusing on the top and bottom surfaces 
of the fiber. Three width and depth measurements were made along the 
length of the fiber, the average values were used to calculate the fiber cross-
sectional area, assuming that the fiber was ellipsoid in shape.
Composition	of	solutions	for	single	fiber	measurements
Concentrated stock solutions of levosimendan (kind gift from Orion Phar-
ma, Espoo, Finland) were prepared in DMSO and stored at –20 °C. Before 
use, levosimendan stock solutions were diluted with experimental solu-
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tions. The final concentration of DMSO did not exceed 0.02%. Control ex-
perimental solutions contained 0.02% DMSO (vehicle). Relaxing solution 
consisted of 1.0 mM MgCl2, 4.0 mM Na2ATP, 5 mM EGTA, 10 mM imi-
dazole, 15 mM creatine phosphate and sufficient KCL to adjust the total 
ionic strength to 150 mM at pH 7.0. The negative logarithm of the free Ca2+ 
concentration (pCa) of the relaxing solution was 9.0 while in activating so-
lutions the pCa ranged from 7.0 to 4.5 (with maximal activation at pCa 4.5). 
To achieve appropriate pCa in activating solutions, sufficient CaCl2 was 
added to solutions. 
Diaphragm	muscle	single	fiber	experimental	protocol
The response of 5 COPD diaphragm fibers to different doses of levosimen-
dan was determined during sub-maximal activation (at pCa 5.8). Figure 1 
shows that levosimendan enhanced sub-maximal force generation with a 
maximal effect at 10 μM, which is in accordance with previously reported 
dose-response curves for cardiac fibers 10. During the rest of the experi-
ments contractile properties of each diaphragm fiber were tested with ex-
perimental solutions containing either levosimendan (10 µM) or vehicle. 
Maximal force was determined by perfusing the experimental chamber 
with solutions of, successively, pCa 9 and 4.5. Then pCa 9.0 solution was 
perfused through the chamber to relax the fiber. Subsequently, fibers were 
perfused with solutions containing incremental Ca2+ concentrations. Each 
time a plateau was reached, the next pCa solution was perfused through 
the experimental chamber. To improve functional stability of muscle fibers, 
we applied Brenner cycling 16 as modified by Sweeney et al. 17, throughout 
the experimental protocol. Accordingly, no functional decline in maximal 
force generation over time was observed. MIDAC software (Radboud Uni-
versity, Nijmegen, The Netherlands) and a data-acquisition board were 
used to record signals.
Diaphragm	muscle	single	fiber	contractile	determinations
Maximum specific force was determined by dividing the isometric force 
generated at pCa 4.5 by CSA. The force-pCa relationship was derived by 
plotting recorded force against pCa of the corresponding activating solu-
tion. Graphpad software (Graphpad Software Inc., San Diego, CA) was used 
to calculate the Ca2+ concentration required for half-maximum activation, 
pCa50 (pCa = -10log[Ca2+]), as an index of Ca2+ sensitivity of force generation 
and the Hill coefficient, as a measure of myofilament cooperativity 18. 
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Figure 1 Dose-response effects of levosimendan on diaphragm fiber sub-maximal force gen-
erating capacity.	Incremental	levosimendan	concentrations	were	added	to	COPD	diaphragm	fibers	
(n=5)	during	sub-maximal	activation	at	pCa	5.8.	Force	generation	increases	with	rising	levosimen-
dan	concentration,	with	a	maximal	effect	at	10µM.
Myosin	heavy	chain	isoform	composition	determination
Because pCa50 is significantly different between slow and fast diaphragm 
fibers 19, diaphragm fibers were designated as slow or fast on the basis of 
myosin heavy chain isoform determination. Determination of myosin heavy 
chain isoform composition by SDS-PAGE was described previously 13. 
Data treatment & statistical methods
Differences regarding force-pCa relations between groups were statisti-
cally analysed with a two-way repeated measures ANOVA test with pCa 
as the repeated measures factor and the presence of levosimendan as the 
second factor. One-way ANOVA with post-hoc Student-Newman-Keuls 
testing was performed to evaluate the statistical significance of differences 
between groups of other contractile characteristics. A probability level of 
p<0.05 was considered significant. Mean ± SEM values are presented in 
text, tables and figures.
Sample size of 25 fibers (i.e. 12-13 per treatment group), calculated a priori, 
was based upon the assumption to detect an increase of sub-maximal force 
of at least 15% by 10 µM levosimendan 10 with a standard deviation of 15% 
5, 80% probability and an alpha level of 0.05. Because we aimed to deter-
mine the effect in both slow and fast fibers a total of 100 diaphragm fibers 
obtained from 5 COPD patients and 5 non-COPD patients were measured, 
i.e. 10 fibers per patient (5 with 10 μM levosimendan and 5 with vehicle
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RESULTS
Patients characteristics
Patient characteristics and pulmonary function data are shown in Table 1. 
Based on GOLD classification, two patients had mild COPD (stage I), two 
patients had moderate COPD (stage II) and one patient was classified as 
very severe COPD (stage IV). One non-COPD patient had a mild restriction 
and another non-COPD patient had a reduced lung diffusion capacity.
Diaphragm	fiber	contractility
Levosimendan increased calcium sensitivity of force generation in dia-
phragm fibers from COPD and non-COPD patients, which is indicated by 
a leftward shift of the force – pCa relation in levosimendan exposed fibers 
(Figure 2). During sub-maximal activation, for instance at pCa 6.0, levosi-
mendan increased diaphragm fiber force by 20-30% compared to vehicle 
exposed fibers. Accordingly, the pCa50, a measure for calcium sensitivity of 
force generation, is higher in levosimendan treated fibers than in vehicle 
treated fibers, for both COPD and non-COPD diaphragm fibers (Figure 3). 
Separation of the results into fibers expressing slow or fast myosin heavy 
chain showed that levosimendan’s effect was more pronounced in slow 
fibers (Figure 3A) than in fast fibers (Figure 3B). Myofilament cooperativ-
ity, indicated by the Hill coefficient, did not differ between vehicle and 
levosimendan treated fibers; for slow non-COPD fibers (1.47 ± 0.11 vs. 1.77 
± 0.22), for slow COPD fibers (1.55 ± 0.16 vs. 1.30 ± 0.13), for fast non-COPD 
fibers (2.85 ± 0.18 vs. 3.09 ± 0.73) and for fast COPD fibers (3.18 ± 0.56 vs. 
2.02 ± 0.18). Also, levosimendan did not significantly affect diaphragm fi-
ber maximal force generation in both COPD and non-COPD fibers (Figure 
4).
COPD versus non-COPD
The effect size of levosimendan on calcium sensitivity was not different 
between COPD and non-COPD diaphragm fibers, for both slow and fast 
typed fibers (Figure 3). Vehicle treated COPD fibers displayed lower calci-
um sensitivity and maximal force generating capacity compared to vehicle 
treated fibers from non-COPD patients (Figure 3 and 4), which confirms 
our previously published data 5.
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Figure 2 Force-calcium characteristics of non-COPD and COPD diaphragm fibers in the 
presence of 10 µM levosimendan or vehicle activating solutions.	Isometric	force	generation	in	
response	to	solutions	with	incremental	calcium	concentrations	was	determined.	Sub-maximal	force	
generation	is	higher	in	diaphragm	fibers	treated	with	levosimendan	compared	to	vehicle.	
*:	two-way	repeated	measures	analysis	showed	that	force-pCa	relations	of	fibers	treated	with	levosim-
endan	were	significantly	different	from	force-pCa	relations	of	fibers	treated	with	vehicle,	for	both	slow	
and	fast	fibers	(Figures	2A	en	2B	respectively).	Data	are	presented	as	means	±	SEM.
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Figure 3 Values of pCa50, an index for calcium sensitivity of force generation, from non-
COPD and COPD diaphragm fibers in the presence of 10 µM levosimendan or vehicle so-
lution.	Calcium	sensitivity	is	lower	in	COPD	fibers	than	in	non-COPD	fibers.	Diaphragm	fibers	
treated	with	levosimendan	display	higher	calcium	sensitivity	than	fibers	treated	with	vehicle,	for	both	
slow	and	fast	fibers	(Figures	3A	en	3B	respectively).	Data	are	presented	as	means	±	SEM.	*:	p<0.01	
compared	to	vehicle-treated	fibers	within	subject	group;	#:	p	<	0.05	compared	to	vehicle	treated	non-
COPD	fibers	within	fiber-type	group.	Abbreviations:	pCa50 = -10log[Ca2+]	at	which	50%	of	maximal	
force	is	generated.
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Figure 4 Maximal force generation of non-COPD and COPD diaphragm fibers in the pres-
ence of 10 µM levosimendan or vehicle solution.	COPD	diaphragm	fibers	generated	lower	maxi-
mal	forces	than	non-COPD	fibers,	in	both	slow	and	fast	fibers	(Figures	4A	en	4B	respectively).	Maxi-
mal	force	generation	is	not	significantly	different	between	levosimendan	and	vehicle	treated	fibers	
within	patient	groups.	Data	are	presented	as	means	±	SEM.	*:	p<0.05	compared	to	vehicle-treated	
non-COPD	fibers	within	fiber-type	group.
DISCUSSION
The present study is the first to show that pharmacological modulation 
of the troponin complex improves diaphragm muscle fiber contractility in 
patients with COPD.  Recently, we have shown that calcium sensitivity of 
force generation in the diaphragm of patients with COPD is impaired 5. 
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Data of the present study confirm these findings and moreover show that 
levosimendan improves calcium sensitivity in diaphragm muscle fibers of 
these patients. Interestingly, levosimendan also improved calcium sensi-
tivity of diaphragm fibers from the diaphragm of non-COPD patients. Un-
der certain conditions, calcium sensitization offers promising mechanism 
for treatment of diaphragm weakness, especially in patients with COPD. 
Respiratory failure is a prominent manifestation in COPD and is character-
ized by an increased energy demand on weakened respiratory muscles 1. 
Increasing the workload on weakened respiratory muscle leads to reduced 
efficiency of respiratory muscles, which further restricts the limited energy 
reserves of the diseased body 20,21. To break this viscous circle it is therefore 
clinically relevant to seek for therapies that aim to improve efficiency of 
the respiratory muscles. Levosimendan has been developed in attempts 
to find solutions for similar questions in cardiac muscle 22. The positive 
inotropic effects of levosimendan are thought to result mainly from cal-
cium sensitization of cardiac muscle fibers 23. In vivo, both the heart and 
diaphragm muscle undergo repetitive cycles of contraction and relaxation. 
This requires continuous sequestration of calcium at the muscle fiber level, 
which is an energy consuming process, in fact comprising 30-40% of total 
muscle energy consumption during normal contractions 24. Current and 
previous 5 data show that more calcium is needed in diaphragm fibers 
from COPD patients to generate the same amount of force as compared to 
non-COPD patients. Accordingly, the stimulation frequency of diaphragm 
fibers should be increased. Indeed, discharge frequency of motor neurons 
that activate the diaphragm is twofold increased in patients with COPD 
during resting breathing 25. This will however impose a higher burden on 
the calcium sequestration, rendering diaphragm performance less efficient. 
Conversely, improvement of diaphragm efficiency could be established by 
generating the same amount of force with less calcium, i.e. increasing the 
sensitivity of myofilaments for calcium. The present study demonstrates 
that levosimendan is able to increase the calcium sensitivity of diaphragm 
fibers from patients with COPD. 
Mechanisms	of	action
In cardiac muscle, levosimendan is presumed to increase calcium sensitiv-
ity by stabilizing the conformation of the troponin complex which triggers 
muscle contraction 26. Indeed, troponin C has been shown to interact with 
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levosimendan in cardiac muscle 11. Two isoforms of troponin C exist in 
muscle tissue, the cardiac/slow isoform, present in cardiac and slow type 
skeletal muscle, and the fast isoform, present in fast type skeletal muscles. 
The present finding that levosimendan improves contractility of slow dia-
phragm fibers can be explained by interaction with cardiac/slow troponin 
C. In addition we observed that levosimendan enhances fast diaphragm 
fiber contractility. Fast skeletal and slow skeletal troponin C are about 
70% identical 27, but whether levosimendan can also bind to fast troponin 
C has, as far as we know, never been described. Our observations in fast 
diaphragm fibers suggest a possible interaction of levosimendan with fast 
troponin C. Another possibility is that some fibers co-express fast myosin 
heavy chain and slow troponin C. Increased expression of slow troponin 
C has previously been demonstrated in the diaphragm of patients with 
COPD 12. It was however then postulated that this results from a reduction 
of fast fibers rather than from an altered isoform expression within fast 
fibers. Our results support this postulation, because levosimendan’s effect 
size in COPD fibers was identical to the effect size observed in non-COPD 
fibers. Furthermore, adult skeletal muscle generally co-expresses fast myo-
sin heavy chain with fast troponin C 28, so we do not expect that expression 
of slow troponin C explains the effect of levosimendan in fast fibers. Nev-
ertheless, the effect of levosimendan on pCa50 was more profound in slow 
fibers compared to fast fibers (Figure 2). This indicates that the effect size of 
levosimendan depends on the isoform expression of myofibrillar proteins. 
A recent study showed that specific structures in troponin I influence levo-
simendan binding to the troponin complex. It could therefore be that the 
effect size of levosimendan is modulated by isoforms of different myofi-
brillar proteins. The advantage of slow fibers over fast fibers together with 
an increased slow to fast fiber ratio in the COPD diaphragm 12 suggests 
that levosimendan treatment would be more effective in COPD patients 
than in healthy subjects. In all diaphragm fibers levosimendan did not af-
fect maximal force generation, which implies that the maximal amount of 
attached cross-bridges as well as force per cross-bridge was not affected by 
levosimendan.
Study limitations
The effect of levosimendan on diaphragm muscle fibers was tested in vit-
ro, which brings several advantages. Using skinned muscle fibers we were 
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able to specifically study the effects of levosimendan on contractile protein 
function. This would not be possible in vivo, as measured force in vivo de-
pends on many other factors including patient motivation, neuromuscular 
transmission, and intracellular calcium signaling. In addition, the cardio-
vascular effects of levosimendan may affect respiratory muscle function in 
patients with COPD. Thus, skinned diaphragm fibers provide an excellent 
model to study the effects of levosimendan on diaphragm contractility. 
The data of the present study provide a strong rationale to test the effects 
of calcium sensitizers on diaphragm muscle function in vivo under appro-
priate conditions. 
The levosimendan concentration used in the present study (10 µM) was 
derived from previous studies on cardiac fibers 10. Although 0.1 µM levo-
simendan resulted in enhanced force generation, the dose-response curve 
on COPD diaphragm fibers revealed that 10μM levosimendan induces a 
maximal effect on force improvement. This concentration is slightly higher 
than plasma concentrations measured after infusion using clinically rec-
ommended dosages (24h infusion with 0.1 – 0.4 μg/kg/min) 29. Further-
more, intracellular levosimendan concentrations seem to be more relevant 
and could exceed blood values. Local concentrations are however difficult 
to determine because in vivo levosimendan has a short half-life (~1 hour) 
as it is reduced to OR-1855 by intestinal bacteria 30. OR-1855 is further me-
tabolized by acetylation to OR-1896, which has similar calcium sensitizing 
properties as levosimendan 23, but a much longer half-life 30
Clinical implications 
The pathophysiology of weaning failure from mechanical ventilation is 
complex and multifactorial 31. However, it has been recognized that in pa-
tients with COPD maximal inspiratory pressure is significantly lower at 
the time of weaning failure, then at the time of successful weaning 32. In 
addition, patients with severe COPD failing to wean from mechanical ven-
tilation generate lower inspiratory transdiaphragmatic pressure compared 
to patients without severe COPD 33. Accordingly, improving respiratory 
muscle contractility may contribute to successful weaning from mechani-
cal ventilation in these patients. Moreover, as levosimendan also improves 
contractility in diaphragm fibers from non-COPD patients, this agent may 
appear beneficial to other patients difficult to wean from mechanical ven-
tilation. The results of the present study provide an excellent rationale to 
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test the efficacy of levosimendan in this clinical setting. However, it should 
be kept in mind that in vivo levosimendan affects other cell processes be-
sides calcium sensitivity. For instance, opening of ATP-sensitive potassium 
channels in vascular smooth muscle affects pulmonary and systemic vas-
cular resistance, resulting in reduction in mean arterial blood pressure 34. 
The final effects of levosimendan on cardiac contractility, respiratory mus-
cle function and oxygen transport in non heart failure patients are difficult 
to predict, but should be answered by clinical studies. By increasing pCa50 
levosimendan could improve respiratory muscle function during wean-
ing without increasing energy expenditure. The latter is important because 
respiratory muscles could fatigue during weaning trails 32,35. A major cause 
of fatigue is the accumulation of inorganic phosphate, resulting from the 
excessive breakdown of phosphocreatine during periods of high energy 
demand 36. Elevated inorganic phosphate levels depress calcium sensitiv-
ity 37, which evidently impairs contractile muscle function. Hence, levosi-
mendan seems highly appropriate to counteract fatigue-induced muscle 
weakness, since it enhances the sensitivity for calcium without increasing 
energy demand. Very recently, Levine and co-workers showed that con-
trolled mechanical ventilation induces rapid atrophy of human diaphragm 
muscle fibers 38. Although not studied, it is likely that atrophy will result in 
impaired diaphragm contractility in these patients. Therefore, levosimen-
dan, may appear beneficial in difficult mechanical ventilation weaning of 
non-COPD patients as well. In this study we showed that levosimendan in-
creased calcium sensitivity of diaphragm fibers from non-COPD subjects.
Levosimendan is generally well tolerated by patients, hypotension is one 
of the most observed side effects, but is not common when the treatment 
remains within the recommended dose, or can be easily counteracted by 
low dose norepinephrine 39,40.  
In conclusion, the present study clearly demonstrates that levosimendan 
enhances force generating capacity of diaphragm fibers from COPD and 
non-COPD patients by increasing calcium sensitivity of force generation. 
The results of the present study provide a strong rationale for testing the 
effect of calcium sensitizers on respiratory muscle contractility in patients 
with COPD during elevated loading, such as weaning from mechanical 
ventilation.
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SUMMARY
Diaphragm muscle weakness commonly occurs in patients with HF and 
strongly contributes to the limitation of daily life activities. However, the 
pathophysiology of diaphragm dysfunction in HF is largely unknown. 
Previous investigations merely indicated mild structural and metabolic 
alterations in the diaphragm of both patients and animals with HF, which 
do not seem to explain the large reductions of force generating capacity. 
This thesis aimed to investigate the effect of HF on contractile protein 
function in the diaphragm. In addition, the effect of specific pharmacological 
modulations on contractile protein function was examined.
Results from studies in Chapter 2 show that HF in rats, induced by coronary 
artery ligation, significantly impairs diaphragm contractility. Maximal and 
sub-maximal force generation of diaphragm bundles isolated from HF rats 
were reduced by respectively ~20% and ~30% compared to sham-operated 
rats. Of note, sub-maximal force generation was more reduced than maximal 
force generation, suggesting impaired calcium handling in HF diaphragm 
fibers. In addition, maximal shortening velocity was reduced by ~20% and 
maximal power generation by ~35% in diaphragm bundles from HF rats. 
These data are of physiological relevance as in vivo the diaphragm shortens 
against a certain load rather than performing isometric contractions. 
Investigations on the ultra-structure, by use of electron microscopy, revealed 
abnormalities in diaphragm fibers from HF rats. These abnormalities 
were mainly marked by focal degradation of sarcomeric constituents 
and expansion of intermyofibrillar spaces with swollen and degenerated 
mitochondria. Immunofluorescence microscopy showed reduced staining 
intensities of myosin in HF diaphragm fibers compared to sham, which 
could either point to structural modulation of a specific epitope on myosin 
or the loss of myosin. No differences were found regarding the distribution 
of sarcolemma-associated proteins, indicating an intact sarcolemma in HF 
diaphragm fibers. Based on these findings it was concluded that ultra-
structural modifications could at least partly explain impaired diaphragm 
contractility in an animal model for HF. 
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Studies in Chapter 3 of this thesis focused on contractile protein function 
in HF diaphragm. Results from these studies showed that skinned single 
fibers from the diaphragm of HF rats generate less force per cross sectional 
area. In these fibers, myosin content per half sarcomere was concomitantly 
reduced. In addition to reduced maximal force generation, HF decreased 
calcium sensitivity of force generation and slowed cross-bridge cycling 
kinetics in slow and fast diaphragm fibers. These data indicate that 
impairments at the contractile protein level contribute to diaphragm 
dysfunction in HF.  Furthermore, similar results were found for every fiber 
type, implicating that HF induced diaphragm dysfunction results from 
intrinsic impairments rather than a fiber type redistribution. Finally, myosin 
loss in HF diaphragm was associated with increased proteolytic activities 
of caspase-3 and the proteasome. This suggests that enhanced myosin 
breakdown through the ubiquitine-proteasome pathway contributes to 
HF-induced diaphragm weakness.
To investigate if myosin was indeed degraded through the ubiquitine-
proteasome pathway we studied the effect of the proteasome inhibitor 
bortezomib on diaphragm single fiber contractility in Chapter 4. As 
expected, bortezomib treatment of HF and sham-operated rats significantly 
reduced proteasome activities in the diaphragm muscle. Myosin content in 
diaphragm fibers was increased by ~30% after bortezomib treatment in HF 
rats. In accordance, bortezomib treatment significantly improved diaphragm 
single fiber force generating capacity (~30-40%) and cross-bridge cycling 
kinetics (~20%) in HF rats. These data demonstrate that enhanced myosin 
breakdown through the ubiquitin-proteasome pathway results in impaired 
contractile performance of the HF diaphragm. Interestingly, these findings 
indicate that HF induces degradation of functional myosin in diaphragm 
fibers. Further support for the involvement of an activated ubiquitin-
proteasome pathway is provided by the finding that mRNA expression 
of muscle specific E3-ligases, MuRF-1 and MAFbx, was increased in the 
diaphragm of HF rats. 
Passive elastic structures are crucial for optimal muscle function as they 
maintain sarcomeric stability during calcium activation. Titin is the most 
important passive elastic structure within the sarcomere and keeps myosin 
centrally positioned during force generation. The aim of Chapter 5 was to 
study the effect of HF on passive elasticity of diaphragm fibers. Passive 
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tension generation upon stretch was significantly reduced (>35%) in skinned 
diaphragm fibers from HF rats compared to sham. SDS-gel electrophoresis 
of diaphragm homogenates showed that titin content was significantly 
reduced (~25%) in HF diaphragm. This was confirmed by reduced 
intensities of inmmunostaining with antibodies against titin in diaphragm 
cryosections of HF rats compared to sham. No differences in titin’s length 
or weight were found between HF and sham diaphragm. Interestingly, 
soleus fibers from HF and sham rats did not display differences in passive 
tension or in titin immunostaining. Based on these results we conclude 
that passive elasticity is selectively impaired in the diaphragm of HF rats, 
mainly resulting from titin loss. 
Results from studies in chapter 3 showed that reduced sensitivity of the 
myofilaments for calcium contribute to diaphragm dysfunction in HF rats. 
Therefore we examined the effect of the calcium sensitizer levosimendan 
on contractile function of diaphragm fibers from HF animals in Chapter 6. 
Levosimendan is clinically used to improve cardiac muscle function, but the 
effects on skeletal muscle contractility have not been investigated. Hence, 
we first tested the effects of levosimendan on skinned fibers from rat soleus 
and extensor digitorum longus muscle, composed of respectively slow 
and fast myosin heavy chain isoforms. It was shown that levosimendan 
increases the sensitivity for calcium in fibers from both soleus and  extensor 
digitorum longus muscle. These results are of potential clinical relevance 
for the treatment of diseases associated with skeletal muscle weakness. 
Subsequently, we investigated the effect of levosimendan on contractile 
performance of diaphragm fibers from HF rats. Data demonstrate that 
levosimendan partly reverses the reduction of calcium sensitivity in 
HF diaphragm fibers. These findings prompted us to examine the effect 
of levosimendan on human diaphragm fibers. Previous studies from 
our lab demonstraded reduced calcium sensitivity in the diaphragm of 
patients with COPD. Chapter 7 examines the effect of levosimendan on 
COPD diaphragm fiber contractility. The results show that levosimendan 
significantly improves calcium sensitivity of diaphragm fibers from both 
COPD as non-COPD patients.
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DISCUSSION
Traditionally, the origin of diaphragm weakness in HF has been attributed 
to a muscle fiber type shift. However, the current thesis demonstrates that 
diaphragm force generation is reduced in single fibers of every fiber type 
(chapter 3). In these fibers the content of myosin is significantly reduced. Since 
force per myosin molecule is not decreased, myosin loss can largely explain 
the reduced isometric force generating capacity of diaphragm fibers in HF. 
Myosin loss in HF diaphragm fibers was supported by reduced staining 
intensities with antibodies against different myosin heavy chain isoforms 
(chapter 2). It has previously been hypothesized that specific targeting of 
myosin constitutes an initial step during muscle wasting and that loss of 
other myofibrillar proteins follows later in the progression of muscle atrophy 
1. Accordingly, the ratio of myosin to other myofibrillar proteins is reduced 
in diseases associated with muscle wasting, such as COPD 2 and cancer 3. 
In the diaphragm of HF animals, however, the major myofibrillar proteins 
titin and nebulin were concomitantly reduced with myosin (chapter 5). 
Since diaphragm protein content was analyzed in a chronic phase of HF, it 
still could be that myosin loss preceded disappearance of titin and nebulin. 
Time–course studies of HF-induced diaphragm weakness are therefore 
needed to provide more information on the development of myofilament 
protein loss. Remarkably, reduced myosin and titin fluorescence staining 
was dispersed throughout the HF diaphragm fibers (chapter 2 and 5), while 
the ultra-structural abnormalities (chapter 2) were observed focally next to 
areas that appeared intact. This suggests that myofilament loss precedes 
degeneration of sarcomeric integrity. Loss of titin, the major contributor of 
sarcomeric stability, has indeed been associated with increased susceptibility 
of sarcomeric injuries 4.  
The loss of major myofibrillar proteins in HF diaphragm fibers occurs 
without a reduction of cross-sectional area (chapter 3), which could engender 
an increased myofilament lattice spacing. Previous studies demonstrated 
that increased myofilament lattice spacing results in slower rates of tension 
redevelopment 5 and decreased calcium sensitivity 6. This may explain 
slower cross-bridge cycling and reduced sensitivity for calcium in HF 
diaphragm fibers (chapter 3). A role for increased lattice spacing is further 
supported by the finding that restored myosin concentration is associated 
with improved rate constant of tension redevelopment (chapter 4). Expansion 
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of intermyofibrillar spaces observed by the use of electron-microscopy on 
HF diaphragm fibers (chapter 2) confirms a reduced ratio of myofibrils per 
fiber volume. 
The distinct loss of several myofibrillar proteins indicate that catabolic 
processes exceed anabolic processes. The involvement of increased 
contractile protein degradation is supported by enhanced proteolytic 
activities of the proteasome (chapter 3 and 4). Moreover, treatment of HF 
animals with a proteasome inhibitor results in the reversal of myosin loss, 
which strongly suggests that myosin is degraded through the ubiquitin-
proteasome pathway in the HF diaphragm. Whether titin and nebulin 
loss in HF diaphragm are also a consequence of increased activity of this 
pathway is currently unknown. In favor of this explanation, the E3- ligase 
MuRF1, which is known to ubiquitinate titin and nebulin 7, is upregulated 
in the diaphragm of HF rats (chapter 4). The proteasome is, however, limited 
in the admittance of large proteins 8 and interactions between myofilament 
proteins protect proteins from degradation 9. Thus, for proteasomal 
degradation of such large proteins as titin (~3500 kDa) and nebulin (~700 
kd), prior cleavage into smaller fragments is needed. Results from previous 
studies indicate that calpains are able to cleave both titin and nebulin 10,11 
and increased calpain activities have been reported in diaphragm of HF 
rats 12. Likewise, caspase-3 is thought to cleave actin, enabling myosin 
molecules to enter the proteasome and to be degraded 13. Caspase-3 
activity is increased in the HF diaphragm (chapter 3 and 4). Interestingly, 
reversal of myosin loss after proteasome inhibition was accompanied by 
reduced caspase-3 activities (chapter 4). It can therefore be hypothesized 
that the inhibition of caspase-3 is responsible for the improved diaphragm 
contractility. Unexpectedly however, HF did not result in an accumulation 
of actin cleaving products in the diaphragm (unpublished data). Thus, the 
necessity of caspase-3 activation in HF diaphragm wasting is uncertain and 
remains to be investigated, for instance by the use of specific caspase-3 
inhibitors.
The ubiquitin-proteasome pathway plays a key role in recognition and 
subsequent degradation of dysfunctional proteins, but is involved in the 
turnover of functional proteins as well 14,15. In this aspect it is important to 
note that the increased amount of myosin molecules in HF diaphragm fibers 
after proteasome inhibition are functional (chapter 4), since fiber force per 
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myosin content was unaltered after proteasome inhibition. Myosin content 
is the net result of its synthesis and degradation. Therefore these data 
indicate that either (1) proteasomes in the HF diaphragm degrade myosin 
that is not functionally compromised or (2) that proteasome inhibition 
stimulates myosin synthesis. The latter option is contradicted by the recent 
observation that proteasome inhibition represses protein synthesis rate in 
non-muscle cells 16. It may therefore be anticipated that myosin turnover is 
increased in the HF diaphragm. This could be established by investigating 
the synthesis rate of myosin. 
Inducers of proteolysis
With the unambiguous evidence that contractile protein degradation 
contributes to HF-induced diaphragm weakness (chapter 4) an important 
next step is to identify the triggers that induce proteolysis. Several 
mechanisms have been proposed to be involved. First, muscular protein 
degradation can be initiated by damage of the muscle membrane probably 
through an increased influx of extracellular Ca2+ 17. Increased diaphragm 
loading is known to induce injuries of the muscle cell membrane 18 and the 
diaphragm is increasingly loaded in HF 19,20. However, the sarcolemma of 
HF diaphragm fibers is not disrupted and there is no evidence for a leaky 
membrane (chapter 2), while intracellular protein degradation is increased 
(chapter 2-5). Therefore, it is not likely that increased proteolysis in the HF 
diaphragm results from a loss of sarcolemmal integrity. 
An increased amount of circulating catabolic cytokines is another trigger 
proposed to induce muscle wasting in HF. Indeed blood levels of TNF-
alpha, interleukin-6 and interleukin-1 correlate with the severity of 
peripheral muscle wasting 21. Nevertheless, in non-cachectic HF patients 
cytokine levels are normal 21, while respiratory muscle dysfunction already 
occurs in this sub-group 22,23.  This suggests that either additional catabolic 
factors are involved in inducing proteolysis in HF diaphragm or that local 
concentrations exceed circulating concentrations. Angiotensin-2 might 
be an alternative candidate, since its levels are commonly raised in HF 
patients and are associated with poor prognosis 24. Angiotensin-2 infusion 
in mice indeed leads to activation of proteolytic systems, like caspase-3 
and furthermore inhibits anabolic pathways 25. A recent study showed that 
infusion of angiotensin-2 in concentrations comparable to those observed 
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in HF led to skeletal muscle apoptosis in healthy rats 26. Moreover, the 
incidence of apoptosis was 4 times higher in diaphragm muscle than in 
peripheral muscles, suggesting that the diaphragm is highly susceptible to 
angiotensin-2.  
Because cytokines can act autocrine and paracrine, an increased local 
expression of cytokines could explain muscle wasting in the absence of 
high cytokine blood levels. The expression of cytokines has never been 
determined in the diaphragm, but is increased in peripheral muscles of 
HF patients 27 and exceeds serum levels in HF rats 28. Important to note is 
that loaded breathing, as occurs in HF patients 19,20, is a stimulus to increase 
diaphragm cytokine expression 29,30,31. Future investigations should 
therefore focus on the expression of cytokine levels in the diaphragm of 
HF patients.
Mechanisms and therapeutic applicability of interventions
Bortezomib
Reduced inspiratory muscle force generation is a major clinical problem 
in several disease states, such as HF, COPD and prolonged mechanical 
ventilation. Yet, no adequate intervention is currently available to improve 
inspiratory muscle contractility. From a muscle physiological point of 
view two approaches can be followed. The first one aims to reverse the 
loss of contractile protein content. Since increased proteolytic activities 
of the proteasome are associated with myosin loss in the diaphragm of 
COPD patients 32 and HF animals (chapter 3), proteasome inhibition could 
recover myosin content. Indeed, treatment with the proteasome inhibitor 
bortezomib increased myosin content and force generating capacity of the 
diaphragm in animals with HF (chapter 4) and COPD 33. However, the exact 
mechanisms by which proteasome inhibition enhances force generation 
are not clear. The possible involvement of increased protein turnover in 
HF diaphragm and the effect of proteasome inhibition on protein synthesis 
have been discussed above. In addition, bortezomib reduced MuRF-1 
expression and caspase-3 activity (chapter 4). Because MuRF-1 and caspase-3 
act upstream in the ubiquitin-proteasome pathway, modulation of these 
enzymes could play an important role in accomplishing the positive effects 
of bortezomib. MuRF-1 gene expression is activated by NFκB 34. Because 
bortezomib is well known to prevent NFκB activation in non-muscle cells 
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35, we speculate that proteasome inhibition reduces MuRF-1 levels in the 
HF diaphragm via an NFκB dependent pathway. In vitro experiments 
showed that bortezomib does not affect recombinant caspase-3 activity 
(chapter 3), suggesting that bortezomib indirectly inhibits caspase-3 in vivo. 
For example, inhibition of the degradation of caspase-3 inhibitor XIAP by 
the proteasome may be involved 36. Thus indirect effects of proteasome 
inhibition probably contribute to bortezomib-induced muscle force 
improvement in HF animals. Despite its availability for human use, the 
application of bortezomib in HF is at this moment strictly experimental. 
Taking the basic housekeeping cell functions of the proteasome 37 into 
consideration, further research on side effects should warrant the 
therapeutic applicability of modulating ubiquitin-proteasome activation 
in muscle weakness.
Levosimendan
The reduction of sub-maximal force generation in diaphragm bundles from 
HF rats is disproportional to the loss maximal force generation (chapter 
2). This can be explained by reduced sensitivity of the myofilaments to 
Ca2+ (chapter 3). Similar results were previously found in diaphragm fibers 
from COPD patients 38. Reduced force generating capacity corrected for 
contractile protein loss indicates that remaining contractile proteins are 
dysfunctional. Thus, a second approach that can be followed to improve 
diaphragm contractility is to increase the functionality of the remaining 
contractile proteins. In vitro experiments showed that the Ca2+ sensitivity of 
diaphragm fibers from HF animals and COPD patients can be increased by 
the addition of the calcium sensitizer levosimendan (chapter 6 and 7). Thus, 
levosimendan is able to restore impaired sub-maximal force generation 
in human diaphragm fibers. Levosimendan has been shown to improve 
cardiac contractility in vivo 39 and is at this moment clinically used in 
more than 40 countries worldwide. An advantage of levosimendan over 
experimental Ca2+ sensitizers is that it increases cardiac force generation 
without increasing myocardial oxygen demand 40. Since the oxygen cost 
of respiration is significantly increased in HF and COPD patients 41,42,43, 
improved efficiency of respiratory muscles would also be favorable in 
these patients. Importantly, the effect of levosimendan treatment on the 
efficiency of respiratory muscles should preferably be investigated in 
subjects without cardiac problems to exclude positive effects from improved 
haemodynamics.
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SAMENVATTING
Kortademigheid en verminderde inspanningscapaciteit zijn de meest 
frequente symptomen van patiënten met chronisch hartfalen (HF). 
De ernst van deze klachten correleert echter slecht met hartfunctie, 
uitgedrukt als linker ventrikel ejectiefractie. De mate van kortademigheid 
en inspanningscapaciteit is daarentegen duidelijk gerelateerd aan de 
afname van ademspierfunctie. Met name de krachtontwikkeling van 
inademingspieren is significant (30-60%) verminderd bij HF patiënten 
en blijkt een belangrijke voorspeller voor mortaliteit. Het diafragma 
(middenrif) is de belangrijkste spier voor inspiratie. Voorgaande studies 
hebben slechts milde structurele en metabole veranderingen aangetoond 
in het diafragma van HF patiënten. HF induceert bijvoorbeeld een 
gedeeltelijke omzetting van snelle naar langzame spiervezeltypes in het 
diafragma. Echter deze milde veranderingen lijken niet de significante 
afname van diafragma krachtgeneratie bij HF patiënten te kunnen verklaren. 
Dit betekent dat de pathofysiologie van HF geïnduceerde diafragma 
disfunctie nog grotendeels onbekend is. Het doel van dit proefschrift is 
om het effect van HF op het functioneren van contractiele eiwitten in het 
diafragma te beschrijven. Vervolgens is onderzocht of modulatie van slecht 
functionerende contractiele eiwitten een aangrijpingspunt kan zijn voor 
farmacologische interventies. 
Contractiele eigenschappen van het diafragma kunnen in vitro bepaald 
worden door electrische stimulatie van spierbundels uit het diafragma. In de 
studies beschreven in hoofdstuk 2 is de contractiliteit van diafragmabundels 
uit ratten met chronisch HF onderzocht. De resultaten laten zien dat HF de 
krachtgeneratie van het diafragma sterk vermindert. Zowel maximale als 
sub-maximale isometrische krachtgeneratie van diafragma spierbundels uit 
ratten met HF zijn met respectievelijk ~20% en ~30% afgenomen. Daarnaast 
tonen de resultaten uit hoofdstuk 2 aan dat de verkortingssnelheid van 
diafragmabundels uit HF ratten met ~20% is afgenomen. Een gangbare 
maat om spierfunctie uit te drukken is vermogen, welke een product is 
van snelheid en kracht. Uit de afname van zowel kracht als snelheid kan 
berekend worden dat het maximale vermogen dat ontwikkeld kan worden 
~35% lager is in diafragmabundels uit ratten met HF t.o.v. gezonde ratten. 
Tijdens normaal ademhalen in vivo verkort het diafragma en produceert het 
dus kracht onder non-isometrische condities. Daarom zijn de bevindingen 
171
9
met betrekking tot snelheidsontwikkeling van de HF diafragmabundels 
van klinisch fysiologisch belang. Onderzoek naar de ultrastructuur van 
diafragmavezels van HF ratten werd uitgevoerd met behulp van een 
elektronenmicroscoop. Er werden verschillende structurele afwijkingen 
gevonden in het HF diafragma, zoals schade van sarcomeren, verwijding 
van ruimte tussen de myofibrillen en gezwollen en degenererende 
mitochondria. Tevens werd een verminderde kleuringintensiteit van stukjes 
ingevroren diafragmaweefsel met fluorescent gelabelde antilichamen 
tegen zowel langzame als snelle myosine types gevonden. Dit zou 
kunnen wijzen op een afname van myosine en/of een modulatie van een 
specifiek epitoop op myosine. Er werden geen afwijkingen gevonden met 
betrekking tot het aankleuren van eiwitstructuren in de membranen van 
de diafragmavezels. Deze bevindingen suggereren dat ultrastructurele 
afwijkingen in diafragmavezels een verklaring vormen voor de afwijkende 
contractiele eigenschappen van het HF diafragma. 
De resultaten uit hoofdstuk 2 suggereren dat HF de functie van contractiele 
eiwitten in het diafragma verstoort. Daarom is in hoofdstuk 3 van dit 
proefschrift onderzoek gedaan naar het functioneren van contractiele 
eiwitten, met name myosine en troponine. Hiervoor werden spiervezels uit 
het diafragma gepermeabiliseerd. Door deze vezels vervolgens met calcium 
te activeren en krachtgeneratie te meten kan de functie van contractiele 
eiwitten bestudeerd worden.Resultaten van deze studies laten zien dat 
krachtgeneratie van gepermeabiliseerde spiervezels uit het diafragma 
van HF ratten afgenomen is. In diezelfde spiervezels is de hoeveelheid 
myosine proportioneel verminderd. Daarnaast tonen de experimenten 
in dit hoofdstuk aan dat  de gevoeligheid voor calcium afgenomen is in 
spiervezels uit het hartfalen diafragma. Daarnaast is ook de snelheid van 
de myosine-actine interactie cyclus (zgn. “cross-bridge cycling”) vertraagd 
in HF diafragmavezels. Deze resultaten tonen aan dat afwijkingen op 
het nivo van contractiele eiwitten significant bijdragen aan diafragma 
disfunctie bij HF. Deze bevindingen werden bovendien waargenomen in 
verschillende spierceltypen, wat bewijst dat HF geïnduceerde diafragma 
disfunctie veelmeer een gevolg is van afwijkingen in de spiervezels dan 
een verschuiving tussen spiervezeltypen. Tenslotte laten de resultaten in 
hoofdstuk 3 tevens zien dat het verlies van myosine geassocieerd is met 
een toegenomenproteolytische activiteit van caspase-3 en enzymen uit 
het proteasoom. Van deze enzymen is bekend dat zij spiereiwitten, zoals 
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myosine, kunnen afbreken. Deze resultaten  suggereren daarom  dat HF een 
toegenomen myosine afbraak induceert en dat daardoor de krachtgeneratie 
van het diafragma afneemt. 
Om te onderzoeken of myosine inderdaad wordt afgebroken door het 
proteasoom is in hoofdstuk 4 het effect van de proteasoomremmer 
bortezomib op diafragma contractiliteit bestudeerd. Zoals verwacht 
wordt de proteasoomactiviteit in het diafragma van HF ratten geremd na 
behandeling met bortezomib. De hoeveelheid myosine in diafragmavezels 
van HF ratten neemt toe met ~30% na behandeling met bortezomib. 
Overeenkomstig neemt ook de maximale krachtgeneratie en cross-bridge 
cyclingsnelheid van diafragmavezels uit HF ratten toe met respectievelijk 
~30% en ~20%. Deze data tonen aan dat diafragma disfunctie bij HF 
ratten veroorzaakt wordt door een toename van myosineafbraak door 
het proteasoom. De resultaten uit hoofdstuk 4 suggereren bovendien dat 
functioneel myosine wordt afgebroken in het HF diafragma, omdat de 
toename van myosine, na proteasoomremming, gepaard gaat met een 
toename van krachtgeneratie. 
Elastische structuren zijn cruciaal voor het optimaal functioneren van 
spiervezels, omdat ze voor stabiliteit zorgen tijdens contractie. Titine 
bepaalt voor een belangrijk deel de passief elastische eigenschappen van 
de spiervezel en waarborgt daarmee de centrale positie van myosine in het 
sarcomeer tijdens contracties. Het doel van de studies in hoofdstuk 5 was 
om het effect van HF op elasticiteit van diafragmavezels te onderzoeken. 
Passieve krachtgeneratie na uitrekking is met ~35% afgenomen in 
gepermeabiliseerde diafragmavezels uit HF ratten tov controle ratten. De 
hoeveelheid titine in diafragmavezels uit HF ratten is met ~25% afgenomen. 
Er werden geen verschillen gevonden met betrekking tot de lengte van 
titine eiwitten. Interessant genoeg vertonen soleus vezels uit HF ratten 
geen verminderde elasticiteit en titineverlies. Aan de hand van deze data 
kan geconcludeerd worden dat elasticiteit selectief is afgenomen in het 
diafragma van ratten met hartfalen en dat deze afname vooral het gevolg 
lijkt te zijn van titine verlies. Ook de concentratie van een ander groot eiwit 
uit het sarcomeer, nebuline, is met ~25% afgenomen in het diafragma van 
HF ratten. Bovendien bevestigen de resultaten uit dit hoofdstuk het eerder 
aangetoonde verlies van myosine (hoofdstuk	 3&4). Tezamen suggereren 
deze bevindingen dat HF de afbraak van diverse contractiele eiwitten in 
het diafragma induceert.
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Resultaten uit hoofdstuk 3 lieten zien dat diafragmavezels uit ratten met 
hartfalen minder gevoelig zijn voor calcium dan diafragmavezels uit controle 
ratten. Daarom is in hoofdstuk 6 het effect bestudeerd van de calcium 
sensitiser levosimendan op de contractiliteit van diafragmavezels uit HF 
ratten. Levosimendan wordt in de kliniek al toegepast om de contractiliteit 
van de hartspier te verbeteren, maar het effect op skeletspieren is nog 
onbekend. Daarom hebben we eerst onderzocht of levosimendan de calcium 
gevoeligheid van gezonde skeletspieren kan verbeteren. De resultaten uit 
hoofdstuk 6 tonen aan dat levosimendan de calciumgevoeligheid van zowel 
langzame skeletspieren (soleus) als snelle skeletspieren (extensor digitorum 
longus) verbetert. Bovendien wordt in hoofdstuk 6 aangetoond dat 
levosimendan de afname in calciumgevoeligheid van diafragmavezels uit 
HF ratten herstelt en daarmee de sub-maximale krachtgeneratie verbetert. 
Deze bevindingen spoorden ons aan om het effect van levosimendan 
op humane diafragmavezels te bestuderen. Voorgaande studies uit 
ons lab lieten zien dat de calciumgevoeligheid van diafragmavezels 
afkomstig uit patiënten met chronisch obstructief longlijden (COPD) 
is afgenomen. De resultaten van de studies in hoofdstuk 7  bevestigen 
deze eerdere bevindingen en laten bovendien zien dat levosimendan de 
calciumgevoeligheid van diafragmavezels uit COPD patiënten verbetert. 
Dit betekent dat levosimendan sub-maximale krachtgeneratie van 
humane diafragmavezels kan verbeteren. Deze resultaten zijn van klinisch 
belang omdat ze laten zien dat calcium sensibilisatie een mogelijke 
behandelingsstrategie kan zijn voor ziekten geassocieerd met zwakte van 
ademhalingsspieren en/of perifere spieren.
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DISCUSSIE
De oorzaak van diafragmazwakte bij patiënten met HF werd vooralsnog 
met name toegeschreven aan een spiervezeltype verschuiving. Echter, 
resultaten van studies beschreven in dit proefschrift tonen aan dat HF leidt 
tot verminderde spierkracht van alle vezeltypen in het diafragma (hoofdstuk	
3 & 4). In deze spiervezels is de myosine content significant afgenomen. 
Omdat de afname van kracht en myosine content proportioneel zijn, 
kan de afgenomen krachtgeneratie verklaard worden door het verlies 
van myosine. Naar aanleiding van resultaten uit eerdere studies naar 
spiermassaverlies bij andere ziekten dan HF is de hypothese gepostuleerd 
dat de afbraak van myosine een van de eerste stappen is tijdens de progressie 
van spieratrofie en dat het verlies van andere myofibrillaire eiwitten later 
volgt. In het diafragma van ratten met HF is echter de hoeveelheid van 
twee andere grote myofbrillaire eiwitten, titine en nebuline, met de zelfde 
mate afgenomen als de hoeveelheid mysoine (hoofdstuk	5). In deze studie 
zijn de eiwitconcentraties in het diafragma  pas 15 weken na het induceren 
van HF geanalyseerd, wat niet uitsluit dat myosine verlies vooraf ging aan 
het verlies van titine en nebuline. Het bestuderen van eiwitconcentraties 
op verschillende tijdspunten na inductie van hartfalen zou meer inzicht 
kunnen verschaffen in de ontwikkeling van eiwit verlies in het diafragma. 
Opvallend is verder dat verminderde immunofluorescente kleuring van 
myosine en titine over de hele diafragmavezel te zien is (hoofdstuk	2	&	5), 
terwijl de ultra-structurele beschadigingen juist locaal te vinden zijn naast 
gebieden die intact lijken te zijn. Dit suggereert in ieder geval dat het verlies 
van myofibrillaire eiwitten vooraf gaat aan het verlies van de structurele 
integriteit van het sarcomeer. 
Het verlies van myofibrillaire eiwitten in de HF diafragmavezels gaat 
niet gepaard met een afname van dwarsdoorsnede oppervlak, wat zou 
kunnen betekenen dat de ruimte tussen de myofilamenten groter wordt. 
De toegenomen ruimte tussen de myofibrillen, die is waargenomen met de 
electronen-microscoop (hoofdstuk	2), bevestigt een afname van het aantal 
myofibrillen per vezel volume. Voorgaande studies hebben aangetoond dat 
het vergroten van de ruimte tussen myofilamenten resulteert in langzamere 
snelheid van krachtontwikkeling en afgenomen calcium gevoeligheid. Dit 
zou dus een verklaring kunnen zijn voor de langzamere “cross-bridge 
cycling” en lagere calciumgevoeligheid in HF diafragmavezels (hoofdstuk	3). 
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Daarnaast kunnen structurele veranderingen, zoals oxidatie of nitrosylatie, 
van de nog aanwezige contractiele eiwitten een verklaring  vormen voor 
deze afwijkende contractiele eigenschappen.
Een	rol	voor	spiereiwit	afbraak
Het verlies van myofibrillaire eiwitten in HF diafragmavezels impliceert 
dat eiwitafbraak de overhand heeft over eiwitaanmaak. Een rol voor 
toegenomen eiwitafbraak wordt ondersteund door verhoogde activiteiten 
van proteolytische enzymen (hoofdstuk	 3	 &	 4). Bovendien resulteert de 
behandeling van HF ratten met een protesoomremmer voor een afname 
van het myosine verlies (hoofdstuk	 4). Dit suggereert dat myosine in het 
HF diafragma wordt afgebroken door het proteasoom. Of dit ook geldt 
voor titine en nebuline is op dit moment onbekend. Het is in elk geval 
wel bekend dat de E3-ligase MuRF1 ubiquitine-ketens kan koppelen aan 
titine en nebuline. Deze ubiquitine-ketens kunnen door het proteasoom 
herkend worden als signaal om gekoppelde eiwitten af te breken. De 
genexpressie van MuRF1 is toegenomen in het HF diafragma (hoofdstuk	4), 
wat zou kunnen resulteren in een toegenomen koppeling van uibiquitine-
ketens aan titine en nebuline. Het proteasoom is echter gelimiteerd in 
het toelaten van grote eiwitten. Bovendien zorgen interacties tussen 
myofibrillaire eiwitten voor een bescherming tegen afbraakprocessen. 
Het lijkt er daarom op dat voorafgaand aan afbraak van titine en nebuline 
door het proteasoom, deze eerst eiwitten eerst geknipt moeten worden 
door andere proteases. Resultaten uit eerdere studies hebben laten zien 
dat calpaïne een enzym is dat nebuline en titine kan knippen en dat de 
activiteit van calpaïne is toegenomen in het HF diafragma. Van caspase-3 
wordt verondersteld dat het actine moleculen kan knippen, waardoor 
myosine vrij kan komen en door het proteasoom kan worden afgebroken. 
De enzymactiviteit van caspase-3 is toegenomen in het diafragma van HF 
ratten (hoofdstuk	3	&	4).	Het is interessant dat de behandeling van HF ratten 
met een protesoomremmer ook de caspase-3 activiteit verlaagd (hoofdstuk	
4). Caspase-3 speelt daarom mogelijk een sleutelrol bij het ontstaan van 
spiermassaverlies in hartfalen ratten. Daar staat tegenover dat HF niet 
resulteert in een toegenomen aanwezigheid van geknipte actine producten 
in het diafragma (ongepubliceerde data). De noodzakelijkheid van caspase-3 
activiteit tijdens HF geïnduceerd spiereiwit verlies in het diafragma is 
daarom onzeker en moet verder worden onderzocht, bijvoorbeeld door 
gebruik te maken van specifieke capsase-3 remmers.   
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Veroorzakers	van	spiereiwit	afbraak
De bevindingen uit dit proefschrift laten duidelijk zien dat de afbraak van 
myofibrillaire eiwitten bijdraagt aan diafragmadisfunctie geïnduceerd 
door HF. Een belangrijke volgende vraag die nu voor ons ligt is welke 
triggers verantwoordelijk zijn voor de inductie van eiwitafbraak. 
Verschillende mechanismen zouden een rol kunnen spelen. Ten eerste is 
bekend dat spiereiwit afbraak geïnitieerd kan worden door een verhoogde 
extracellulaire Ca2+ influx, als gevolg van beschadigde spiercelmembranen. 
Verhoogde diafragma-arbeid kan beschadiging van de spiercelmembranen 
induceren. Echter, hoewel aangetoond is dat HF ademhalingsspier arbeid 
kan verhogen, laten de resultaten uit hoofdstuk	 2 in dit proefschrift zien 
dat de membranen van diafragmavezels uit HF ratten intact lijken. Een 
andere trigger die verantwoordelijk zou kunnen zijn voor degradatie 
van spiereiwitten is de verhoogde aanwezigheid van circulerende 
cytokines. Plasmaconcentraties van bijvoorbeeld tumor necrosis factor-α, 
interleukine-6 en interleukine-1 zijn verhoogd bij patiënten met HF en 
correleren met de ernst van perifeer spiermassa verlies. Desondanks zijn 
deze concentraties niet verhoogd in het plasma van HF patiënten zonder 
perifeer spiermassa verlies, terwijl ademhalingsspier zwakte wel optreed 
bij deze patiëntengroep. Dit suggereert dat andere circulerende katabole 
mediatoren een rol spelen en/of dat locale cytokine concentraties in het 
diafragma wel verhoogd zijn. Het is daarom belangrijk dat toekomstig 
onderzoek zich o.a. richt op het effect van HF op concentraties en expressie 
van cytokines in het diafragma. Met name omdat verhoogde ademarbeid, 
bij HF patiënten, een bekende stimulus is voor cytokine expressie in het 
diafragma. Angiotensine-2 is een andere circulerende katabole factor die 
verantwoordelijk zou kunnen zijn voor de inductie van eiwitafbraak in 
het HF diafragma. De concentratie van angiotensine-2 is verhoogd in het 
plasma van patiënten met HF en is tevens geassocieerd met een verhoogde 
sterftekans. Recente proefdierstudies hebben aangetoond dat toediening 
van angiotensine-2, in fysiologische concentraties, leidt tot verhoogde 
activiteit van caspase-3 in spieren. Bovendien bleek het diafragma van 
deze proefdieren 4 keer zo gevoelig voor angiotensine-2 dan de perifere 
spieren van dezelfde dieren.    
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Mogelijke behandelingsstrategieën
Diafragmazwakte is niet alleen een belangrijk klinisch probleem bij HF, 
maar ook bij andere aandoeningen zoals COPD en langdurige beademing. 
Op dit moment zijn er geen geschikte farmacologische interventies 
voorhanden die diafragmafunctie kunnen verbeteren. Vanuit fysiologisch 
oogpunt zijn er verschillende behandelingstrategieën mogelijk in een 
poging diafragmazwakte als gevolg van spiereiwit verlies tegen te gaan. 
Ten eerste zou er getracht kunnen worden de concentratie van spiereiwitten 
weer terug op peil te brengen. In dit proefschrift is aangetoond dat myosine 
wordt afgebroken door het proteasoom en dat interventie met de klinisch 
beschikbare proteasoomremmer bortezomib myosine verlies tegengaat en 
diafragmafunctie bij HF ratten verbetert. Momenteel wordt bortezomib 
gebruikt bij de behandeling van kanker. Hoewel dierexperimentele studies, 
zoals in dit proefschrift gepresenteerd, suggereren dat proteasoom remmers 
humane spieratrofie kunnen tegengaan, vormt het bijwerkingen profiel van 
deze groep medicijnen een beperking. De exacte mechanismen waarmee 
protesoom inhibitie de diafragmafunctie verbetert zijn bijvoorbeeld nog 
niet bekend. Bovendien vervult het proteasoom een vitale rol bij normale 
celfysiologische processen. Het is daarom belangrijk om uiterst zorgvuldig 
te handelen bij verder onderzoek naar de klinische toepasbaarheid van 
bortezomib bij spierzwakte gerelateerde aandoeningen.  Een alternatieve 
behandelingsstrategie zou het verbeteren van de functie van nog aanwezige 
spiereiwitten kunnen zijn. De resultaten van in vitro studies uit dit proefschrift 
laten zien dat de afgenomen calcium gevoeligheid van diafragmavezels uit 
HF ratten en COPD patiënten verbeterd kan worden door incubatie met 
de calcium sensitizer levosimendan. Op dit moment wordt levosimendan 
al in meer dan 40 landen in de kliniek gebruikt om de hartspierfunctie 
te verbeteren. Een voordeel van levosimendan ten opzichte van andere 
calcium sensitizers is dat levosimendan krachtgeneratie verbetert zonder 
het zuurstofverbruik te verhogen. Omdat patiënten met HF en COPD al 
meer zuurstof verbruiken voor hun ademhaling zou levosimendan hierop 
een gunstig effect kunnen hebben.  
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CONCLUSIE
De bevindingen in dit proefschrift laten zien dat diafragmazwakte 
geïnduceerd kan worden door HF en dat deze  veroorzaakt wordt door 
afbraak en disfunctioneren van contractiele eiwitten in de diafragmavezels. 
Bovendien blijkt dat het remmen van eiwitafbraak en het verbeteren van 
eiwitfunctie in het HF diafragma twee mogelijke aangrijpingspunten zijn 
voor succesvolle interventies. Toekomstig onderzoek zou zich enerzijds 
moeten richten op de klinische toepasbaarheid van deze interventies 
en anderzijds op de triggers die verantwoordelijk zijn voor afbraak en 
disfunctioneren van contractiele eiwitten.
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van onschatbare waarde voor bijna alle hoofdstukken in dit proefschrift. 
Ik ben jullie enorm dankbaar voor de altijd prettige samenwerking 
en ben er zeker van dat deze ook in de toekomst nieuwe vruchten zal 
afwerpen. Theo, bedankt voor de altijd mooie histologieplaatjes, die 
onze theoretische concepten visueel inzichtelijk maken. Tevens ben ik je 
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is nu gekomen om “de brug te slaan”, de eerste stappen hebben we al 
voorzichtig gezet. Mijn huidige en ex-kamergenoten, Herwin, Hanneke W, 
Luc, Freek, Jorien, Anke en ook Willem-Jan, wil ik bedanken voor de altijd 
levendige discussies (af en toe ook op wetenschappelijk vlak) en de daarbij 
behorende humor. Naast jullie zijn ook Rob, Hilda, Helga en Saskia van het 
secretariaat verantwoordelijk voor het feit dat ik elke dag met plezier het 
aquarium (ik noem het zelf liever de denktank) van de afdeling binnenstap. 
Een bijzonder woord van dank gaat uit naar mijn paranimfen. Alma, jouw 
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een relativerende invloed op mij gehad. Het is soms verhelderend om te 
horen of te zien dat (mijn) wetenschappelijk onderzoek helaas toch niet 
centraal staat in deze wereld. Coen, ik had me de afgelopen jaren geen 
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